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SUMO (small ubiquitin-like modifier) is a well characterized ubiquitin-like 
molecule. It shares a high degree of homology with ubiquitin both in its three-
dimensional structure and the conjugation pathway. However, the sumoylated 
substrates are not targeted for degradation as that of ubiquitination; instead of 
degradation, sumoylation alters the subcellular localization, protein-protein 
interaction or activities of the substrates, and they can improve protein stabilities. 
Similar to ubiquitination, the conjugation pathway of sumoylation consists of El 
(sumo-activating enzyme), E2 (sumo-conjugating enzyme) and E3 (sumo-ligase). 
PIAS (Protein Inhibitors of Activated STATs) family is a group of E3 ligases. 
Up to now, five PIAS members in human have been identified; they are 
PIASl, PIAS3, PIASxa, PIASxp and PIASy. All of them contain two highly 
conserved domains, SAP (SAF-A, Acinus and PIAS) and SP-RING (Siz/PIAS 
RING). SAP is essential for A/T-rich DNA binding while SP-RING is responsible 
for the ligation of SUMO from E2-SUM0 to the substrates. However, the region in 
. t h e PIAS proteins that is important for providing substrate specificity remains 
enigmatic. 
The long term goals of this project are characterization of the molecular basis 
of sumoylation played by PIAS, identification of the sumoylated substrates in human 
liver cell lines and expression as well as purification of the PIAS proteins in attempt 
to solve their three-dimensional structures in order to determine how these E3 ligases 
provide the substrate specificity in sumoylation as well as their functional basis. 
In this study, the tissue specificities of the PIAS family were verified by PGR 
screening of Human MTC (multiple tissue cDNA) Panels. All PIAS members had 
xi 
Abstract 
their patterns of specific tissue distribution, but all of them showed a relatively high 
expression level in testis, pancreas and liver. Also, the PIAS proteins localized inside 
the nucleus showed a speckled pattern when they were overexpressed in WRL-68 
and HepG2 cell lines under the EGFP expression system. Deletion studies showed 
that the SP-RING may be a crucial component for nuclear retention and a SUMO 
interacting motif may be involved in the speckle formation. The differential nuclear 
protein expression profiles of both EGPF-SUMO-1 overexpressing WRL-68 and 
HepG2 were established by two-dimensional gel electrophoresis, comparing with the 
mock transfection control overexpressing EGFP HepG2 cells, two up-regulated 
proteins were identified by mass spectrometry, they were heterogeneous nuclear 
ribonucleoprotein A2/B1 isoform B1 (hnRNP A2/B1 isoform Bl) and uracil DNA 
glycosylase (UDG). Their differential expression at the transcriptional and 
translational level in SUMO-1 overexpressing HepG2 cells was further verified by 
RT-PCR analysis and western blotting respectively. 
For the structural study, the expression of full length PIAS proteins, PIASl, 
PIAS3, PIASxa and PIASxp were attempted in the prokaryotic system, the yield was 
. t o o low for purification. Nevertheless, the four fragments of PIASl (PIAS 1-141-410, 
PIASl-141-476，PIASl-321-410 and PIAS 1-321-476) flanking the SP-RING were 
designed and cloned into vectors with different fusion tags (His6, GST and MBP) for 
expression. The expression conditions for the fragments conditions were optimized, 
and various attempts including purification with MBP tag, co-expression with E2 and 
addition of 2M urea were employed for purification. However, aggregation was still 
an unsolved problem during the purification. 
To conclude, various experiments for characterization of the PIAS family 
were performed including overexpression of the GFP-PIAS fusion proteins by 
xii 
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transfection and deletion analyses. The results provide insight for understanding the 













直至現在，最少有五個人類的P I A S成員被發現，它們分別是 
P I A S 1 � P I A S 3 � P I A S x a � P I A S x p 和 PIASy。它們都共同有兩個保 
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Chapter I Introduction 
Cdajyter i Introduction 
SUMO presenting Small Ubiquitin-like Modifier is highly conserved in the 
three dimensional structure and conjugation pathway of ubiquitin. It is involved in 
many cellular activities. Both the ubiquitination and sumoylation pathways, the three 
dimensional structures of SUMO and ubiquitin and their biological functions would 
be discussed and compared in this chapter. One class of the sumoylation E3 ligases, 
PIAS (Protein Inhibitors of Activated STATs)，would be discussed in depth to show 
how important they are. 
LI V.6iquitmation 
1.1.1 Ubiquitin 
Ubiquitin is a small protein encodes 76 amino acid residues with a homology 
of over 96 percent, is highly conserved from yeast to human (Fig. 1.1). Not only is 
the amino acid sequence well conserved during evolution, but also the tertiary 
structure as well [Vijay-Kumar et al, 1987b]. Ubiquitin forms a highly packed 
structure that consists of three and one-half turns of a helix, five strands of p sheet 
and seven reverse turns, while the C-terminal region is unstructured that protrudes 
out for conjugation [Vijay-Kumar et al, 1987a]. Such rigid structure may protect the 
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ubiquitin from degradation during protease cleavage of the conjugated substrate for 
recycling. 
Hono HQ IFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGI PPtiQQRLIFA^LEDGRTLSL"YH bO 
Kus MO I FVtTLTGCT I TLEVEPSDT IENVKAKIODPIGIPPCCQRLIFAC I：' JLEDGRTLSDYK iO 
Rattus MQI FVKTLTGKT I TLEVEPSDT IEHVKAKIQDKEGIPPDQQRLIFAG i：' )LEDGRTLSEiYH 60 
Xenopus HO IFVKTLTGCTITLEVEPSITI ENVKiKIQDJIG IPPDOQRLIFAC。)LEDGF,TLSL'YH i 0 
Drosophila MQ IFVVCTLTGKTI TLEVEPSDT IENV K J^KIQDKEG IPPDQQRLIF AC K JLEDGR.TLSDYH feO 
Saccharonyces MOIFYirrLTGJO-ITLEVESSDTIDHVKSKIODPrEGIPPDOQRLIFAC !: (LEDGRTLSE'YH iO 
HOMO IQKESTLHLVLRU糊 76 
Mus I 0 K E S T L H L V 1 R L _ 76 
Rattus I W E S T L H L V L R L糊 76 
Xenopus IQKESTLHLVIRLF% 76 
Drosophila IQKESTLHLVLRLi’ SG 76 
Saccharonyces IQKESTIHLTIRLFg 76 
Fig. 1.1 Sequence alignment of ubiquitin from human (acc no.: P62988), mouse (acc no.: 
P62991), rat (acc no.: NP一620250), xenopus (acc no.: P62972), drosophila (acc no.: P68198) and 
yeast (acc no.: P61864). It was generated from ClustalW provided by www.embl.org. The Lys-48 and 
the GlyGly motif essential for polyubiquitin chain formation and conjugation are boxed. 
Each ubiquitin contains two glycine residues at the C-terminal to form a 
GlyGly motif (Fig. 1.1) for conjugation. The last glycine covalently bonds with the 
8-amino group of the lysine of the target substrate [Monia et al, 1990]. Although one 
ubiquitin includes seven lysine residues, only the Lys-48 is a fundamental lysine for 
polyubiquitin chain formation signaling the degradative process [Chau et al, 1989]. 
Lys-48 resembles the lysine in a protein substrate that ligates with the glycine of the 
next ubiquitin in the repeating ubiquitination. Another lysine, Lys-63 has also been 
identified as participating in the formation of polyubiquitin; however, such 
multiubiquitin chain is generally shorter and involves in other cellular activities 
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rather than subjecting the modified protein to degradation [Spence et al, 1995; 
Hofmann & Pickart，1999]. For other lysine residues, Lys-6, Lys-11, Lys-27, Lys-29 
and Lys-33 have been discovered as being involved in the formation of 
multiubiquitin chain in vivo [Peng et al, 2003], but the function of these 
polyubiquitin chains is still unknown. 
1.1.2 Ubiquitination Pathway 
Ubiquitination is a process that covalently conjugates the ubiquitin to the 
target protein. The process involves El (ubiquitin-activating enzyme), E2 
(ubiquitin-conjugating enzyme) and E3 (ubiquitin protein ligase). Then the 
ubiquitinated protein is broken down by 26S proteasome while the ubiquitin is 
regenerated for the next ligation [Hochstrasser, 1996]. 
” Ubiquitin is firstly activated and forms a high energy thioester bond is formed 
at its C-terminal carboxyl-group with the cysteine residue of E l , the process requires 
hydrolysis of ATP and the ubiquitin is adenylated [Ciechanover et al, 1982; Hass et 
al, 1982]. Then the activated ubiquitin is transferred from El to E2 transiently and 
forms a thioester bond with E2 similar to that of El [Haas et al, 1988a; Haas et al, 
1988b]. In most cases, E3 is required for the transfer of ubiquitin from E2 to a target 
substrate. E3 is usually considered as providing substrate specificity; it is the key 
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component for the determination of which protein would be ubiquitinated (Fig. 1.2). 
I , 0 � ” I 
广 Substrate \ 
26S proteasome ^ 
^ � \ / a < S ) 
I Ub Precursor \ / 
A J © 
U&Sl 
Fig. 1.2 The schematic diagram of the ubiquitination pathway. Ubiquitin is firstly expressed 
as a precursor form which is matured by proteolysis. It is then activated by El in an ATP-dependent 
manner. The activated ubiquitin is transferred to E2 and then ligated to the target substrate with the 
help of E3. Modified from a review written by Schwartz and Hochstrasser, 2003. 
‘ There are two large groups of E3 ligases, HECT (Homologous to the E6-AP 
Carboxyl lerminus) [Huibregtse et cd, 1995] and RING (Really Interesting New 
Gene) finger containing [Lorick et al, 1999]. They transfer ubiquitin from E2 in 
different ways but both types of E3 ligases interact with E2 physically [Nuber et al, 
1996; Kumar et al, 1997; Huang et al, 1999; Moynihan et al, 1999; Yokouchi et al, 
1999; Zheng et al, 2000] . HECT comprises a strictly conserved cysteine residue for 
the formation of intermediate thioester bond with ubiquitin from E2 prior to the 
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transfer [Scheffner et al, 1995]. The HECT containing E3-ubiquitin then interacts 
with the substrate and transfers the ubiquitin to it. For the RING consisting E3 
ligases, they simply act as an adapter to bring the E2-ubiquitin and the target 
substrate together, then the E2 transfer the ubiquitin to the target substrate directly 
[Seol et al, 1999]. Polyubiquitin chain is constructed by repeating the conjugation of 
a ubiquitin to the previous ubiquitin. 
Usually, the polyubiquitin chain on the substrate is'recognized by one of the 
subunits of the 26S proteasome complex, subunit 5, for the degradation [Deveraux et 
al, 1994]. Different subunits of the 26S proteasome play different roles, some of 
them are involved in the release and regeneration of ubiquitin from the 
ubiquitin-substrate remnant [Eytan et al, 1993; Papa & Hochstrasser, 1993], while 
some of them are responsible for the degradation of the protein substrate [Verma et al, 
. 2002]. Thus, the protein substrate is finally digested while the ubiquitin is 
regenerated as free form for the next conjugation reaction (Fig. 1.2). 
1.1.3 Functions of Ubiquitination 
Ubiquitination is one of the post-translational modifications that plays an 
important role in many cellular biological activities including cell cycle regulation, 
signal transduction and gene expression control at both transcriptional and 
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translational levels [Galcheva-Gargova et al, 1995; King, et al, 1995; Conaway et al, 
2002; Sasaki et al, 2003]，etc. However, the knowledge about the signal involved in 
ubiquitination is limited. The PEST enriches in proline (P), glutamic acid (E), serine 
(S) and theronine (T) [Rogers, et al, 1986] has been documented as the consensus 
phosphorylation site and triggering ubiquitination [Marchal et al, 2002; Spencer et al, 
2004]. 
The best characterized ubiquitination signal is the N-end rule, which has been 
suggested that as an element, comprising of a destabilized amino acid and lysine 
residue, determines the stability of the protein [Bachmair et al, 1986; Bachmair & 
Varshavsky, 1989; Johnson et al, 1990]. One of the ubiquitin E2 has been confirmed 
as an interacting partner of the recognition component of the N-end rule pathway 
[Dohmen et al, 1991]. Destruction box is another ubiquitination signal which is 
‘ commonly found in cyclins and cell-cycle regulators, such as cyclin A and cyclin B 
[Sudakin et al, 1995; King et al, 1996]. The destruction box is usually present at the 
N-terminal of the protein. Mutation that occurs inside the destruction box would 
cause the accumulation of these cyclins and the cell cycle is arrested. In some cases, 
phosphorylation at a specific site of a target substrate is prerequisite before 
ubiquitination, e. g. the G1 regulators, cyclin D1 [Diehl et al, 1997] and cyclin E 
[Won & Reed, 1996]. The ubiquitination-mediated degradation would then be 
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prevented by mutating the phosphorylation site and the cell would become quiescent. 
Ubiquitination also involves in signal transduction, e.g. signal transducing 
receptors including estrogen receptor [Tateishi et al, 2004] and EGF receptor 
[Grovdal et al, 2004]. However, the ligand binding induces distinct effects to them, 
for estrogen receptor, binding of ligand stabilizes the receptor and prevents it from 
ubiquitin-proteasome degradation while in EGF receptor, the binding of EGF 
provokes the breakdown of this receptor, this demonstrates that ubiquitination is 
required for signal transduction but in a different manner. 
Moreover, transcription is highly regulated by ubiquitination, p53 
[Ciechanover et al, 1991; Maki et al, 1996] and c-Jun [Nateri et al, 2004] are the two 
well known examples. In c-Jun, the presence of the 5 domain at the N-terminal 
renders it to be ubiquitination sensitive [Treier et al, 1994], while phosphorylation 
. h a s a dual effect on the induction of ubiquitination-proteasome degradation [Fuchs et 
al, 1996]. This shows that phosphorylation does not always trigger ubiquitination; it 
sometimes produces an adverse effect. p53 not only includes a PEST element at the 
N-terminal, the C-terminal is also involved in the ubiquitin-mediated degradation, 
since both N- and C-terminal are necessary for the E3 ligase, Mdm2, interaction [Gu 
et al, 2000; Rodriquez et al, 2000]. The sequences fundamental for ubiquitination in 
c-Jun and p53 indicate that some other signal sequences for ubiquitination still have 
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not been identified, 
Ubiquitination has also been reported to be related to other cellular activities; 
e.g. degradation of misfolded proteins [Yoshida et al, 2005], ubiquitination targets 
the misfolded proteins to degradation in order to prevent their accumulation of and 
help the regeneration of the functional protein from the non-functional one. Another 
example is endocytosis of plasma membrane receptor; in this case, ubiquitin 
targeting is a signal for internalization of the receptor but not for degradation [Hicke 
& Riezman，1996]. These discoveries suggest that the identification of ubiquitin 
related function still has room to expand. 
1.1.4 Ubiquitin Like Proteins 
In recent years, some ubiquitin-like modifiers (UBL) have been discovered; 
. t h e y include Small Ubiquitin-like Modifier (SUMO), Nerual precursor cell 
Expressed Developmentally Downregulated gene 8/Related to UBiquitin 
i (NEDD8/Rubl) , Ubiquitin Cross-Reactive Protein/IFN-Stimulated Gene \5 
(UCRP/ISG15), Free UBiquitin (Fub), AutoPhaGy 12 (Apgl2) and Ubiquitin 
Related Modifier i (Urml) [Hochstrasser, 2000; Kim et al, 2002]. They share the 
conjugation mechanism of ubiquitin but the fate of the target protein is not merely 
degradation, they covers a wide range of functions, such as providing the surface for 
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protein-protein interaction and subcellular targeting, etc. Among these UBLs, SUMO 
has been the most intensively characterized. 
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L2 SUMO Trotevns 
1.2.1 SUMO Isoforms 
Small Ubiquitin-like MOdifier (SUMO) is one of the better studied 
ubiquitin-like modifiers (UBL). Although ubiquitin has been studied for several 
decades, the study of SUMO has been started for several years. SUMO is a small 
protein that is encoded by around 100 amino acid residues and was first identified in 
S. cerevisiae [Meluh & Koshland，1995]. 
In yeast and other lower eukaryotes, only one SUMO gene has been found 
while in plants, there are nine SUMO encoding genes but only four of them have 
been confirmed to be expressed in cells [Kurepa et al, 2003]. In human, there are at 
least eight SUMO-1 pseudogenes and 23 SUMO-2 pseudogenes [Su & Li, 2002], 
and only four SUMO isoforms are expressed in cells; they are SUMO-l, SUMO-2, 
• SUMO-3 and SUMO-4 [Okura et cd, 1996; Lapenta et al, 1997; Kamitani et al, 1998; 
Bohren et al, 2004]. 
By multiple sequence alignment, the similarities between these SUMO 
proteins were found; SUMO-1 is around 50 percent identical to SUMO-2 and 
SUMO-3 while there is 95 percent identity between SUMO-2 and SUMO-3. Besides, 
SUMO-4 shares about 85 percent identity with SUMO-2 and 82 percent identity with 
SUMO-3 (Fig. 1.3). 
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Sumo-2 MADE-KP-KEGVKTENN-DHIHLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMR 5 6 
Sumo-3 MSEE~KP-KEGVKTEN~DHIHLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMR 5 5 
Sumo-4 MANE~KP-TEEVKTENN-NHIHLKVAGQDGSVVQFKIKRQTPLSKLMKAYCEPRGLSVK 56 
Sumo-1 MSDQEAKPSTEDLGDKKEGEYIKLKVIGQDSSEIHFKVKMTTHLKKLKESYCQRQGVPMH 60 
» : ： * * , * : : : * : « • • * * * . * : : » * ： * « • « * ： ： » • ： : » : . : . 
Sumo-2 QIRFRFDGQPIHETDTPAQLEMEDEDTIDVFQQQTGG VY 95 
Sumo-3 QIRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGGVPESSLAGHSF 103 
Sumo-4 QIRFRFGGQPISGTDKPAQLEMEDEDTIDVFQQPTGGVY 95 
Sumo-1 SLRFLFEGQRIADNHTPKELGMEEEDVIEVYQEQTGGHSTV 101 
: * * N * . » ： * » » : » * . * : * : » : * » * 
Fig. 1.3 Sequence alignment between the human S U M O isoforms. The accession numbers o f 
SUMO-1, SUMO-2, SUMO-3 and S U M O - 4 are AAC50996 , AAH71645 , A A H 0 0 0 3 6 and A A R 0 4 4 8 4 
respectively. It is generated from ClustalW provided by www.embl.org. 
1.2.2 SUMO Structure 
SUMO is similar to ubiquitin in its secondary structure and tertiary structure 
but not in its amino acid sequence, which share only about 18% identity. In both 
SUMO-1 and ubiquitin, their secondary structures have p p a p p a p ubiquitin-fold; 
they are highly conserved in their tertiary structure as well (Fig. 1.4). The only 
difference is the presence of an extra N-terminal extension in SUMO-1 [Bayer et al, 
1998; Jin et al, 2001; Sheng et al, 2002], which is very flexible and strongly charged. 
At the C-terminals of SUMO and ubiquitin, GlyGly motif is exposed for conjugation 
to the substrates. 
The structures of SUMO-2 and SUMO-3 have been solved recently. It is not 
surprising that they have ubiquitin folds superimposing with SUMO-1 [Huang et al, 
2004; Ding et al, 2005], and contain a flexible N-terminal tail. Although the exact 
structure of SUMO-4 has not been solved yet, due to the high homology between the 
amino acid sequences of SUMO-2/3 to SUMO-4, it is likely that SUMO-4 has a high 
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possibility of having the similar structure. 
Fig. 1.4 The structures of SUMO-1 and ubiquitin. They share the similar ubiquitin fold. The 
N-terminal extension of SUMO-1 is highlighted in the orange box. The structural images were 
generated by RasMol, the PDB ID of SUMO-1 is 1A5R while that of ubiquitin is 1D3Z. 
In order to maintain the hydrophobic core in both SUMO and ubiquitin, some 
hydrophobic residues in p strands and the a l helix are highly conserved in the 
proteins, thus the helix and the sheets could interact properly [Bayer et al, 1998; 
Ding et al’ 2005]. Nevertheless, the charge topologies between these two proteins are 
distinct. The surfaces of SUMO-1, SUMO-2 and SUMO-3 are highly charged which 
display positively charged epitopes, a negatively charged surface and a negatively 
charged pocket; all of them are absent on the corresponding surface of the ubiquitin 
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[Bayer et al, 1998; Ding et al, 2005]. Between these SUMO proteins, there is a slight 
difference that SUMO-1 demonstrates a positive concave region near the C-terminal 
while it is neutral in SUMO-2 [Huang et al, 2004]. Such specific charge distribution 
may provide the substrate specificity to the SUMO isoforms. 
The surface of E2, Ubc9, responsible for the SUMO binding is mainly 
positively charged [Giraud et al, 1998] while the surface charge distribution of 
SUMO is mainly negatively charged but it is positive in ubiquitin, this reveals that 
Ubc9 would only bind to SUMO. Also, the specific charge distribution of SUMO 
implies that SUMO may interact with proteins which may not interact with ubiquitin, 
and that is why SUMO recruits different enzymes for conjugation but does not 
employ those for ubiquitin. 
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L3 SumoyCation 
1.3.1 Functions of Sumoylation 
Although the sequences between these SUMO homologues are very similar, 
they show diverse effects in cellular proteins. SUMO-1 is mostly found in a 
conjugated form while SUMO-2 and SUMO-3 are mainly found in a free form under 
normal conditions but the conjugation would be induced by stress conditions such as 
heat shock [Saitoh & Hinchey, 2000]. The substrate specificity of SUMO-4 is not 
known but the single nucleotide polymorphism in SUMO-4 has been found to be 
related to type I diabetes [Bohren et al, 2004] and it may be act through the N F K B 
signaling pathway [Guo et al, 2004]. 
In general, sumoylation happens in other tissues because most of the 
substrates are for the maintenance of the universal functions of the various cells 
-including cell division, cell signaling and gene expression control, etc. In this study, 
it is found that one class of E3 ligase, PIAS, genes are relatively highly expressed 
testis，liver and pancreas while many studies have been focused on the relationship 
between testis and sumoylation, we moved onto another tissue. Liver is our target 
organ because the number of sumoylated substrates is comparatively small although 
liver is such a huge multifunctional organ. Only a few sumoylated substrates relating 
to the normal functioning, e.g. bile production and transportation [Janka et al, 2005; 
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Lee et al, 2005], of liver have been identified, which comprise a small proportion of 
the total identified substrates. Also, liver cancer is induced by differential expression 
of genes in transcription or translation level, those related to hepatocellular 
carcinoma and sumoylation are just a few, we then hope to find out more through this 
study. 
1.3.1.1 General Functions of Sumoylation 
As mentioned, similar to many post-translational modifications including 
ubiquitination, sumoylation is involved in many cellular activities by targeting to a 
wide variety of substrates which take part in genome structure maintenance, 
transcription regulation, nuclear bodies recruitment and signal transduction, etc 
(Fig. 1.5) [Minty et al, 2000; Hoege et al, 2002; Lin et al, 2003]. Although the sumo 
• substrates could be categorized into different groups, most of them have the same 
property that they are located at the nucleus. Therefore, one of the functions of 
sumoylation has been suggested as nucleus trafficking [Endter et al, 2001; Joseph et 
al, 2002; Kotaja et al, 2002]. 
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Sumoylated 
Substrates 
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CREB " T U L V N / 
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y / (Seder & Dejean, 2003) 
Fig. 1.5 Categorization of some sumoylated substrates. Adapted from a review [Seder & 
Dejean, 2003]. 
With sumoylation, unlike ubiquitination, the modified protein (i.e. the SUMO 
tagged protein) is usually not degraded by the 26S proteasome; sumoylation 
sometimes protects the protein targeted by u b i q u i t i n a t i o n since both modifications 
require the same lysine residue for conjugation. Hence, they compete with each other 
or the rate/proportion of the particular proteins to be sumoylated or ubiquitinated are 
highly regulated; the sumoylated target is then unavailable for ubiquitination 
[Desterro e/ al, 2000; Stelter & Ulnch，2003]. Moreover, similar to other 
post-translational modification, sumoylated proteins contribute a binding interface 
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for their interacting partner to act on [Girdwood et al, 2003; Song et al, 2004]. Such 
interface could be provided directly by SUMO itself as some proteins contain SUMO 
interacting motif, \|;\|/XSXS/Taaa ( ' > " is a hydrophobic residue; "a" is an acidic 
residue and X is any amino acid residue) [Minty et al, 2000; Ahn et al, 2001; 
Engelhardt et al, 2003]. This may help to modulate the function of SUMO tagged 
proteins. 
1.3.1.2 Function of Sumoylation on Transcription Factors 
Since most of the SUMO substrates are transcription factors, the 
consequences of sumoylation on transcription factors have been studied in depth. 
Sumoylation give a more direct effect on their transactivation activity, either elevated 
or repressed after the SUMO conjugation [Gostissa et al, 1999; Rodriguez et al, 1999; 
Ross et al, 2002; Sachdev et al, 2001; Sapetschnig et al, 2002]. There are several 
proposals about the regulation of the transactivation activity, i) Sumoylation would 
cause the recruitment of transcription cofactors, activators, or even repressors to the 
transcription factors. This is suggested by the fact that some of the PIAS (E3) 
proteins associate with the repressors or activators which are located in the nuclear 
bodies, the interaction of PIAS to those sumoylated proteins would bring the SUMO 
tagged protein to this gene regulatory centre [Tussie-Luna et al, 2002; Long et al, 
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2003]. ii) The conformation of the SUMO tagged transcription factors may be 
changed for the assembly with the transcription complexes or co-repressor 
complexes [Long et al, 2004]. iii) Sumoylation may also change the DNA binding 
affinity of the transcription factors by masking their DNA binding motif [Ungureanu 
et al, 2005] or induction of conformational change favorable to DNA binding 
[Goodson et al, 2001; Hong et al’ 2002]. iv) Sumoylation modulates the subnuclear 
localization of the transcription factors in order to bring them to their specific 
subnuclear region, especially nuclear bodies, to carry out their functions [Ishov et al, 
1999; Zhong et al, 2000; Ross et al, 2002]. 
1.3.1.3 Specific Function of SUMO-2/3 Conjugation 
Sumoylation is also critical during stress conditions. It has been shown that 
stress conditions would elevate the percentage of SUMO-2/3 [Saitoh & Hinchey， 
2000] to be conjugated and the targets for conjugation would shift to some 
chaperones, antioxidants and DNA damage signaling proteins [Manza et al, 2004]. In 
vitro and in vivo studies illustrate the formation of SUMO-2/3 polymeric chain but 
not in SUMO-1 [Tatham et al, 2001; Vertegaal et al, 2004], while the crystal 
structure of SUMO-2 reveals the formation oftrimer as well [Huang et ah 2004]. The 
ability of polymeric chain formation in SUMO-2/3 is due to the presence of Lys-11 
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with sumoylation motif \|/KXE while the motif is not conserved in SUMO-1 [Tatham 
et al, 2001]. Concluding these two definite features of SUMO isoforms, it is 
suggested that each SUMO has its specific substrates and the conjugation pattern is 
regulated at different cellular conditions, e.g. stress or defined stages of cell cycle. 
Identification of SUMO-2/3 substrates would provide more insight to the 
significance of the conjugation. 
1.3.2 Sumoylation Pathway 
In sumoylation, not only is the structure of SUMO highly similar to that of 
ubiquitin, but the conjugation pathways are also greatly conserved. Sumoylation 
pathway contains El (SUMO-activating enzyme), E2 (SUMO-conjugating enzyme) 
and E3 (SUMO-ligase). All the SUMO isoforms share the same conjugation pathway 
[Tatham et al, 2001; Tatham et al, 2003; Lois & Lima, 2005] 
Alike ubiquitination, SUMO is firstly expressed as a precursor form which 
requires SUMO-specific proteases to cleave the last several amino acid residues in 
order to expose the GlyGly motif at the C-terminal for the conjugation [Kim et al, 
2000; Mossessova & Lima, 2000; Zhang et cd, 2002]. The matured form of SUMO is 
then activated and forms a thiol ester bond with El in a ATP-dependent manner 
[Johnson et cd, 1997] (Fig. 1.5). Thereafter, the ubiquitin-like domain inside the El 
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recruits the E2 [Lois & Lima, 2005], Ubc9, and transfers the activated SUMO to the 
E2 by formation of a thiol ester bond between the cysteine residues on Ubc9, thus a 
E2-SUM0 complex results [Desterro et al, 1997] (Fig. 1.6). Finally, SUMO is 
transferred to the target substrate and ligated to the lysine residue of the sumoylation 
motif with the help of E3 [Johnson & Gupta, 2001; Takahashi et al, 2001a] (Fig. 1.6). 
The SUMO Pathway 
r ' s ^ M ^ G G r ' s U M O ^ ^ 
� ^ - 1 
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crsAEr:> 二二 s / 
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Fig. 1.6 The sumoylation pathway. "Ulp" represents SUMO-specific protease. Modified 
from a review [Schwartz & Hochstrasser，2003], 
There are several El and E2 in ubiquitination; however, only one El 
heterodimer is formed by the assembly of two subunits, SAEl and SAE2 [Johnson et 
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al, 1997; Desterro et al 1999]，and one E2，Ubc9, [Desterro et al, 1997] have been 
identified so far to be involved in the sumoylation pathway. 
The heterodimer of El is similar to the El monomer of ubiquitination; SAEl 
resembles the N-terminal part while SAE2 looks like the C-terminal part of ubiquitin 
El . Nonetheless, El for ubiquitination could not activate SUMO and vice versa, this 
is probably due to the C-terminal extension in SAE2 which is absent in ubiquitin El 
and some amino acid residues in SUMO isoforms are serving as specificity 
determinant for SUMO El , especially Gln94, Thr95, Gly96 and Gly97, which are 
involved in direct contacts with SAE2 [Lois & Lima, 2005]. 
Ubc9 is also specific for sumoylation. As mentioned before, the charge 
distributions of the interface between Ubc9 and SUMO isoforms play the key roles in 
the recognition [Giraud et al, 1998; Liu et al, 1999]. The positively charged region at 
the N-terminal of Ubc9 is believed to be the binding site for SUMO proteins; all 
SUMO isoforms show the same affinities to this region [Tatham et al, 2003]. In 
addition, Cys93 of Ubc9 is the site for thiol ester bond formation with SUMO 
molecules [Liu et al, 1999; Tatham et al, 2003]. The Cys93 nearing residues are 
suggested as distinguishing the sumoylation motif [Bernier-Villamor et al, 2002; Lin 
et al, 2002], thus Ubc9 may be also a part of substrate recognition. 
E3 in sumoylation is the most enigmatic when compared with El and E2. . 
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Least is known about the mechanism underlying the recognition of substrates, 
interaction with E2 and catalysis of SUMO transfer from E2 to substrate trough E3. 
The most update findings of E3 would be discussed in depth in the next section. 
» 
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1,4 X3 Ligases in SumoyCation 
1.4.1 Types and Functions of E3 Ligases 
There are at least three different types of human E3 ligases in sumoylation; 
they are Ran-Binding Protein (RanBP2) [Pichler et al, 2002], Polycomb Protein (Pc2) 
[Kagey et al, 2003] and Protein Inhibitors of Activated Stats (PIAS) [Johnson & 
Gupta, 2001; Takahashi et al, 2001b; Schmidt & Muller, 2002; Kotaja et al, 2002]. 
However, among the different types of SUMO E3 ligases, only the PIAS 
family has the most conserved structure compare with that of ubiquitination, 
classified as the RING type [Hochstrasser, 2001], whereas both RanBP2 and Pc2 
have been identified as neither HECT nor RING type [Pichler et al, 2004; Kagey et 
al, 2005]. It is then interesting to know how and why the RING domain is conserved 
from ubiquitination to carry out a different function. The mechanism of sumoylation 
and especially the role of E3 inside the sumoylation pathway of sumoylation 
becomes the topic of study with raising awareness. 
The general functions of E3 conferring to the sumoylation are strongly 
increasing the sumoylation rate [Johnson & Gupta, 2001; Kahyo et al, 2001; Kagey 
et al, 2003] and providing substrate specificity. Although there are several reports 
about the fact that El and E2 are the minimum components for in vitro sumoylation 
assays [Takahashi et al, 2003; Menica & de Lorenzo, 2004], the rate of sumoylation 
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is greatly facilitated by E3 in vitro and E3 is essential in vivo [Johnson & Gupta, 
2001]. 
The mechanism for the catalysis of SUMO conjugation from E2 to a target 
substrate is firstly predicted to be similar to that of ubiquitination; bringing the E2 
and substrate into close proximity. The structure of a complex consisting of RanBP2 
(E3), Ubc9-SUM0-1 complex and a substrate, RanGAPl, solved showed that 
RanBP2 binds with E2 and its substrate during catalysis [Reverter & Lima, 2005] 
while with another pair, E2 and Pc2, the mechanism underlying the catalysis is 
suggested to be more or less the same [Kagey et al, 2003; Kagey et al, 2005]. For 
PIAS, its mechanism has not been reported yet. 
Substrate specificity of the E3 ligases provided may be due to the presence of 
motifs essential for substrate binding. These motifs in RanBP2 [Pichler et al, 2004] 
and ？c,2 [Kagey et al, 2005] have been mapped while which motifs are involved in 
PIAS still have not been defined yet. 
1.4.2 Structure of PIAS 
u p to now, there are five PIAS members that have been identified, they are 
PIASl, PIAS3, PIASxa, PIASxp and PIASy while PIASxa and PIASxP are 
probably the different spliced products from PIASx gene [Chung et al, 1997; Liu et 
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al, 1998; Kotaja et al, 2000; Rodel et al, 2000; Shuai, 2000; Liu et al, 2001]，all the 
PIAS are very similar in that the only difference is the C-terminal region. The PIAS 
proteins are highly conserved especially with regard to the two key domains, SAP 
(SAF-A/B, Acinus，and PIAS) [Aravind & Koonin，2000] and SP-RING (Siz/PIAS 
RING) [Hochstrasser，2001] whereas the C-terminal is a hypervariable region that 
PIAS proteins showing the lowest degree of homology (Fig 1.7). 
PIASl -MADSAELKf；^  WSLRVSELQVLLGYAGRWKHGRKHELLTKALHLl KAGCSPAVQMKIKELYRRRFPQKIMTPADLS IPWVHSSP 
P1AS3 1 VMSFRVSELQVLlJiF^RMSGRKHELLAKALHL KSSCAPSVQMKIKELYRRRFPRKTLGPSDLS LLSLPPGT 
PIASX-Ot -MADFEELRW VSSFRVSELC!VL,^f^ P^sGRKHDLLMRALHL� KSGCSPAVQIJaRELYRRBYPRTLEGLSDLSTIKSSVFSLDGGS 
PIASx-p -MADFEELRW VSSFRVSELQVLlI^^^NKSGKKHDLLHBALHL KSGCSPAVQIKIRELYRRRYPRTLEGLSDLSTIKSSVFSLDGGS 
PIASy MAAELVEAKW VMSFRVSDLQMLLGFVGRSKSGLKHELVTP.ALQLl QFDCSPKLFKKIKELTETKYAKKNSEPAPQP HRPLDPLT 
PIASl MPATL SPSTIPQLTYDGHPASSPLLPVSLLGPKHELELPHLTSALHPVHPDIKLQKLPFYDLLDELIKPTSLASDNSQRFPETCF 
PIAS? SPVG SPGPLAPIP PTIiLAPGTLLGPKREVDMH-PPLP^?PVHPDVTMKPLPFyEVYGELIRPTTLASTSSQRrEEAHF 
PTRSx-u SPVSPDIAVAGIHSLPSTSVTPHSPSSPVGSVLLODTKPTrXMWPSPPIPPVHPDVQLKTJlPFTDVLDVLIKPTSLVQSSIQRFQEKFF 
PIASx-p SPVEPDLAVAGIfSLPSTSVTPHSPSSPVGSVIilQDTlCPTFEMOQPSPPIPPVHPDVQLKNLPFYDVLDVLIKPTSLVfJSSIQRFOEKrF 
PIASy MHSTYD RAGAVPRTPLAGPNIDYPVLYGKYLNGLG KLPAKTLKPEVRLVKLPFFNMLDSLLKPTELVP^JHNEKLQESPC 
PIASl AFALTPO^lVQQISSSMDIS-GTKCDrTVQVgLRFCLSETSCP-SEDHFPPNLCVKVNTKPCSLPGYLPPTKNGVEPKRPSRPINITSLVRL 




PIASl STTVPNTIVVSWTAEIGKNySMAVyLVKQLSSTVLLQRLRAKGIRNPDHSRALIKEKLTADPDSEIATTSLRVSL； :PLGKMRLTIPCRA 
PIAS3 SATVPNTIVVNWSSEFGHNYSLSVYLVRgLTAGTLLQKLRAKGIRNPDHSRALIKEKLTADPDSEVATTSLRVSU :PL丨样f^TVPCRA 
PIASx-a SSAVPNQISISWASEIGKKYSMSVYLVROLTSAMLLCRLKMKGrRNPDHSRALI>:iKLTADPDSEIATTSLRVSLr P^L^ MlfPCRA 
PIAS:<-p SSAVPWQTSISWASEIGKNySMSVYLVRQLTSAMLLQP.LKMKGIRNPDHSRALIKEKLTADPDSEIRTTSLRVSLf :PL?KM?LTIPCPJV 
PIASy SSAT-NRITVTWG-NYGKSYSVALYLVRQLTSSELLQRLKTIGVKHPEIiCKALVrJEKLRLDPDSEIATTGVRVSL； JPLVKMKLSVPCPA 
PIAS^  IiTCSHLgCFDATLYIQMNEKKPTWVCl VCDKKAPYEHLIDGLFMEILKYCTDCDEIC'FKSDEEEEEPSAKRTCPSLSPTSPLN-NKGIL 
PIAS3 LTCAH^SJDAiLj^MNEKKPTWTCl VCDKKAPYESLIDGLFMEILSSCSDCDEIQFMSDEEDLPPTKKHCSVTSAAIPALPGSKGVL 
PlASx-a VTCTnl^ j^ lQlMMEKKPTWICl VCDKKAAYESLILDGLFMEIL^IDCSDVDEIKFQSDEEEDPP-AKRKCIFMSETQSSP-TKGVL 
PiASx-p vtctel^ IdaalyTcmhekkptwici vcdkkaaveslildglfmkilndcsdvdeikfqsdeeedpp akrkcifmsetqssp-tkgvl 
PIASy ETCAHLQCFDAVFYLQMNEKKPTWMCI VCDKPAPYDQLIDGLLSKILSKCEDADEIEYLf^SMENGKPGADVVDLTLDSSSSSE 
PIASl SLPH'2ASPVSRTPSLPAVDTSYIfITSH'2DYRHPFHMTPMP——yDLQGLDFFPFLSGDKQHYNTSLLAAAAAAVSDDQDLIilSSKFrPy 





PTAS3 RGTPSHFLGPLAPTLGSSHCSRTPRPPPGRVSSIVAPGGRLREGHGGPLPSGP SLTGCKSDISLD 
PIASx-u WDINNELKLGTSSDTV^K? : 
PIASx-p --PPMFLDSLTSPLTASSTSVTTTSS-HESSTHVSSSSSRSETGVITSSGS 
Fig. 1.7 Multiple sequence alignment of human PIAS proteins. The accession numbers are 
NP—057250 for PIASl, NP_006090 for PIAS3，NP—775298 for PIASx-a, NP—004662 for PIASx-p 
and NP一056981 for PIASy. The alignment was generated from ClustalW provided by www.embl.org. 
SAP domain is a DNA-binding motif that appears not only in PIAS, but is 
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also commonly found in some scaffold attachment factors A and B, such as 
DNA-repair protein KU70 [Aravind & Koonin, 2000], and Acinus, which is a 
nuclear factor responsible for chromatin condensation during apoptosis [Sahara et al, 
1999]. This domain contains two amphiphatic helices that mainly bind to the A/T 
rich region of scaffold attachment regions of DNA [Kipp et al, 2000]. For PIAS, the 
SAP domain has also been defined as A/T rich DNA binding motif. Its tertiary 
structure in PIASl has been solved. It consists of four helixes while one end of the 
four-helix bundle may be the binding site for the minor groove of DNA [Okubo et al, 
2004]. Hence, for other PIAS proteins, the SAP domain may be also responsible for 
the DNA-binding. 
Another conserved domain is SP-RING which is a highly conserved 
zinc-binding motif being present in all PIAS proteins and it has been demonstrated as 
an essential domain for the ligase activity [Kahyo et al, 2001; Takahashi et al, 2001a; 
Kotaja et al, 2002; Schmidt & Muller, 2002]. It is also responsible for the binding of 
Ubc9, an E2 in sumoylation pathway, and some substrates. Besides the high degree 
of homology of SP-RING inside the PIAS proteins, it also shows some similarity 
with the RING finger containing E3 ligases of ubiquitination, such as Anaphase 
Promoting-Complex. Both RING domains are cysteine/histidine-rich [Hochstrasser, 
2001; Jackson, 2001]; the main difference between these two domains is that 
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SP-RING lacks the second and sixth cysteine residues when compared with that of 
ubiquitination [Schmidt & Muller, 2003]. However, up to now, its structure has not 
been solved yet. 
As mentioned, all the PIAS proteins have variable C-terminal regions. In 
yeast, it has been suggested as participating in localization signal for bud-neck 
targeting [Takahashi et al, 2003]; however, in human, it is involved in protein 
binding instead [Liao et al, 2000;，Jimenez-Lara et al, 2002.]. 
1.4.3 Function of PIAS 
PIAS not only takes part in the E3 ligase activity of sumoylation, but also 
participates in the signaling pathway. As designated, PIAS, protein inhibitors of 
activated STATs, inhibits the signaling molecules, STATs, of JAK-STAT pathway by 
direct interaction, but the fates of the STATs are different. STATl and STAT3 would 
be prevented from DNA association after the binding with PIASl and PIAS3 
respectively [Chung et al, 1997; Liao et al, 2000]. On the other hand, PIASx and 
PIASy also bind to their specific STAT molecules but they inhibit the STATs function 
not by reducing the DNA binding activity, but through facilitating binding with other 
inhibitors instead [Liu et al, 2001; Arora et al, 2003]. 
Moreover, PIAS proteins regulate the activity of other transcription factors 
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through manifold mechanisms including sumoylation-dependent or 
sumoylation-independent processes [Ohshima & Shimotohno，2003; Yang & 
Sharrocks, 2005]. 
Taken the functions of PIAS together, these proteins are involved in many 
cellular activities through sumoylation or sumoylation-independent pathway. The 
finding of PIAS function is still expanding. The multifunctional activity of PIAS 
raises the interest of investigating their structures, relating to their functions and 
exploring the unknown function and interacting partner or target substrate. 
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L5 Mms of Study 
The ultimate goals of this project are characterization of the roles played by 
PIAS proteins and their molecular basis in sumoylation as well as the relationship 
between sumoylation and the liver functions especially development of 
hepatocellular carcinoma by the following attempts: 
1. characterization of the expression level of the PIAS genes in different 
tissues by PCR screening of multiple human tissue cDNA panels, 
2. investigation of the subcellular localization of the SUMO pathway and 
mapping the regions responsible for the PIASl location by 
overexpression of EGFP fusions of the SUMO pathway components, 
3. identification of the SUMO-1 related proteins including identifying 
putative novel sumoylated substrates in normal and cancerous liver cell 
• lines by two dimensional electrophoresis and mass spectrometry, 
4. verification of the transcriptional and translational level of the 
upregulated proteins after overexpression of SUMO-1 by RT-PCR and 
western blotting respectively, 
5. and expression as well as purification of the PIAS proteins for the 
structural study and functional analyses. 
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Cfiaj)ter 2 ^ M ^ i t e r f a f & MetfiocCs 
2A ToCymerase Cfiain "Reaction (TCn) 
Screening of MuCtij>Ce J-Cuman Tissue 
cT>MA (M'TC'^) TaneC 
2.1.1 Primer Design 
The oligonucleotide primers were designed basing on the sequences of 
human PIASl, PIAS3, PIASxa, PIASxP and PIASy obtained from NCBI (National 
Center for Biotechnology Information, (http://www.ncbi.nih.gov/). They flanked the 
region around 500 base pair inside the PIAS genes with annealing temperature 70 to 
74 (Table 1). They were then synthesized by Proligo Singapore Pte Ltd (Helios, 
Singapore) and delivered in de-ionized water at a concentration of lOO^M as stock 
solution. The primers were diluted to 5|^M as working solution. 
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Gene Accession Primer sequence 
No. 
PIASl NP—057250 Forward 5 ' -CCCGCACCCCAAGCCCTTCCT - 3' 
R e v e r s e 5， - GGATGCCGTGTCCGTGCTGC - 3, 
NP一006090 Forward 5' - A C G C T G T T G G C C C C T G G C A C - 3, 
R e v e r s e 5 ' - GGGCTCGGCCCCATTCTTGG - 3, 
PIASxa NP—775298 Forward 5' - T G G T G T C C A A T G A G A C C G A A G A A A G 
A - 3， 
R e v e r s e 5 ’ - TGTTGCACAGTATCAGAAGATGTTC 
C A A G C - 3 , 
PIASxp NP_004662 Forward 5，- TGACTGTAGCCAGTGAGGCAAGC 
A - 3 ' 
R e v e r s e 5 ’ - CATGGGAGCTGGTGGTGGTGAC 
A - 3 ' 
P I A S y N P _ 0 5 6 9 8 1 Forward 5' - TCCGCTGGCAGGCCCCCAATA — 3 , ^ 
I  Reverse 5 , - TGATGCAATTGGTGGCCGAG - 3, 
Table 1 Primer sequences used for PGR screening of MTC Panel. 
2.1.2 Semi-quantitative PCR 
2.1.2.1 Human MTC™ Panel 
, H u m a n Multiple Tissue cDNA (MTC'^'^) panel I and II were purchased from 
BD Clontech (Palo Alto, CA, USA) and used as template for the PCR. One panel 
contained eight different human tissue cDNA (Table 2) and one control cDNA 
library which was composed of all human tissue cDNA. 
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P a n e l I I Testis 
, Ovary 
I Small Intestine 
Colon 
Peripheral Blood Leukocyte 
Table 2 The tissue cDNA components of each MTC panel. 
2.1.2.2 PGR 
• . 2^1 of each tissue cDNA was used as a template for one PGR. Hence, there 
were totally 16 PGR for 16 different tissues, one positive control by using control 
cDNA library and one negative control without template. PGR was performed with 
lOOnM of gene specific forward and reverse primers (Table 1)，200|aM dNTP 
(Invitorgen Life Technologies, Carlsbad, CA，USA), IX Taq PGR buffer (lOmM 
Tris-HCl pH9.0, 50mM KCl and 0.1% Triton® X-100), 2.5mM MgCb and 2.5 unit 
of Taq polymerase (Promega Biosciences, San Luis Obispo, CA, USA), autoclaved 
NanoPure water was used to add up the final reaction volume to 50p i The reaction 
mixture was then denatured at 95°C for 2 minutes, 36 to 44 cycles of 95 for 36 . 
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seconds, 55 X for 36 seconds and 72 for 30 seconds. The total number of cycles 
were optimized for each gene, and then followed with a final extension temperature 
of 72 for 10 minutes. 
For semi-quantitative purpose, lO^il of PGR product was extracted at specific 
cycles and mixed with 2\i\ of 6X loading dye (0.25% w/v bromophenol blae, 0.25% 
w/v xylene cyanol FF and 40% glycerol) immediately to stop the reaction. The PGR 
product of each PIAS gene was extracted at different cycles (Table 3) for intra-panel 
comparison. 
Gene I Cycle for extraction 
T I A ^ “ 2 t \ 3 ( f , 33rd and cycle ‘ 
" P I A ^ 32"', 36"\ 4 ( r and 44^" cycle 
" P I A ^ 27"\ 32"� , 37" and 4广 cycle 
PIASxp 28"\ 3 2 , 36"^  and cycle 
2 f \ 3 r \ and cycle 
Table 3 List of cycle extraction for each PIAS gene. 
. The extracted PGR product was analyzed by 1% TAE (40mM Tris base, 
ImM EDTA and 20mM acetic acid) ethidium bromide stained agarose gel. 
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2.2 CConing 
2.2.1 Amplification of El, E3 (PIAS), PIASl Fragments 
2.2.1.1 Primer Design 
The oligonucleotide primers were designed basing on the sequences of 
human El (Sael and Sae2), E3 (PIASl, PIAS3, PIASxa, PIASxP) obtained from 
NCBI (National Center for Biotechnology Information, http://www.ncbi.nih.gov/). 
The PIASl fragments were aimed at the amino acid sequences; 141 - 4 1 0 , 141 - 476, 
321 - 4 1 0 and 321 - 476, all included the ligase activity essential SP-RING domain. 
Primers flanked the cDNA sequences of the genes with annealing temperature 70 to 
74 Additional oligonucleotides, TAGGGC，were added to each 5,end of a primer 
as a clamp to facilitate the binding of restriction enzymes. Restriction site was also 
included in a primer following the 5' clamp for restriction digestion. A set of primers 
were then designed for cloning into different vectors (Table 4). They were 
synthesized by Invitrogen Life Technologies Inc. (Carlsbad, CA, USA) and delivered 
as lyophilized powder. The stock solution with the concentration of 100|aM was 
prepared by dissolving the powder in autoclaved NanoPure water. The primers were 
diluted to 5|LIM as the working solution. 
Gene || Accession 1  Primer Sequence Vector for 
No. Forward (F) / Reverse (R) Cloning 
F I  5' - TAGGGCGTCGACATGGTGGAG ~ ‘ 
A AGG AGG AGGCTG - 3 ’ pEGFP-C 1 
R 5' -TAGGGCGGATCCTCACTTGGGG 
CCAAGGCACTCC-3' 
34 
Chapter 2 Materials & Methods 
i ； ^ 1 I  F I  5，-TAGGGCAGATCTATGGCACTGT I 
C G C G G G G G C T G - 3， p E G F P - C l 
R 5 ' - T A G G G C G T C G A C T C A A T C T A A T I 
GCT ATG AC ATC ATC A A AG - 3, | 1 
F 5,-TAGGGCGAATTCATGGCGGAC pGEX-6P-l, 
AGTGCGGAACTAAA-3' pET-28m 
R 5 ' - T A G G G C G C G G C C G C T C A G T C C A 
A T G A A A T A A T G T C T G G T A T 一 3， | 
F 5，-T A G G G C A G A T C T A T G G C G G A C 
A G T G C G G A A C T A A A - 3 , J p E G F P - C l I 
R 5' - T A G G G C G T C G A C T C A G T C C A A T 
G A A ATA A T G T C T G G T A T - 3 ' | 
, IAS1 l ^ A 5 ' - T A G G G C G A A T T C T T A C C A T T T T 1 
r a g m e n t s A T G A T T T A C T G G A T G A A C - 3’ 
F 5 ' - T A G G G C G A A T T C A G T G A A A T A p G E X - 6 P - l , 
1 G C T A C A A C C A G C C T A A - 3 , pET-28m， 
R 5’-TAGGGCGTCGACTCAGCCATCC pMAL-c2P 
TCCTT A A ATTGT ATTTC AT — 3， | 
R 5' -TAGGGCGTCGACTCAGGCAGAT 
G G C T C T T C T T C C T C T T - 3 ' [ 
F 5’ 一 T A G G G C A G A T C T T T A C C A T T T T 
A T G A T T T A C T G G A T G A A C - 3 ’ | 
\ Y ~ \ 5 ‘ - T A G G G C AG A T C T A G T G A A ATA 
‘. I GCTACAACCAGCCTAA-3- pEGFP-Cl 
R 5'-TAGGGCGTCGACTCAGCCATCC I 
T C C T T A A A T T G T A T T T C A T - 3 , � 
R 5’ - TAGGGCGTCGACTCAGGCAGAT 
GGCTCTTCTTCCTCTT-3 ' j 
^ ^ “ F 5' -TAGGGCGAATTCATGGTGATGA 
GTTTCCGGGTGTCT-3' pGEX-6P-l, 
R 5' - TAGGGCGCGGCCGCTCAGTCCA pET-28m 
G G G A A A T G A T G T C T G A - 3， 
F 5，-TAGGGCAGATCTATGGTGATGA j 
GTTTCCGGGTGTCT-3' j | 
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R 5' -TAGGGCGTCGACTCAGTCCAGG pEGFP-Cl 
GAAATGATGTCTGA - 3’ 
p i A S x a 5，- TAGGGCGAATTCATGGCGGATT 
TCG A AG AGTTC AGG — 3， J pGEX-6P-1, 
~ 5' -TAGGGCGCGGCCGCTCACTGTT pET-28m 
GC AC AGTATC AG A AG A T - 3 ' 
F 5’ - TAGGGCAGATCTATGGCGGATT 
TCG A AG AGTTG AGG 一 3， pEGFP-C 1 
" R 5 ' -TAGGGCGTCGACTCACTGTTGC 
AC AGTATC AG A AG A T - 3 ' 
p i A S x p 5 , - T A G G G C G A A T T C A T G G C G G A T T ' ” 
TCG A AG AGTTC AGG - 3 ‘ pGEX-6P-1, 
5' -TAGGGCGCGGCCGCTTAGTCCA pET-28m 
IA T G A G A T G A T T T C A G G A A T - 3' 
5’-TAGGGCAGATCTATGGCGGATT 
TCG A AG AGTTG AGG - 3， pEGFP-C 1 
^ 5' -TAGGGCGTCGACTTAGTCCAAT 
I GAGATGATTTCAGGAAT - 3 ’ 
Table 4 Primers used for the cloning. 
2.2.1.2 PCR 
. P C R was set for each gene for cloning into the vector. One PCR contained 
lOOnM of each forward and reverse primers, 200|aM dNTP (Invitorgen Life 
Technologies, Carlsbad, CA, USA), IX Pfu reaction buffer (20mM Tris-HCl pH8.8, 
lOmM KCl, lOmM (NH4)2S04, 0.1% Triton® X-100 and 5|.ig nuclease-free BSA), 
1.5unit of Pfu polymerase (Promega Biosciences, San Luis Obispo, CA, USA), 0.5|al 
of Human Marathon liver cDNA library (Clontech Laboratories Inc., Palo, Alto, CA, 
USA) as template and autoclaved NanoPure water was used to add up the final 
volume to 50)il. For the amplification of Sael and Sae2 gene，0.5|.il of plasmid, 
Sae2-Sael-pGEX-4T-l (a kind gift from Prof. R. T. Hay), was used as template ‘ 
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instead. The reaction mixture was then denatured at 95''C for 2 minutes, 33 cycles of 
95 for 36 seconds, 55 for 36 seconds and 72 for 4 minutes followed with a 
final extension temperature of 72 for 20 minutes. 
The PGR product was mixed with 6X loading dye and then analyzed by 1% 
TAE ethidium bromide stained agarose gel. The DNA bands were visualized under 
UV illumination. 
2.2.1.3 Purification ofPCR Product 
The DNA band in the agarose gel was excised and then purified by using 
QIAquick Gel Extraction Kit (Qiagen Inc.，CA, USA), and the procedures as 
suggested by the manufacturer were followed. 
Three volumes of Buffer QG were added to one volume of the excised gel. 
The mixture was then incubated at 5 5 � � u n t i l the gel slice dissolved completely. One 
gel volume of isopropanol was added and mixed thoroughly. The gel solution was 
then applied to the spin column with collection tube which was provided by the kit 
and centrifuged for one minute at 13.4K rpm. The flow-through was discarded and 
the spin column was placed back to the collection tube again, addition of 750|al of 
Buffer PE was followed. It was centrifuged for one minute to remove the washing 
Buffer PE. The flow-through was also discarded, and then centrifuged for another 
one minute at 13.4K rpm to get rid of the residual buffer. The spin column was 
placed into a clean 1.5ml microcentrifuge tube. 30|^1 of elution buffer (EB) was 
added to the spin column and incubated for one minute at room temperature. Finally, 
DNA was eluted by centrifugation at 13.4K rpm for one minute. 
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2.2.2 Restriction Digestion 
The purified PGR product was used to carry out restriction digestion. The 
reaction mixture contained the purified PGR product, IX reaction buffer, specific 
restriction enzymes (Amersham Biosciences, Buckinghamshire, UK) for different 
combinations for corresponding genes and vectors (Table 5). In the mean time, a 
separate digestion reaction was carried out for the vector with similar composition 
but the PGR product was replaced by the vector used for cloning. The restriction 
digestion mixture was then incubated at 37�C for two hours. 
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I  Restriction 
Gene Vector Enzyme & Reaction Buffer & Content 
Unit 
Sail 8U 2X One- 20mM Tris-acetate (pH 7.5) 
Sael pEGFP-Cl BamHl ^ Phor-All 20mM Magnesium acetate 
lOOmM Potassium acetate 
Sae2 
Bglll 4U 
• p ^ 50mM Tris-HCl (pH 7.5) 
PIASl pEGFP-Cl H buffer lOmM MgCh 
fragments ImM Dithiothreitol 
" P I A ^ S a i l 8U lOOmMNaCl 
PIASxa 
PIASxp 
" P I A ^ ^ 50mM Tris-HCl (pH 7.5) 
P I A S 3 p G E X - 6 P - l H buffer lOmM MgCb 
PIASxa pET28m Not I 4U~ ImM Dithiothreitol 
PIASxp lOOmMNaCl 
pGEX-6P-l EcoRl ^ 50mM Tris-HCl (pH 7.5) 
fragments pET28m H buffer lOmM MgCli 
pMAL-c2P p ^ ^ ImM Dithiothreitol 
Il lOOmM NaCl 
Table 5 List of restriction enzymes and reaction buffers used for cloning different genes into 
various vectors. 
The digested PCR product and vector were added with 6X loading dye 
analyzed by 1% TAE ethidium bromide stained agarose gel and visualized under UV 
illumination. The DNA bands were excised for purification by using QIAquick Gel 
Extraction Kit (QIAGEN Inc., CA, USA). The procedures were the same as those 
listed in section 2.2.1.3. 
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2.2.3 Ligation 
The digested PCR product and vector were purified for ligation. The reaction 
was set up with lOng vector and 30ng insert (digested PCR product), IX ligation 
buffer (50mM Tris-HCl pH 7.5’ lOmM MgCb, ImM ATP, lOmM dithiothreitol 
(DTT), 25|.ig/ml BSA), 200 units of T4 DNA ligase (New England BioLabs Inc, 
Beverly, MA, USA) and autoclaved NanoPure water. Meanwhile, double cut control 
of vector was prepared by using autoclaved NanoPure water instead of insert. The 
ligation reaction was then incubated at 16°C for overnight. 
2.2.4 Transformation 
2.2.4.1 Preparation of Chemically Competent Cells (DH5a) 
The preparation was generally based on the Hanahan method [Hanahan, 
1983]. Glycerol stock of DH5a was streaked on a LB plate and then incubated at 
37°C for overnight. Single colony from the streaked culture was inoculated into 10ml 
of LB medium and incubated at 37 for overnight with shaking at 250rpm. 5ml 
overnight culture was sub-cultured into 500ml LB medium; it was then shaken at 
250rpm at 37 until the optical absorbance at wavelength 600nm reached 0.3 to 0.5. 
The bacterial cells were collected by centrifugation at 4 "^ C with 2500rpm for 10 
minutes. LB medium was discarded while the pellet was resuspended in one-third of 
the original volume, 167ml, of filter-sterile RFl (100 mM RbCl, 50 mM 
MnCl2-4H20, 30 mM potassium acetate, 10 mM CaCl2-2H20 and 15% glycerol [w/v], 
pH 5.8). The suspension was incubated on ice for 15 minutes. The cells were 
harvested again by centrifugation at 4 with 2500 rpm for 10 minutes. The 
supernatant was decanted and the pellet was resuspended in 1/12.5 volume of 
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original volume, 40ml，of filter-sterile RF2 (10 mM MOPS, 10 mM RbCl, 75 mM 
CaCl2-2H20 and 15% glycerol [w/v], pH 6.8). The suspension was incubated on ice 
for 15 minutes and then aliquoted into 200|al each. The aliquoted cells were quickly 
frozen in liquid nitrogen for storage at -80°C fridge. 
2.2.4.2 Transformation of Ligation Product 
Frozen competent DH5a was thawed on ice. Once the cells were thawed, the 
ligation product was added to the cells and mixed thoroughly. After that, the cells 
were incubated on ice for 15 minutes and then heat shocked at 42 for one minute. 
They were then incubated on ice again for one minute and recovered by addition of 
800^1 of LB medium and shaking at 250rpm at 37 oc for 45 minutes. 
The cells were harvested by centrifugation at 13.4K rpm for one minute. 
850|al of LB medium was removed while the residual medium was used to resuspend 
the pellet. The suspension was spread on an antibiotic added LB plate for selection. 
The choice of antibiotic was depended on the anti-biotic resistant gene of various 
vectors (Table 6). The spread LB plate was incubated at 37 for overnight. 
Vector Antibiotic Resistant Gene || Antibiotic Concentration in LB Plate 
pEGFP-Cl Kanamycin 30|ag/ml 
pGEX-6P-l Ampicillin 100|ig/ml 
pET28m Kanamycin 30|ig/ml 
pMAL-c2P Ampicillin lOOfig/ml 
Table 6 Table showing the antibiotic resistant genes in different vectors used and the 
concentration of antibiotic applied in LB plate for selection. 
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2.2.5 Plasmid Preparation 
Single colonies were inoculated into 3ml of LB medium with specific 
antibiotic and incubated at 3 7 � C for overnight with shaking at 250rpm. The cells 
from the overnight culture were harvested by centrifugation at 13.4K rpm for 10 
minutes while the medium was decanted. The plasmids inside the bacterial cells were 
extracted by means of the Rapid Plasmid Miniprep System (Marligne Biosciences 
Inc., MD, USA). The procedures were generally carried out according to the 
manufacturer's suggestions. 
The pellet of the harvested cells was completely resuspend in 250|il of G1 
Cell Suspension Buffer, then 250|^1 of G2 Cell Lysis solution was added and mixed 
gently by inverting the microcentrifuge tube for five times. The mixture was 
incubated at room temperature for five minutes. 350|al of M3 Neutralization Buffer 
was added and then mixed immediately. The cell debris was pelleted by 
centrifugation at 13.4Krpm for 10 minutes. The supernatant was applied to a spin 
cartridge which was provided from the kit and centrifuged at 13.4Krpm for one 
minute. The flow-through was discarded, and the spin cartridge was placed back to 
the collection tube. Then 500|al of GX Optional Wash Buffer was added to the 
cartridge. The buffer was passed through the column by centrifugation at 13.4Krpm 
for one minute. The flow-through was also decanted. Another Wash Buffer, G4，was 
applied to the spin cartridge in a volume of 750|^1 and then centrifuged for one 
minute at 13.4Krpm. The flow-through was discarded and the residual buffer was 
removed by centrifugation at 13.4K rpm for another one minute. The spin column 
was placed into a 1.5ml recovery tube (supplied from the kit) and then 100|il of TE 
Elution buffer which was pre-warmed to 70 was applied to the cartridge. It was 
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incubated at room temperature for one minute. Plasmids were eluted by 
centrifugation at 13.4Krpm for two minutes. 
2.2.6 Screening for Recombinant Clones 
The presence of insert inside the purified plasmids was confirmed by 
restriction digestion. Restriction digestion was set up with l^ig of plasmid, restriction 
digestion buffer specific for each enzyme pair listed in section 2.2.2, corresponding 
restriction enzyme pairs used for cloning and autoclaved NanoPure water, the final 
volume was added up to 20|al. The reaction mixture was incubated at 37 X for two 
hours. The mixture was then analyzed by 1% TAE ethidium bromide stained agarose 
gel and visualized under UV illumination. 
2.2.7 Sequencing of Recombinant Plasmid 
Sequencing of recombinant plasmid was carried out by Tech Dragon Ltd 
(Shatin, N.T., Hong Kong). l|ag of plasmid was used for one sequencing reaction and 
- p r i m e r s used for sequencing were listed as follows (Table 7). 
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Vector f o r “ Primer Name Primer Sequence 
Cloning 
pEGFP-Cl pEGFP-Cl F 5' - CRTGGTCCTGCTGGAGTTCGT - 3， 
pEGFP-Cl R 5’ - TCATTTTATGTTTCAGGTTCAGGG - 3’ 
pGEX-6P-l pGEXF 5’ - GGGCTGGCAAGCCACGTTTGGTG - 3， 
pGEXR 5' - GATCTGCCTCGCGCGTTTCGGTG - 3 ， ^ 
pET28m T 7 F 5' -TAATACGACTCACTATAGGG-3 ' 
T7 terminator R 5 ' - GCTRGTTATTGCTCAGCGG - 3’ 
p M A L - c 2 P M A L E F 5' - GGTCGTCAGACTGTCGATGAAGCC - 3' 
M 1 3 p - M A L R 5 ， - CGCCAGGGTTTTCCCAGTCACGAC - 3’ 
Table 7 List of sequencing primers with corresponding cloning vectors. 
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2.3 SuBceCCuCar LocaCization Study 
2.3.1 Midi Scale Plasmid Preparation 
Before studying subcellular localization of the sumoylation components; El 
(Sael & Sae2), E2 (Ubc9), E3 (PIASl, PIAS3, PIASxa, PIASxp, PIASl fragments 
including amino acid 141 - 410, 141 - 476, 321 一 410 & 321 - 476) & SUMO-1， 
plasmids with these genes cloned into pEGFP-Cl were prepared in midi scale for 
lipofectAMINE based transfection. 
The recombinant plasmids were firstly transformed into chemically 
competent DH5a prepared as described previously. A single colony was selected for 
inoculation into 150ml of LB medium with 30|dg/ml ofkanamycin. The medium was 
incubated at 37�C for overnight with shaking 250rpm. The bacterial cells were then 
harvested by centrifugation for 6000 x g for 10 minutes at 4 The high purity 
plasmids were then extracted by using HiSpeed™ Plasmid Midi Kit (QIAGEN Inc., 
CA, USA). The protocol was accorded to the manufacturer's suggestion. 
After centrifugation for cell harvesting, the medium was decanted while the 
pellet was resuspended in 6ml of PI Buffer. 6ml of Buffer P2 was added to the 
suspension and then mixed gently and thoroughly by inverting 4 - 6 times, it was 
then incubated at room temperature for five minutes. After that, 6ml of Buffer P3 
was applied to the suspension and also mixed by inverting the tube 4 - 6 times. The 
suspended lysate was poured into the barrel of the QIAfilter cartridge and incubated 
at room temperature for 10 minutes. In the meantime, the HiSpeed Tip was 
equilibrated by applying 4ml of QBT Buffer and being allowed to empty by gravity 
flow. The cap of the QIAfilter outlet nozzle was removed and the plunger was 
inserted gently to filter the cell lysate into the previously equilibrated HiSpeed Tip. • 
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After the HiSpeed Tip was emptied by gravity flow, it was then washed by 20ml of 
QC Buffer. DNA was then eluted by 5ml of QF Buffer; 3.5ml of isopropanol was 
added to precipitate the DNA. The eluate/isopropanol mixture was incubated at room 
temperature for overnight. The mixture was then transferred into a 20ml syringe with 
QIAprecipitator Midi Module attached at the outlet nozzle; it was filtered trough the 
QIAprecipitator by application of a plunger with constant pressure. The 
QIAprecipitator from the 20ml syringe was removed and the plunger was pulled out. 
The QIAprecipitator was attached again and the plunger was inserted to dry the 
membrane by pressing air through the QIAprecipitator quickly, this step was 
repeated to dry the membrane completely. The outlet nozzle of the QIAprecipitator 
was dried by the absorption of absorbent paper. The QIAprecipitator was then 
reattached to a new 5ml syringe outlet nozzle. 300|j.l of TE Buffer was added to the 
5ml syringe and then the plunger was inserted to elute the bound DNA from the 
QIAprecipitator to a 1.5ml microcentrifuge tube. 
The DNA concentration was measured by absorbance at wavelength 260nm. 
It was then calculated by multiplying the DNA coefficient 50|ig/ml and dilution 
factor., 
2.3.2 Transfection of GFP Recombinant Plasmids 
2.3.2.1 Cell Culture ofWRL-68 & HepG2 Cell Lines 
Both WRL-68 and HepG2 were cultured in RPMI 1640 medium (Gibco BRL 
Life Technologies Inc., Carlsbad, CA, USA) supplemented with 10% Fetal Bovine 
Serum (FBS) (Gibco BRL Life Technologies Inc., Carlsbad, CA, USA) and 1% 
Penicillin-Streptomycin (PS) mixture (Gibco BRL Life Technologies Inc., Carlsbad, 
CA，USA). They were allowed to grow at 37�C with 5% CO2 concentration. 
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2.3.2.2 LipofectAMINE Based Transfection 
Before the day of transfection, cells (WRL-68 or HepG2) were seeded with 
50% confluence into a 6-well plate containing a sterile cover slip in each well. The 
recombinant pEGFP-Cl plasmids were transfected by using LipofectAMINE 
PLUS™ reagent (Invitrogen Life Technologies Inc., Carlsbad, CA, USA). The 
amount of reagent used and the procedures suggested by the manufacturer were 
followed.. 
Ijag of recombinant pEGFP-Cl plasmid was pre-mixed with 6\i\ of PLUS 
reagent in lOO i^l of serum-free RPMI medium and then incubated at room 
temperature for 15 minutes. In the meanwhile, of lipofectAMINE was diluted in 
another 100|il of serum-free RPMI medium. After the incubation, the 
lipofectAMINE/RPMI mixture was added to the pre-mixed PLUS/DNA mixture and 
also incubated at room temperature for 15 minutes. During the incubation, the 
medium of the cells were decanted and they were washed by PBS twice to remove 
any remaining serum. Then 800|al of serum-free RPMI was added to the cells. 
Finally the DNA-lipofectAMINE-PLUS reagent complexes were added to each well. 
The cells were then incubated at 37 with 5% CO2 concentration again for three 
hours. After three hours incubation, the serum-free RPMI medium was replaced by 
1ml of serum containing RPMI medium. The cells were then allowed to grow at 
37°C with 50/0 CO2. 
One well was occupied by one type of recombinant pEGFP-Cl plasmid. For 
the control, an empty pEGFP-Cl plasmid was used instead of the recombinant 
plasmids. 
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2.3.3 Immunostaining of Endogenous SUMO-1 & -2/3 
24 hours after transfection, the cells were washed by Phosphate-Buffer Saline 
(PBS) (137mM NaCl, 2.7mM KCl, lOmM NazHPCU, 1 . 8 m M K H 2 P O 4 ) for three 
times to remove any residual medium. The cells were then fixed by 3.7% Para-
formaldehyde which was diluted by PBS for 10 minutes at room temperature. Para-
formaldehyde was decanted and the cells were washed by PBS for three times. The 
cells were then permeabilized by 0.2% Triton® X-100 in PBS for one minute; they 
were then washed by PBS for three times. After the permeabilization, the cells were 
incubated with 1% Bovine Serum Albumin (BSA) in PBS for 30 minutes and then 
rabbit anti-SUMO-1 or goat anti-SUMO-2/3 antibody (Santa Cruz Biotechnology 
Inc., California, USA) was added in a dilution of 1:50. The cells were allowed to 
bind with the antibody for overnight by incubating at 4°C. The cells were then 
washed by PBS for three times. 1% of BSA in PBS was added to the cells and 
incubated for 30 minutes at room temperature. Secondary antibody, anti-rabbit 
conjugated with Cy3 for anti-SUMO-1 while anti-goat conjugated with Cy3 for anti-
SUMO-2/3 (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) 
with a 'dilution of 1:1000 was added to the cells and incubated for two hours at room 
temperature. The secondary antibody containing BSA was removed and the cells 
were washed with PBS for three times. 
2.3.4 Nucleus Staining by DAPI 
The nuclei of the immunostained cells were stained by 4'6-diamidino-2-
phenylindole, dihydrochloride (DAPI) (Molecular Probes Inc., Eugene, USA). 
300nM of DAPI was added to the cells and incubated for 30 minutes at room 
temperature. PBS was used to wash the cells thoroughly for three times and the cover 
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slips were mounted onto glass microscope slides with the help of mowiol (22% w/v 
of Mowiol & 11% v/v of glycerol). The glass slides were wrapped by aluminum foil 
and allowed to dry at room temperature. The images were then visualized under 
fluorescent microscopy. 
2.3.5 Fluorescent Microscopic Visualization 
The mounted glass slide was visualized by using Eclipse TE2000U (Nikon 
Inc., Melville, NY, USA). The images were captured by the attached digital camera, 
while they were edited with the help of software SPOT™ version 4.0 (Diagnostic 
Instruments, Sterling Heights, MI, USA). 
2.3.6 Western Blotting 
2.3.6.1 LipofectAMINE Based Transfection 
The expression of the recombinant GFP fusion of E l , E2, E3 and SUMO-1 
was checked by western blotting. Before that, the cells were transfected with the 
-corresponding recombinant pEGFP-Cl plasmids by using LipofectAMINE PLUS™ 
reagent (Invitrogen Life Technologies Inc., Carlsbad, CA, USA) similar to section 
2.3.2.2. 
Before the day of transfection, cells were seeded into 60mm dish at 50% 
confluency. They were then allowed to grow at 37°C with 5% CO2. 
2)j,g of the various recombinant pEGFP-Cl plasmids were transfected into the 
HepG2 and WRL-68 cells separately. 2|dg of DNA was pre-mixed with 8|al of PLUS 
reagent in 250|al of serum-free RPMI medium, the mixture was incubated at room 
temperature for 15 minutes. During the incubation, \l\i\ of lipofectAMINE was . 
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diluted by 250|al of serum-free medium. After incubation, these two mixtures were 
mixed together and then allowed to stand at room temperature for 15 minutes. 
Meanwhile, the medium of cells was discarded and they were washed by PBS twice. 
2ml of serum-free RPMI was added to the cells and finally the DNA-PLUS-
lipofectAMINE reaction complexes were added to the cells after the incubation. The 
cells were allowed to incubate with the DNA at 37�C with 5% CO2 for three hours. 
Thereafter, the medium of the cells was replaced by 2.5ml serum containing RPMI 
medium. The cells were then incubated at 37�C with 5% CO2 for 24 hours. 
2.3.6.2 Protein Extraction 
After 24 hours transfection, the cells in each 60mm^ dish were washed by 
PBS for three times and then trypsinized by 200|al of Trypsin-EDTA (Gibco BRL 
Life Technologies Inc., Carlsbad, CA, USA). The trypsinized cells were collected by 
adding 300fil of serum containing medium and centrifuged at SOOOrpm for 10 
minutes at 4 � C . The medium was then decanted; the cell pellet was then resuspended 
in 1ml of PBS and then centrifuged at 5000rpm for five minutes at 4°C, this step was 
repeated twice to wash the cells thoroughly. 
The washed cells were lysed by votexing with 150|il of lysis buffer (50mM 
Tris pH8.0, 300mM NaCl, lOmM EDTA，1% NP40, 0.1% SDS, 0.2mM 
phenylmethylsulfonyl fluoride (PMSF) and cocktail of protease inhibitors (Roche 
Diagnostics Corporation Ltd., Basel, Switzerland)). The lysate was then sonicated for 
five minutes and then incubated on ice for two hours. Protein was harvested by 
centrifugation at 14Kx g for 10 minutes and the supernatant was collected. 
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2.3.6.3 Protein Quantification 
The protein content of the cell lysate was quantitated by the Bio-Rad Protein 
Assay (Bio-Rad Laboratories, Hercules, CA, USA). Working protein assay solution 
was diluted to five-fold from the stock solution by distilled water. A standard curve 
was established by using Bovine Serum Albumin (BSA). 
For the standard curve setup, different concentrations of BSA (0 mg/ml, 0.2 
mg/ml, 0.4 mg/ml, 0.6 mg/ml and 0.8 mg/ml) was prepared from 1 mg/ml BSA stock 
solution, and then 1 of BSA with a specific concentration was added to 999 [i\ of 
protein assay solution (200^1 of IX protein assay & 799)^1 of distilled water). The 
mixture was allowed to stand at room temperature for five minutes. The absorbance 
of various BSA samples at wavelength 595nm was measured. The standard curve 
was then plotted. 
For the estimation of the protein content of the l y s a t e s，1 o f protein sample 
was mixed with 999|al of protein assay solution as mentioned above. It was then 
incubated at room temperature for five minutes and the absorbance at v. avelength 
595nm was recorded. The exact protein concentration was estimated from the 
equation of the standard curve established. 
2.3.6.4 SDS-PAGE Analysis 
100|Lig of protein sample was loaded into 10% polyacrylamide gel for 
« ‘ 
, analysis for GFP fusion protein detection. 
Protein sample was mixed with 6X SDS gel-loading buffer (300mM Tris 
pH6.8, 12% SDS w/v, 0.6% w/v bromophenol blue, 60% v/v glycerol and 600mM 
dithiothreitol) and then boiled at 9 9 � C for 10 minutes. The boiled sample was spun 
down for a while to pellet the debris and then the supernatant was loaded to the gel. 
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The proteins were then separated by electrophoresis in SDS electrophoresis buffer 
(25mM Tris, 250mM glycine, 0.1% SDS w/v). 
2.3.6.5 GFP Fusion Proteins Detection 
After the electrophoresis, the proteins in the gel were transferred to a PVDF 
(polyvinylidene difluoride) Immobilon™-P 0.45^m Transfer Membranes (Millipore 
Corporation Ltd., Billerica, Mass, USA) by semi-dry electroblotter in the presence of 
transfer buffer (25mM Tris, 192mM glycine, 10% methanol v/v). Proteins were 
transferred under 15V for 1.5 hour. 
The transferred membrane was incubated with a blocking solution, 10% (w/v) 
skimmed milk powder dissolved in PBST (137mM NaCl, 2.7mM KCl, lOmM 
Na2HP04, 1.8mM K H 2 P O 4 and 0.1% Tween-20), at room temperature for one hour 
with gentle shaking. After blocking, a primary antibody, rabbit anti-GFP, (Santa 
Cruz Biotechnology Inc., California, USA) was added to the blocking solution in a 
dilution of 1:500 (v/v). The proteins on the membrane were then bound with the 
primary antibody at 4 � C for overnight also with gentle shaking. The blocking 
solution with the primary antibody was discarded and then the membrane was rinsed 
with PBST for three times with 15 minutes each. Then it was incubated with a 
secondary antibody, goat anti-rabbit conjugated with horseradish peroxidase (HRP) 
diluted in the milk solution with dilution 1:5000 (v/v), and then incubated at room 
temperature for two hours. Again, the milk solution was decanted and the membrane 
was washed with PBST for three times with 15 minutes each. 
Signal was then detected with the help of Western Lightning™ 
Chemiluminescence Reagent Plus (PerkinElmer Life Sciences Inc., Wellesley, MA, 
USA). 4001^1 of Enhanced Luminol Reagent was mixed with 400|il of Oxidizing ‘ 
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Reagent provided with the kit. The mixture was added to the polypropylene sheet 
and the membrane was placed as upside down to the sheet. Another polypropylene 
sheet was placed on the other side of the membrane. Before signal detection on a X-
ray film (Fuji Photo Products Corporation Ltd., Tokyo, Japan), the membrane was 
faced up again and a X-ray film was exposed to the membrane. Then the signal was 
developed by a developer (Eastman Kodak Company Ltd., Rochester, NY, USA) and 
then fixed by a fixer (Eastman Kodak Company Ltd., Rochester, NY, USA). 
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2.4 TwO'VimensionaC QeC XCectrojpfioretic 
JAnaCyses 
2.4.1 Sample Preparation 
2.4.1.1 Protein Extraction from the Nucleus 
WRL-68 or HepG2 cells were seeded into 60mm^ dishes before the day of 
transfection. SUMO-l-pEGFP-Cl and a control, pEGFP-Cl, were transfected into 
the seeded cells separately according to section 2.3.6.1. The transfection efficiency 
was estimated by visualization of the GFP fluorescent signal directly fluorescent 
microscopy. 
Before protein extraction, three 60mm^ dishes for transfecting the same 
plasmid (SUMO-l-pEGFP-Cl or pEGFP-Cl) were rinsed with PBS and then 
trypsinized. The trypsinized cells were pooled together and collected by 
centrifugation at SOOOrpm for 10 minutes. The cell pellet was washed by 
resuspending in 1ml of PBS and centrifugation, and the washing step was repeated 
for three times. Then the subcellular protein was fractionated by using the 
ProteoExtract™ Subcellular Proteome Extraction Kit (Calbiochem®, HMD 
Biosciences Inc., Darmstadt, Germany). The extraction protocol was modified from 
the manufacturer's suggestion as follows. 
The washed cell pellet was washed again with 1ml of ice cold Wash Buffer; it 
was resuspended in the Wash Buffer and then centrifuged at 200 x g for 10 minutes 
at 4°C. The supernatant was discarded by aspiration. The cell pellet was then 
resuspended and vortexed in 500|il of ice cold Extraction Buffer I，5|il of Protease 
Inhibitor Cocktail and 25mM of N-ethylmaleimide were added. It was then incubated 
on ice for 10 minutes. The insoluble material was sedimented at 750 x g for 10 . 
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minutes at 4 � C . The supernatant was transferred into a tube and kept on ice; it was 
the cytosolic fraction (Fraction 1). The insoluble part was mixed with SOOjil of ice 
cold Extraction Buffer II and 5\x\ of Protease Inhibitor Cocktail; an extra 25mM of 
N-ethylmaleimide was added. The mixture was vortexed and then incubated on ice 
for 30 minutes. Soluble and insoluble materials were separated by centrifugation at 
5500 X g for 10 minutes at 4°C. The soluble fraction was saved into a tube and kept 
on ice; it was the membrane fraction (Fraction 2). The insoluble part was solubilized 
in 250|il of Extraction Buffer III with 5^1 of Protease Inhibitor Cocktail plus 25mM 
of N-ethylmaleimide and l.S^il of Benzonase®. It was vortexed vigorously and then 
incubated on ice for 10 minutes. The insoluble part was pelleted at 6800 x g for 10 
minutes at 4 � C . The supernatant was also saved; which was the nuclear fraction 
(Fraction 3). The last insoluble material was solubilized in a mixture containing 
250|dl of Extraction Buffer IV, 5|al of Protease Inhibitor Cocktail and 25:nM of N-
ethylmaleimide. It formed the cytoskeletal fraction (Fraction 4). 
2.4.1.2 Clean Up of Extracted Nuclear Fraction 
The protein content was estimated before the clean up of the nuclear fraction 
for 2D electrophoresis. The sample was firstly diluted to 10-fold by distilled water 
I 
and then the protein concentration was measured as section 2.3.6.3. Thereafter, 
600|^g of protein was aspirated to a 2ml microcentrifuge tube for the clean up. The 
clean up process was done with the help of a 2-D Clean-Up Kit (Amersham 
Biosciences, Buckinghamshire, UK). The protocol was modified slightly from the 
manufacturer's suggestion. 
Firstly, 900|al of Precipitant was added to the protein sample, it was then 
mixed by vortexing. The mixture was incubated on ice for 15 minutes. 900iil of Co-
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precipitant was added to the mixture and also mixed well by vortexing again. The 
protein precipitate was precipitated out by centrifugation at 8000 x g for 10 minutes. 
The supernatant was aspirated immediately; it was then repositioned into the 
centrifuge again and centrifuged for one more minute. The remaining supernatant 
was removed immediately. 200|^1 of Co-precipitant was added to the pellet and then 
centrifuged for five minutes. lOO i^l of distilled water was added to resuspend the 
pellet. 1ml of pre-chilled Wash Buffer was added to the mixture and also 5\i\ of 
Wash Additive was added. It was vortexed in order to fully disperse the pellet. The 
mixture was incubated at -20°C for one hour. The protein was precipitated out by 
centrifugation at 8000 x g for 10 minutes. The supernatant was decanted carefully 
and the pellet was dried briefly. The dried pellet was resuspended in lOOjal of 
rehydration buffer (8M urea, 2% CHAPS, 40mM DTT, 0.5% IPG (Immobiline pH 
Gradient) buffer (Amersham Biosciences, Buckinghamshire, UK)). 
2.4.2 First Dimensional Isoelectric Focusing (lEF) 
The protein sample in the rehydration buffer was diluted to 10-fold and then 
subjected to protein quantification as mentioned in section 2.3.6.3. 300ng of protein 
was used for loading one lEF immobiline pH gradient (IPG) DryStrip (Amersham 
Biosciences, Buckinghamshire, UK). The final volume was added up to 250|.il by the 
rehydration buffer. Bromophenol blue was added to the sample, the final 
concentration was 0.01% w/v, to give the blue color. 
All the 250}al of protein sample was loaded to one Strip Holder (Amersham 
Biosciences, Buckinghamshire, UK). Then a 13cm IPG strip with liner pH gradient 
from three to ten (Amersham Biosciences, Buckinghamshire, UK) was placed with 
gel facing down into the Strip Holder. 1ml of IPG Cover Fluid (Amersham 
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Biosciences, Buckinghamshire, UK) was applied onto the entire IPG strip to 
minimize evaporation and urea crystallization. 
The strip in the Strip Holder was placed on Ettan™ IPGphor™ platform. 
Protein was absorbed to the strip under low voltage application, 30V for 13 hours. 
The proteins were then separated according to their pi by lEF. The process was 
carried out in 500V for one hour, lOOOV for one hour and 8000V for two hours. The 
accumulative voltage-hour was around 16K Vhr. 
2.4.3 Second Dimension SDS-PAGE 
2.4.3.1 SDS-PAGE Analysis 
The focused IPG strip was equilibrated in two different equilibration buffers 
prior to be carried out Dimension SDS-PAGE. The IPG strip was placed in an 
individual tube with the support film toward the wall. 5ml of the DTT containing 
equilibration buffer (50mM Tris-HCl pH 8.8, 6M urea, 2% SDS (w/v), 30% glycerol 
(v/v), 0.002% bromophenol blue (w/v), 50mg of DTT). The IPG strip was then 
equilibrated at room temperature for 15 minutes with gentle shaking. The 
equilibration buffer was decanted carefully. Second equilibration was then carried 
out in 5ml of lAA containing equilibration buffer (50mM Tris-HCl pH8.8, 6M urea, 
2% SDS (w/v), 30% glycerol (v/v), 0.002% bromophenol blue (w/v), 125mM 
iodoacetamide (lAA)). The strip was incubated with this buffer at room temperature 
for another 15 minutes. ‘ 
The 2nd Dimension electrophoresis was carried out in a SE 600 Ruby丁m 
Standard Vertical Unit (Amersham Biosciences, Buckinghamshire, UK). During the 
incubation, a 10% polyacrylamide gel was prepared. After the equilibration, the IPG 
strip was placed onto the top of the SDS-PAGE and then a small piece of filter paper ‘ 
I 
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applied with SeeBlue Plus2 Pre-stained Standard (Invitrogen Life Technologies Inc., 
Carlsbad, CA, USA) was placed nearby the IPG strip. 750|al of sealing agarose 
(0.5% agarose (w/v)，SDS electrophoresis buffer (section 2.3.6.4), 0.002% 
bromophenol blue (w/v)) was applied on the top of the gel in order to block the 
narrow gaps between the gel edges and the lateral spacers to prevent leakage of the 
upper buffer and prevent the IPG strip from moving or floating in the electrophoresis 
buffer. The 2"'' Dimension electrophoresis was run at 200V for around five hours 
until the bromophenol blue dye front reached the bottom of the gel. 
2.4.3.2 Silver Staining 
The 2nd Dimension SDS-PAGE was stained by PlusOne™ Silver Staining Kit 
(Amersham Biosciences, Buckinghamshire, UK). The general procedures were 
followed according to the manufacturer's suggestion. 
The gel was firstly fixed by 250ml of fixing solution (100ml Ethanol 50ml 
Acetic Acid, 100ml of NanoPure Water) for overnight at room temperature. The 
fixed gel was sensitized by, 250ml of sensitizing solution which was prepared by 
mixing 75ml of ethanol, 10ml of Sodium Thiosulphate (5% w/v), 17g of Sodium 
Acetate and NanoPure water was used to make to 250ml. The gel was incubated in 
the sensitizing solution for 30 minutes at room temperature with gentle shaking. The 
sensitizing solution was then removed; the gel was rinsed with NanoPure water for 
three times with five minutes each. In the meanwhile, silver solution was prepared; it 
was mixed by 25ml of silver nitrate solution (2.5% w/v), 100|il of formaldehyde 
(37% w/v) and NanoPure water making up the final volume to 250ml. After washing, 
silver solution was added to the gel for the silver reaction; it was left for shaking at 
room temperature for 20 minutes. During the incubation, developing solution and ‘ 
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stopping solution were prepared. Developing solution was made of 6.25g of Sodium 
Carbonate, 50|al of Formaldehyde (37% w/v) and NanoPure water adding up the 
final volume to 250ml. For the stopping solution, it was prepared as dissolving 3.65g 
of EDTA-Na2 . 2H2O in 250ml of NanoPure water. After the silver reaction, the 
solution was decanted and the gel was rinsed in NanoPure water twice for one 
minute each. The image of the gel was then developed by using developing solution. 
The gel was shaken with the developing solution until protein spots have been 
appeared. The developing reaction was then stopped by decanting the developing 
solution and adding stopping solution immediately. The gel was allowed to shake 
with the stopping solution for 10 minutes. After that, the gel was stored in NanoPure 
water at room temperature. 
2.4.4 Image Analysis 
The images of the gels were acquired by ImageScanner™ II and the software 
Labscan™ version 3.0 (Amersham Biosciences, Buckinghamshire, UK). The 
intensity difference between the proteins spots on the gels, samples with GFP-
SUMO-l overexpression and GFP overexpression, were compared by using the 
software ImageMaster™ 2D Platinum version 5.0 (Amersham Biosciences, 
Buckinghamshire, UK). All the protein spots with differential expression pattern 
were picked manually. 
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2.4.5 Protein Identification by Mass Spectrometry 
2.4.5.1 Sample Preparation 
The excised protein spot was de-stained by vortexing and then incubation 
with 20|il of destaining solution (15mM Potassium ferricyanide, 50mM Sodium 
thiosulphate) until the dark stain disappeared. The destaining solution was discarded 
and the spot was washed with NanoPure water for three times. The spot was then 
equilibrated with 50|al of 200mM of Ammonium bicarbonate twice for 10 minutes 
each. Ammonium bicarbonate was aspirated after the equilibration, and then lOOjil 
of Acetonitrile (ACN) was added to the spot and incubated for five minutes at room 
temperature for three times in order to dehydrate the spot. The spot was then dried 
completely by speed vac for 5 minutes to make the gel becoming "dust like". The gel 
was rehydrated by incubating in 5[l\ of trypsin solution (40ng/ml trypsin (Sigma, St. 
Louis, MO, USA), 50mM Ammonium bicarbonate) on ice for 30 minutes. 50mM of 
Ammonium bicarbonate solution was added to cover the whole hydrated gel piece. 
Protein was digested by trypsin reaction at 30�C for overnight. 
.. The peptides from the trypsin digestion were then extracted. Firstly, the 
trypsin solution was aspirated and saved in a 1.5ml microcentrifuge tube. Then 20|al 
of 50mM Ammonium bicarbonate was added to the gel and sonicated for 10 minutes. 
The supernatant was pooled with the trypsin solution while the gel was added with 
20|al of ACN : 5% Trifluoro acetic acid (TFA) (1:1 (v/v)) and also sonicated for 10 
minutes. The extracts were also combined with the previous one. This extraction step 
was repeated twice. Thereafter, 10|il of ACN was added to the gel and sonicated for 
10 minutes. The supernatant was also pooled with the previous extracts. The pooled 
extract was then dried by speed vac. 
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The dried sample was redissolved in 10|il of 0.1% TFA (v/v). The sample 
was then desalted by passing through a ZipTip c-i8® Pipette Tip (Millipore 
Corporation Ltd., Billerica, Mass, USA). Before that, the ZipTip was wetted by 
aspirating and dispensing lO^il of wetting solution (50% ACN (v/v)) twice. It was 
then equilibrated also by aspirating and dispensing of 0.1% TFA (v/v). Peptides 
were bound to the ZipTip by aspirating and dispensing the lO^il of redissolved 
sample in the same tube. The resin inside the ZipTip was then washed by aspirating 
and dispensing 10|LI1 of 0.1% TFA (v/v) for five times. The peptides were then eluted 
by aspirating and dispensing 2[l\ of Elution buffer (50% ACN (v/v), 0.1% TFA (v/v)) 
in a clean 0.5ml microcentrifuge tube. 
The Matrix solution (ACH-Cinnamic Acid) was prepared for spotting onto a 
MALDI-plate. A small amount of ACH-Cinnamic Acid was mixed with 500|il of 
Buffer A (50% ACN, 0.5% TFA). It was then vortexed for 30 seconds and then left 
for standing at room temperature for a few minutes to let the insoluble powder to 
settle down. The mixture was then spun down shortly while the supernatant was 
aliquoted into 50|LI1 each and stored at -20°C before use. 
After preparation of Matrix solution, the extracted peptide was ready to be 
spotted on to a MALDI Sample-plate (Applied Biosystems Corporation, Forster City, 
CA, USA). 0.5|al of sample was applied onto the MALDI-plate and air dried at room 
temperature; the step was repeated until all the purified peptides were spotted onto 
the plate. 0.5|j,l of Matrix solution was applied to the sample spot and also air dried at 
room temperature. 
61 
Chapter 2 Materials & Methods 
2.4.5.2 Data Acquisition 
Data of each sample spot on the MALDI Sample-plate was acquired by using 
4700 Proteomics Analyzer and 4700 E x p l o r e r ™ software (Applied Biosystems 
Corporation, Forster City, CA, USA). 
2.4.5.3 Data Analysis of Protein Fingerprinting 
The acquired data was analyzed with the help of Mascot based GPS 
ExplorerTM Software Remote Access Client (Applied Biosystems Corporation, 
Forster City, CA, USA). Protein was identified by combined MS + MS/MS to 
compare with the human database of NCBI. 
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2.5 Confirmation of tfie VijferentiaCCy 
TxpressecC Troteins 6y nrt-TCR & 
yvestern XCotting 
2.5.1 RT-PCR Analysis 
2.5.1.1 RNA Extraction 
HepG2 cells were seeded into 6-well plates at least one day before 
transfection. Two wells were transfected with empty pEGFP-Cl vector while another 
two were transfected with SUMO-pEGFP-Cl vector with the help of 
LipofectAMINE PLUS™ reagent (Invitrogen Life Technologies Inc., Carlsbad, CA, 
USA) similar to section 2.3.2:2. 
The RNA of the transfected cells was extracted after 24 hour transfection. 
The medium was removed and then cells were washed with DEPC-treated PBS once. 
500|al of TRIzol™ reagent (Invitrogen Life Technologies Inc., Carlsbad, CA, USA) 
was added to one well to lyse the cells. After five minutes incubation at room 
temperature, the lysed cells were centrifuged at 12K x g at 4°C for 10 minutes in 
order to remove any insoluble cell debris. The supernatant was transferred to a new 
tube and 200)al of chloroform was added, it was then mixed by vortexing for 15 
seconds. The mixture was incubated at room temperature for five minutes. It was 
then centrifuged at 12K x g for 15 minutes at 4 The upper aqueous layer was 
saved in a new tube and the organic layer was discarded. 500^1 of isopropanol was 
added to the aqueous mixture and then mixed thoroughly. RNA was precipitated by 
incubation with isopropanol added at room temperature for 10 minutes, after the 
incubation, the mixture was centrifuged at 12K x g for 15 minutes at 4 The 
supernatant was removed and the RNA pellet was washed by addition of 1ml of pre-
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chilled 70% ethanol and centrifugation at 12K x g at 4 for five minutes. The 
supernatant was removed and the pellet was air dried. The dried RNA pellet was 
resuspended in 25 of DEPC-treated water. 
3)^ 1 of the extracted RNA was mixed with of 2X RNA loading dye (14% 
(v/v) of stop solution (Gibco BRL Life Technologies, Inc., Carlsbad, CA, USA), 
43% (v/v) of 37% formaldehyde, 29% (v/v) of lOX MOPS (USB, Swampscott, MA, 
USA) and 150|ag of ethidium bromide) and then denatured at 65 "C for 5 minutes. 
The denatured RNA was analyzed by 1% TAE agarose gel to check the integrity. 
2.5.1.2 First Strand cDNA Synthesis 
cDNA was. synthesized from the RNA extracted by using the Duncan RT-
PCR System. 22|^1 of RNA was mixed with of Oligo (dT)25 primers and then 
denatured at 65°C for five minutes. A first strand reaction was performed by mixing 
the RNA with I2[x\ of 5X cDNA synthesis buffer, of lOmM MgCb, 6fil of 
lOmM dNTP Mix, 3[i\ of RnaseOUT™，3fil of Duncan reverse transcriptase and 3|il 
of DEPC-treated water. The reaction mixture was incubated at 42°C for an hour. The 
synthesized first strand cDNA was stored at -20 ""C until use. 
2.5.1.3 Normalization of cDNA Template 
The cDNA template was firstly normalized by amplification of a house-
keeping gene p-actin. The forward primer sequence was 5' — 
GTCGTACCACAGGGCATTGTGATGG - 3' and the reverse primer was 5 ' -
GCAATGCCTGGGTACATGGTGG - 3,. The PGR was performed at denaturing at 
95 X for two minutes and then 30 cycles of 95 for 36 seconds, 57 for 36 
seconds and 72 "C for 30 seconds followed, it was then final extended at 72 for 10 
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minutes. The PGR product was analyzed by 2% TAE agarose gel with ethidium 
bromide staining. 
2.5.1.4 PCR Amplification of the Target Genes 
The mRNA transcript level of heterogeneous nuclear ribonucleoprotein 
A2/B1 isoform Bl (hnRNP A2/B1 isoform Bl) and uracil DNA glycosylase (UDG) 
with overexpression of EGFP-SUMO-1 and EGFP was compared. Primers for 
amplifying hnRNP A2/B1 isoform Bl were 5, -
GCCCCGGTTATGGAGGAGGAAGAGGAGGAT - 3’ and 5' -
TGGCTCTCTGCATCTGCTCTGGTGTCTTCTG - 3’ while that for UDG were 
5 ， - TGCCGTCTAGAAAAACCTGCCAAATATGA - 3’ and 5 ， -
GGGGCTCGGTGGGTCCAGGGGTCTTACTC - 3'. PCR reactions were prepared 
by using normalized cDNA as template. The PCR reaction contained 0.5^il of 
forward primer and another 0.5|il of reverse primer, 2.5^1 of lOX PCR buffer, 2.5[l\ 
of 2mM dNTP, 1.5|_il of 50mM MgCb, 0.25|al of Duncan Taq polymerase, cDNA 
template and NanoPure water was used to add up the final volume as 25|iL The PCR 
reaction mixture was denatured at 95 for two minutes and then 34 cycles of 95 
for 36 seconds, 57 for 36 seconds and 72 for 30 seconds followed, it was then 
final extended at 72 ^C for 10 minutes. 5|il of PCR product was extracted at the 25* 
cycle, 28th cyde, cycle and the 34 '^' cycle. The extracted PCR product was 
analyzed by 1.5% TAE agarose gel with ethidium bromide staining. 
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2.5.2 Western Blotting 
HepG2 cells were seeded into 60mm dishes for transfection. Two plasmids, 
pEGFP-Cl and SUMO-1 -pEGFP-C 1 were transfected into the cells separately. The 
transfection procedures were the same as stated in section 2.3.6.1. 
24 hour after transfection, cells were trypsinized and collected for protein 
preparation. The protein preparation protocol for western blotting was the same as 
section 2.3.6.2. 
The protein concentration of each sample was quantified by Protein Assay 
solution (Bio-Rad Laboratories, Hercules, CA, USA). The protocol was the same as 
section 2.3.6.3. 75fag of each protein sample was loaded into 12% SDS-PAGE as 
section 2.3.6.4. .. “ 
The SDS-PAGE analyzed proteins were transferred to a PVDF membrane for 
signal detection. The transferred membrane was probed with primary and then 
secondary antibody similar to section 2.3.6.5. However, the primary antibodies used 
were rabbit anti-hnRNP A/B (Santa Cruz Biotechnology Inc., California, USA) with 
dilution 1:200 and rabbit anti-UDG (Imgenex Corporation, San Diego, CA, USA) 
with dilution 1:250. 
66 
Chapter 2 Materials & Methods 
2,6 Expression ofJ-Cuman TIJAS ancCTIJASi 
fragments in Trokaryotic System 
2.6.1 Preparation of Competent Cells 
Five bacterial expression cell strains, B834, B834+, BL21, C41 and Rosetta 2 
were prepared as section 2.2.4.1. 
2.6.2 Small Scale Expression 
Small scale expression was used to find out the time point, protein induction 
temperature and expression bacterial strain which gave out the highest yield of 
overexpressed target protein.-
2.6.2.1 Transformation 
1 |il of different plasmids for bacterial expression (Table 8) was added to five 
different bacterial strains, B834, B834+, BL21, C41 and Rosetta 2 separately. The 
cells were incubated on ice for 15 minutes. They were then heat shocked by 
incubating at 42''C for one minute. After that, the cells were placed on ice 
immediately and then recovered by shaking with 800ml of LB medium at 37�C for 
45 minutes; the shaking speed was kept at 250rpm throughout the process. 
Gene Expression Vector Cloned 
PIASl, PIAS3, PIASxa & PIASxp pGEX-6P-l, pET28m “ 
PIASl fragments: 141 — 410, 141 — 476, pGEX-6P-l, pET28m, pMAL-c2P""" 
321 - 4 1 0 , 321 - 4 7 6 
Table 8 Plasmids used for small scale expression. 
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After the recovery, 200^1 of cell suspension was spread on a LB plate with 
suitable antibiotics. The corresponding antibiotic resistant gene to each vector lists in 
Table 6. The spread plate was incubated at 37�C for overnight. 
Single colonies were picked and inoculated into 3ml of LB medium 
containing antibiotics. The inoculated culture was incubated at 37°C for overnight 
with shaking at 250rpm. 
2.6.2.2 IPTG Induced Protein Expression 
The inoculated overnight culture was subcultured. 600^1 of the overnight 
culture was added to 60ml of LB medium with antibiotics. The LB culture was 
incubated at 3TC with shaking at 250rpm until the absorbance at wavelength 600nm 
reached 0.3 to 0.4 which was the log phase of the E. coli growth curve. The culture 
was then equilibrated to the induction temperature for half an hour. Isopropyl-beta-
D-thiogalactopyranoside (IPTG) was added to the culture so that the final 
concentration in the culture attained 0.1 mM. The culture was incubated to the 
induction temperature with shaking at 250rpm. 30ml of the expression culture was 
collected at several time points depending on the expression temperature (Table 9). 
Expression Temperature Time Point of collection of expression culture 
16°C 6 hours & 16 hours after IPTG induction 
6 hours & 16 hours after IPTG induction 
W C 3 hours & 6 hours after IPTG induction 
Table 9 List of time points for the collection of expression culture at different expression 
temperature. 
The absorbance at wavelength 600nm was measured. The cells in the 
collected 30ml of expression culture were harvested by centrifugation at 4000rpm for 
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20 minutes at 4 � C . The cells were then resuspended in lysis buffer (lOmM Tris, 
500mM NaCl, 0.5mM EDTA, 2mM DTT, 0.2mM PMSF，0.2mM Benzamidine, 
while pH was varied with the pi of the protein (Table 10)) with a volume used was 
depended on the absorbance by calculation; the equation used was (ODeoo / 4) x 30. 
The cell suspension was sonicated for 10 seconds for 6 times with amplitude of 60 -
70 on ice, 10 seconds incubating on ice was carried out in between the sonications. 
1ml of sonicated mixture was centrifuged at 14K rpm for 20 minutes at 4°C. The 
soluble protein in the supernatant was transferred into a tube while the insoluble 
material in the pellet was resuspended in 1ml of lysis buffer. 15|il of soluble and 
insoluble fraction was added to 3|LI1 of 6X SDS gel-loading buffer separately. The 
mixture was then heated at 99°C for 10 minutes; it was then spun down for a while to 
pellet the debris. The sample was subjected to SDS-PAGE analysis. 
Protein I pH of Lysis Buffer 
His-PIASl, GST-PI AS 1 pH 8.0 
His-PIAS3,GST-PIAS1 pH 8.5 
His-PIASxa, GST-PIASxa pH 7.5 
His-PIASxb, GST-PIASxb pH 8.0 
His-PIASl fragments pH 7.5 
GST-PIASl fragments pH 7.5 
MBP-PIAS 1 fragments pH 7.5 
Table 10 pH of the lysis buffer of each protein. The pH was at least ± 0.5 of the pi of protein. 
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2.6.3 Large Scale Expression of PIASl Fragments 
2.6.3.1 Transformation 
Ij^l of plasmid was transformed into an E. coli expression strain as listed in 
Table 11. The general procedures were the same as section 2.6.2.1. 
Plasmid E.coli strain used for expression 
^ P I A S l - 1 4 1 - 4 1 0 - p M A L - c 2 P ^ B834 
PIASl-141-476-pMAL-c2P B834+ 
PIASl-321-410-pMAL-c2P B834+ 
PIASl-32 l-476-pMAL-c2P B ^ 
Table 11 List of bacterial strains used for expression of different PIASl fragments. 
After overnight incubation of the spread LB plate with ampicillin, single 
colonies were inoculated in 100ml of LB medium with 100)ig/ml of ampicillin. It 
was then incubated at 37°C for overnight with shaking at 250rpm. 
2.6.3.2 IPTG Induced Protein Expression 
5ml of overnight starter culture was inoculated into each 500ml of LB 
medium with ampicillin. The inoculated bacterial culture was incubated at 37�C with 
shaking at 250rpm until the absorbance at wavelength 600nm has reached 0.3 to 0.4. 
The culture was then incubated at the expression temperature (Table 12) for 30 
minutes. 1ml of the culture was extracted and centrifuged at 13K rpm for one minute; 
it was used as an uninduced control. Then IPTG was added to a final concentration, 
0.1 mM. It was then incubated at specific expression temperature for a few hours to 
overnight (Table 12) according to different expression conditions of each protein. 
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Protein || Expression Hours of incubation after induction 
Temperature 
MBP-PIAS 1-141-410 1 6 ^ 1 6 - 1 8 hours (overnight) 
MBP-PIASl-141-476 25 6 hours 
MBP-PIAS 1-321-410 1 6 � C 1 6 - 1 8 hours (overnight) 
MBP-PIAS 1-321-476 | 16 "C 1 6 - 1 8 hours (overnight) 
Table 12 Expression conditions of each PIASl fragment. 
After expressing the protein at specific expression condition, the cells were 
harvested by centrifugation at 8K rpm for 10 minutes. The cell pellet could be stored 
at -20'C. 
2.6.4 Purification Trial of MBP-PIASl-321-410 
This was a pilot study for finding the optimized purification protocol for 
purification of other PIASl fragments. 
2.6.4.1 Binding of Amylose Resin & On Column Cleavage (with Low 
Concentration of DTT) 
The cell pellet from 4L of bacterial culture expressing MBP-PIASl-321-410 
was resuspended in 80ml of lysis buffer (lOmM Tris pH 7.5, 500mM NaCl，2mM 
DTT, 0.2mM PMSF, 0.2mM Benzamidine), the suspension was then sonicated on 
ice at amplitude of 80 for six minutes with a pulse of 50%, the sonication was carried 
out by using the sonicator with a titanium probe with a diameter of 13mm (Bandelin 
Electronic Corporation Ltd, HeinrichstraPe, Berlin). The sonicated lysate was then 
centrifuged at 20K rpm for 45 minutes at 4°C. Meanwhile, the Amylose resin (New 
England BioLabs Inc., Beverly, MA, USA) was equilibrated with lysis buffer for five ‘ 
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bed volumes in Econo-Column Chromatography Column (Bio-Rad Laboratories, 
Hercules, CA, USA), and one bed volume containing 10ml resin. 
The supernatant containing the soluble protein was then filtered by 0.45nm 
syringe based filter unit (Millipore Corporation Ltd., Billerica, Mass, USA), the 
filtering step would prevent the blockage of resin by large particles or dusts. The 
pellet after centrifugation was discarded. The filtered supernatant was then mixed 
with the equilibrated resin and incubated at 4 � C for one hour with gentle shaking. 
The resin with supernatant was then poured into the empty column again, and then 
the unbound protein was allowed to pass through the column by gravity. The resin 
was then washed with the lysis buffer until there was no protein detected by mixing 
30)LI1 of IX Protein Assay Solution and 5|il of washing. The washing step was 
usually required to rinse the resin with 10 bed volumes (total 100ml of lysis buffer) 
of resin. 
The bound resin was equilibrated by 3 bed volumes (30ml) of cleavage buffer 
(lOmM Tris, 150mM NaCl, 2mM DTT, 0.2mM PMSF, 0.2mM Benzamidine) which 
provided the low salt condition for PreScission protease to carry out its function. 
50|ig- of PreScission protease was added to the resin and incubated at 4 � C for 
overnight with gentle agitation. 
After the overnight cleavage, the resin was poured into the Econo-Column 
Chromatography Column again, and then the cleavage buffer was added and allowed 
to flow through the resin until no color change was observed in the Protein Assay. 
The cleaved protein was in the flowthrough. IS^il of the flowthrough was analyzed 
by SDS-PAGE. 
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2.6.4.2 Elution from the Amylose Resin & Cleavage (with Low 
Concentration of DTT) 
4L of bacterial culture expressing MBP-PIASl-321-410 was prepared and 
then lysed and bound to the amylose resin as section 2.6.4.1. After that, the non-
specific bound proteins were washed with the lysis buffer as mentioned before. The 
fusion protein was then eluted by the elution buffer (lOmM Tris pH 7.5, SOOmM 
NaCl, 20mM Maltose, 2mM DTT, 0.2mM PMSF, 0.2mM Benzamidine) until there 
was no color change detected by the Protein Assay. The salt concentration in the 
elution was diluted by dilution buffer (lOmM Tris pH 7.5, lOmM DTT, 0.2mM 
PMSF, 0.2mM Benzamidine) to a final concentration, ISOmM NaCl. 50|ag of 
PreScission protease was added and then incubated at 4°C for overnight. 15|il of the 
sample was analyzed by SDS-PAGE. 
2.6.4.3 Elution from the Amylose Resin & Cleavage (with High 
Concentration of DTT) 
" The protocol was similar to section 2.6.4.2 but the lysis buffer was replaced 
by buffer with a higher concentration of DTT (lOmM). And the cleavage buffer was 
also contained lOmM DTT. 
2.6.4.4 Purification of PIASl-321-410 by Size Exclusion 
Chromatography 
The HiLoad 16/60 Superdex 75 Column was pre-equilibrated with 120ml of 
Buffer A (lOmM Tris, SOOmM NaCl, lOmM DTT, 0.2mM PMSF, 0.2mM 
Benzamidine) with flow rate 2ml/min. Meanwhile, the sample containing the tag . 
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cleaved fusion proteins was concentrated by a Vivaspin Centrifugal Concentrator 20, 
(Sartorius Ltd, Epsom, Surrey, UK) with a 5kDa cut off, to 2ml finally. The 
concentrated protein sample was then filtered by 022[im syringe based filter unit 
(Millipore Corporation Ltd., Billerica，Mass, USA) in order to remove all particulates 
which could affect the column performance. The filtered sample was injected into the 
column through the sample loop of the AKTA^'^ prime system. Proteins were then 
separated according to their size by continuous pumping of Buffer A into the column 
until one bed volume (120ml) of buffer was all pumped. The flow rate during the 
purification process was 0.8ml/ml with collection of the first 30ml elution at 5ml 
each, while the later 90ml at 2ml each. The elution process was also monitored by 
the software Prime View version 5.0 (Amersham Biosciences, Buckinghamshire, UK). 
The elution fractions showing a high absorbance at wavelength 280nm was 
examined by SDS-PAGE. 
2.6.5 Purification of MBP-PIASl Fragments 
2.6.5.1 Purification by Affinity Column (Amylose) 
The procedures were the similar as section 2.6.4.3 that high concentration of 
DTT was applied to the both the lysis buffer and elution buffer. However, the eluted 
proteins were not cleaved by PreScission protease; they were analyzed by SDS-
PAGE directly and then subjected to the next purification step. 
2.6.5.2 Amylose Resin Regeneration 
After purification, amylose resin was regenerated for the next purification. 
The resin was first washed with three bed volumes of distilled water, three bed 
volumes of 0.1% SDS solution were followed. It was then rinsed with distilled water 
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again with one bed volume. It was stored at ( C . For long term storage, the resin 
should be stored with 20% ethanol. 
2.6.5.3 Purification by Both Affinity and Ion Exchange (Heparin) 
The concentration o fNaCl of the elution from the amylose resin was diluted 
from 500mM to 150mM by dilution buffer (lOmM Tris pH 7.5, lOmM DTT, 0.2mM 
PMSF, 0.2mM Benzamidine) before the next purification step. The diluted sample 
was then filtered by a 0.22|im syringe based filter unit (Millipore Corporation Ltd., 
Billerica, Mass, USA) while the buffers used in this purification step were filtered 
through the Durapore® Membrane Filters (Millipore Corporation Ltd., Billerica, 
Mass, USA) by using a vacuum pump (VWR Scientific Products, West Chester, PA, 
USA). 
Before loading sample, the HiTrap Heparin Column (Amersham Biosciences, 
Buckinghamshire, UK) was equilibrated with Buffer A (lOmM Tris pH 7.5, 150mM 
NaCl, lOmM DTT, 0.2mM PMSF, 0.2mM Benzamidine) for five bed volumes, the 
bed volume of the column was 5ml, the buffer volume for equilibration was then 
25ml： The filtered sample was loaded to the column by peristaltic pump (Amersham 
Biosciences, Buckinghamshire, UK) with flow-rate Iml/min. 
The sample loaded column was then connected to an AKTA^"^ prime system 
(Amersham Biosciences, Buckinghamshire, UK). The column was firstly washed by 
10 bed volumes, 50ml, of Buffer A to wash away any unbound protein. The target 
protein was then eluted with an increasing Buffer B (lOmM Tris pH 7.5, 2M NaCl, 
lOmM DTT, 0.2mM PMSF, 0.2mM Benzamidine) concentration in a non-linear 
manner; the profile of elution was increasing from 0 to 10% of Buffer B 
concentration in the first 10ml elution, it was then increased from 10% to 50% in the • 
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following 40ml elution, and finally the concentration of Buffer B was elevated from 
50% to 100% in the last 20ml elution. During the washing and elution steps, the flow 
rate was maintained at Iml/min. The washing was collected in 5ml for each fraction 
while the elution was collected as 2ml each. The elution was monitored by using 
software Prime View version 5.0 (Amersham Biosciences, Buckinghamshire, UK). 
The contents of flow-through of the column, washing and elution fractions 
were analyzed by SDS-PAGE. 
2.6.5.4 Regeneration of Heparin Column 
The HiTrap Heparin column was regenerated by washing the column with 
Buffer B for another 10 bed ^yolumes (50ml), it was followed by five bed volumes 
(25ml) of filtered distilled water. The column could be used again immediately by 
equilibrating with Buffer A, or it could be stored at 4 � C for the next purification. For 
long term storage, it should be stored at 4°C with 20% ethanol. 
2.6.5.5 Purification by Size Exclusion Chromatography 
‘ T h e HiLoad 16/60 Superdex 200 Column was pre-equilibrated with 120ml of 
Buffer A (lOmM Tris, 500mM NaCl, lOmM DTT, 0.2mM PMSF, 0.2mM 
Benzamidine) with flow rate 2ml/min. Meanwhile, the elution fractions containing 
the target protein were concentrated by centrifuging at 4K rpm at 4 � C in a Vivaspin 
Centrifugal Concentrator 20 (Sartorius Ltd, -Epsom, Surrey, UK) with 30K Dalton 
cut off value until the volume of the protein sample was remained around 2ml. The 
concentrated protein sample was then filtered by 0.22|im syringe based filter unit 
(Millipore Corporation Ltd., Billerica, Mass, USA) in order to remove all particulates 
which could affect the column performance. The filtered sample was injected into the ‘ 
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column through the sample loop of the AKTA™ prime system and then separated by 
the column the same as section 2.6.4.4. 
The elution process was also monitored by software Prime View version 5.0 
(Amersham Biosciences, Buckinghamshire, UK). The elution fractions showing high 
absorbance at wavelength 280nm were examined by SDS-PAGE. 
2.6.5.6 Regeneration of Size Exclusion Chromatography 
The used column was generally washed with one bed volume of filtered 
distilled water. It could then be used again after equilibration with buffer desired for 
the chromatography. 
2.6.6 Co-expression & Purification of PIASl Fragments 
with E2 (Ubc9) 
2.6.6.1 Co-transformation of pMAL-PIASl (Fragments) & pET-
Ubc9 
• 1|LI1 of pMAL-PIAS 1 fragment plasmid and 1 |LI1 of pET-Ubc9 plasmids were 
transformed into the expression bacterial cell strain according to Table 11 in section 
2.6.3.1. The transformation procedures were also similar to section 2.6.2.1 while the 
plate for spreading the recovered cells contained both Ampicillin (100|j.g/ml) and 
Kanamycin (30|Lig/ml). The plate was also incubated at 37°C for overnight. 
Single colonies were picked and inoculated into 50ml LB medium with 
Ampicillin (30|ig/ml) and Kanamycin (30|ig/ml), and then the inoculated in 50ml of 
LB medium containing Ampicillin and Kanamycin was shaken at 37®C for overnight 
to form the starter culture for expression. 
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2.6.6.2 Co-expression of PIASl Fragments & Ubc9 
The expression protocol was similar to section 2.6.3.2. The expression 
condition chosen of each pair expression of PIASl fragment and Ubc9 was the same 
as expressing PIAS fragment alone; the conditions were listed in Table 11. 4L of 
expression culture was grown for each protein preparation. 
2.6.6.3 Purification by Affinity Column (Amylose Resin) 
The cell pellet from 4L of bacterial culture was resuspended in 80ml of lysis 
buffer (lOmM Tris pH 7.5, 150mM NaCl, lOmM DTT, 0.2mM PMSF, 0.2mM 
Benzamidine). A low salt buffer was used instead in order to maintain the interaction 
of PIASl fragment and Ubc9. The suspension was sonicated, centrifuged and filtered 
as mentioned (section 2.6.4.1) before. The pre-equilibrated resin was mixed with the 
filtered supernatant which contained the soluble protein and then incubated at 4 � C for 
an hour. The mixture was poured into the Econo-Column Chromatography Column 
(Bio-Rad Laboratories, Hercules, CA, USA), thereafter, the unbound protein was 
allowed to flow through the column by gravity. The resin was washed by lysis buffer 
untir there was no protein detected in the washing by the Protein Assay. Then the 
bound protein was eluted by elution buffer (lOmM Tris pH 7.5, 150mM NaCl, 
20mM Maltose, lOmM DTT, 0.2mM PMSF, 0.2mM Benzamidine). The elution was 
continued also until there was no protein detected in the elution by the Protein Assay. 
Similar to section 2.6.5.2, the used Amylose resin was regenerated for the 
next purification. 
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2.6.6.4 Purification by Both Affinity & Ion Exchange (Heparin) 
After the SDS-PAGE analysis of the protein content in the elution, the elution 
was further purified by Heparin Column. The elution was filtered by 0.22|^m syringe 
based filtered unit and then passed through the equilibrated Heparin with the help of 
a peristaltic pump. The equilibration buffer was equal to Buffer A (lOmM Tris pH 
7.5, 150mM NaCl, lOmM DTT, 0.2mM PMSF, 0.2mM Benzamidine) in this 
purification. The column was washed and the protein was eluted the same as section 
2.6.5.3. The used column was eventually regenerated as described in section 2.6.5.4. 
2.6.6.5 Purification by Size Exclusion Chromatography 
The elution fractions from the Heparin column were analyzed by SDS-PAGE; 
the fractions containing the target protein were pooled, concentrated, filtered and 
then purified by Size Exclusion Chromatography similar to that described in section 
2.6.5.5. 
The concentrated protein sample was then injected to the HiLoad 16/60 
Superdex 200 Column through the sample loop of the AKTA^^ Prime System. The 
column was equilibrated with Buffer A (lOmM Tris pH 7.5, 150mM NaCl, lOmM 
DTT, 0.2mM PMSF, 0.2mM Benzamidine), this buffer was also kept at low salt 
content to maintain the interaction of PIASl fragment and Ubc9. The loaded protein 
was eluted with monitoring same as section 2.6.5.5. After purification, the column 
was washed as section 2.6.5.6. 
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2.6.7 Urea Treatment for the Purification of PIASl 
Fragments 
2.6.7.1 Transformation 
The transformation procedures of pMAL-PIASl fragment were exactly the 
same as section 2.6.2.1. 
2.6.7.2 IPTG Induced Protein Expression 
The expression protocols and the expression conditions were the same as 
mentioned in section 2.6.2.2. 4L of bacterial culture was grown for each protein 
preparation. 
2.6.7.3 Purification by Affinity Column (Amylose Resin) 
The cell pellet was resuspended and lysed. The target protein was partially 
purified by Amylose resin equivalent to section 2.6.4.1. 
2.6:7.4 Purification by Both Affinity & Ion Exchange (Heparin) 
The elution containing the target protein was diluted and urea added by using 
the urea dilution buffer (lOmM Tris pH 7.5, 6.67M urea, lOmM DTT, 0.2mM PMSF, 
0.2mM Benzamidine) so that the final concentrations of NaCl and urea of the protein 
sample ready for loading to Heparin column were 150mM and 2M respectively. The 
diluted sample was filtered by 0.22|im filter unit. 
Before loading the sample, the Heparin Column was equilibrated by five bed 
volumes of Buffer A (lOmM Tris pH 7.5, ISOmM NaCl, 2M urea, lOmM DTT, 
0.2mM PMSF, 0.2mM Benzamidine). The filtered sample was then loaded into the . 
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column by peristaltic pump. The column was connected to AKTA^'^ Prime System 
for washing and elution. 
Similar to section 2.6.5.3, unbound protein was firstly removed by washing 
the column for 10 bed volumes (50ml) of Buffer A. Proteins bound to the column 
were gradually eluted by increasing the concentration of Buffer B (lOmM Tris pH 
7.5，2M NaCl, 2M Urea, lOmM DTT, 0.2mM PMSF, 0.2mM Benzamidine). 
However, the increase of concentration of Buffer B was not done in a linear manner, 
it was first increased from 0 to 10% in the 10ml of elution, it was then increased 
from 10% to 50% in the following 40ml elution, and finally it was elevated from 
50% to 100% in the last 20ml elution. The flow rate during washing and elution was 
kept at Iml/min. The washing was collected in 5ml for one fraction while the elution 
was collected in 2ml each. The fractions inside the elution peak region were analyzed 
by SDS-PAGE. 
2.6.7.5 Purification by Size Exclusion Chromatography 
Elution fractions containing the target protein were pooled and concentrated 
to final volume around 2ml as section 2.6.5.5. The sample was then loaded to the 
pre-equilibrated HiLoad 16/60 Superdex 200 Column through the sample loop of the 
AKTATM Prime System. Buffer used during the elution of proteins with different 
sizes consisted of lOmM Tris, SOOmM NaCl, 2M Urea, lOmM DTT, 0.2mM PMSF, 
0.2mM Benzamidine. Same as section 2.6.5.5，the elution was monitored by the 
software PrimeView. The elution fractions forming a peak in the elution profile were 
analyzed by SDS-PAGE. 
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Cfiaj>ter 3 KesuCts 
3d Tissue VistriBution of ！Hiiman TIJAS 
Qenes 
3.1.1 Determination of the Number of Cycles for PCR 
At the beginning of the semi-quantitative PCR screening, the cycles for 
extraction of PCR product for quantification were determined by a trial PCR, which 
was performed by using human control cDNA library as template. The human 
control cDNA library is a mixture of panel templates from different panels of 
different tissues so that most of the genes could be amplified from it; hence it could 
be used as a positive control also. The cycle for extraction was then chosen at the log 
phase of the PCR product profile in order to ensure that the amount of template was 
directly proportional to the amount of PCR product. The extraction cycles for each 
PIAS gene were found and they were employed for the screening of the Multiple 
Human Tissue cDNA Panel (MTC). 
3.1.2 General Expression Pattern of AH PIAS Genes 
In order to investigate the tissue specificity of human PIAS genes, PCR 
screening of MTC was employed. The screening recruited in the experiment 
consisted of two panels; tissues contained in each panel are listed in Table 2 of 
section 2.1.2.1. There were 16 different tissues (from cDNA libraries) for the 
screening. 
According to Fig. 3.1，3.2, 3.3，3.4 and 3.5, all tissues expressed the five 
PIAS genes (PIASl, PIAS3, PIASxa, PIASxP and PIASy). Although the exact ‘ 
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expression patterns of PIAS genes were different, they were relatively more 
abundant in testis, pancreas and liver. Each particular expression pattern of each 
PIAS gene would be discussed as follows. 
3.1.3 Tissue Distribution of PIASl 
For PIASl, it was demonstrated to be highly expressed in testis, thymus and 
pancreas. It was moderately expressed in heart, kidney, spleen, prostate, ovary and 
leukocyte. In other tissues; brain, placenta, lung, liver, skeletal muscle, small 
intestine and colon, PIASl was also expressed but in a relatively low but detectable 
level (Fig 3.1). 
3.1.4 Tissue Distribution of PIAS3 
The expression of PIAS3 was detected in all tissues chosen for screening. Its 
expression was the highest in prostate. In other tissues, the expression level was 
similar, it was slightly higher in pancreas, spleen, testis, ovary and lung but it was the 
lowest in small intestine (Fig 3.2). 
3.1.5 Tissue Distribution of PIASxa 
PIASxa, an alternative spliced isoforms of PIASx gene, the primer design 
was specific to the 3，-end of the mRNA where the only difference with PIASxp was 
located. In this experiment, it was shown that its expression was extremely high in 
testis; liver was in the second place while pancreas was the third. It was also 
expressed moderately in kidney and prostate. The amounts of mRNA transcript of 
this gene in other tissues were similar (Fig. 3.3). ‘ 
83 
Chapter 3 Results 
3.1.6 Tissue Distribution of PIASxp 
Although PIASxp is an alternative spliced isoforms of PIASxa, its 
expression pattern was totally different from that of PIASxa. The level of mRNA 
transcript of PIASxP was detected with the highest level in pancreas, and then 
followed by liver, kidney, thymus and testis. However, the expression level in other 
tissues was low but detectable (Fig. 3.4). 
3.1.7 Tissue Distribution of PIASy 
The PIASy tissue distribution was also different from others. However, testis 
was also identified as expressing PIASy in the highest level. Liver and placenta also 
expressed PIASy in the highest level. The mRNA transcript was found out in other 
tissues especially pancreas, spleen and ovary. Heart, brain, lung, skeletal muscle, 
kidney, thymus, prostate, ovary, small intestine, colon and leukocyte expressed 
PIASy but in a relatively low level (Fig. 3.5) 
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3.1.6 Tissue Distribution of PIASxp 
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Fig. 3.1 Tissue Distribution of Human PIASl. 1: Heart, 2; Brain, 3: Placenta, 4: Lung, 5: 
Liver, 6: Skeletal Muscle, 7: Kidney, 8: Pancreas, 9: Spleen, 10: Thymus, 11: Prostate, 12: Testis, 13; 
Ovary, 14: Small Intestine, 15: Colon, 16: Leukocyte, 17: Human cDNA Control (Positive Control). 
Equal amount of template was added in each PCR reaction. 
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3.1.6 Tissue Distribution of PIASxp 
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Fig. 3.2 Tissue Distribution of Human PIASl 1; Heart, 2; Brain, 3: Placenta, 4: Lung, 5: 
Liver, 6: Skeletal Muscle, 7: Kidney, 8: Pancreas, 9: Spleen, 10: Thymus, 11; Prostate, 12; Testis, 13: 
Ovary, 14: Small Intestine, 15: Colon, 16: Leukocyte, 17: Human cDNA Control (Positive Control). 
Equal amount of template was added in each PGR reaction. 
86 
Chapter 3 Results 
3.1.6 Tissue Distribution of PIASxp 
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Fig. 3.3 Tissue Distribution of Human PIASxa. 1: Heart, 2: Brain, 3: Placenta, 4: Lung, 5: 
Liver, 6: Skeletal Muscle, 7: Kidney, 8: Pancreas, 9; Spleen, 10: Thymus, 11; Prostate, 12: Testis, 13: 
Ovary, 14: Small Intestine, 15: Colon, 16: Leukocyte, 17; Human cDNA Control (Positive Control). 
Equal amount of template was added in each PCR reaction. 
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Tissue Distribution of PIASxB 
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Fig. 3.4 Tissue Distribution of Human PIASxp. 1: Heart, 2: Brain, 3: Placenta, 4: Lung, 5: 
Liver, 6: Skeletal Muscle, 7: Kidney, 8: Pancreas, 9: Spleen, 10: Thymus, 11: Prostate, 12; Testis, 13: 
Ovary, 14: Small Intestine, 15: Colon, 16; Leukocyte, 17: Human cDNA Control (Positive Control). 
Equal amount of template was added in each PCR reaction. 
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Tissue Distribution of PIASv 
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Fig. 3.5 Tissue Distribution of Human PIASy. 1: Heart, 2: Brain, 3: Placenta, 4: Lung, 5: 
Liver, 6; Skeletal Muscle, 7: Kidney, 8: Pancreas, 9: Spleen, 10: Thymus, 11: Prostate, 12: Testis, 13: 
Ovary, 14: Small Intestine, 15: Colon, 16: Leukocyte, 17: Human cDNA Control (Positive Control). 
Equal amount of template was added in each PCR reaction. 
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3.2 SuBceCCuCar LocaCization of SUMO 
Tatfiway Components 
In order to determine the occurrence of SUMO pathway inside which 
subcellular compartment, all SUMO components including E l , E2, E3 (PIAS) and 
four PIASl fragments have been cloned into the pEGFP-Cl vector and then 
expressed in two liver cell lines, WRL-68 and HepG2. EGFP is a variant of wild-
type GFP that is much brighter than the wild-type under laser excitation. After 
transient transfection, the SUMO pathway components tagged with EGFP at their N-
terminals could be visualized under fluorescent microscopy. The nuclei of the cells 
for microscopy were stained by DAPI which is a fluorescent dye that is taken by 
cells easily and binds selectively to DNA and forms strongly fluorescent DNA-DAPI 
complexes with no detectable level in cytoplasm. Such staining would be useful to 
locate the nucleus during observation and help focusing under the microscope. The 
endogenous SUMO-1 and SUMO-2/3 have been stained by immunostaining with the 
help of commercially available antibodies. SUMO-2 and SUMO-3 are very similar in 
their amino acid sequences and tertiary structures; hence they could not be 
distinguished in this experiment due to the limited specificity of the antibody. 
3.2.1 Overexpression Confirmation 
Before the visualization of the EGFP fusion of SUMO pathway components, 
their expression in these two mammalian cell lines, WRL-68 and HepG2，have been 
confirmed by western blotting with the anti-GFP antibody. The overexpression of the 
EGFP fusions has been detected to check whether they were expressed correctly. In . 
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this experiment, the two El subunits (SAEl & SAE2), E2 (Ubc9), full length PIAS 
(PIASl, PIAS3 and PIASxa) and the four PIASl fragments ftised with EGFP have 
been expressed with the expected molecular weight (Fig 3.6 and 3.7). However, the 
EGFP-PIASxP could not be expressed in both WRL-68 and HepG2 cells properly, 
and only a protein band with the same size as EGFP was found to be expressed. 
3.2.2 Multiple Bands Detected After Overexpression of 
EGFP-SUMO-1 
There were multiple bands detected by detecting both WRL-68 and HepG2 
cell lysates with overexpression of EGFP-SUMO-1, and their sizes were generally 
larger than the expected size of EGFP-SUMO-1. They were believed to be the 
EGFP-SUMO-1 conjugated proteins because those bands have not been found in 
GFP overexpression control and the cell lysates without transfection; they were not 
the non-specific proteins detected by the anti-GFP antibody. Hence, the EGFP-
SUMO-1 expressed in the liver cell lines was thought to be functional due to the 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 3 Results 
3.2.3 Subcellular Localization of EGFP 
The localization of EGFP without any fusion was investigated. It was a 
control for the experiment for the comparison with other fusion proteins to show that 
any change in the localization of the EGFP-fusion was due to the signal given from 
the fusion protein instead of an effect the EGFP itself, since EGFP localized in the 
whole cell without any specific localization (Fig. 3.19). By comparing with the 
untransfected control (Fig. 3.20), the localizations of the endogenous SUMO-1, 
SUMO-2/3 and their conjugates have not been altered by the EGFP protein; hence 
any difference in their localization after overexpression of an EGFP-fusion was 
mainly due to the effect of the fusion protein. 
3.2.4 Subcellular Localization of El Subunits 
In this study, SAEl (a smaller subunit of E l ) has been found in the 'vhole cell 
but the level is higher in the nucleus while SAE2 (another sunbunit of E l ) is located 
in the nucleus only. SAEl is located in both the cytoplasm and the nucleus in a 
disperse pattern, and it colocalized with endogenous SUMO-1 and SUMO-2/3 (Fig. 
3.8). For SAE2, it is mainly located inside the nucleoplasm but not inside the 
nucleolus, and it also showed some degree of colocalization with SUMO-1 and 
SUMO-2/3 (Fig. 3.9). Both SAEl and SAE2 are expressed with a similar ^ pattern in 
WRL-68 and HepG2; this suggests that liver caner may not be directly related to the 
change of El localization. 
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3.2.5 Subcellular Localization of E2 (Ubc9) 
Similarly, the recombinant EGFP-Ubc9 was located in a similar pattern in 
these two cell lines, WRL-68 and HepG2. It is mainly located inside the nucleus with 
a much lower level in the cytoplasm as shown by the overlay images of EGFP-Ubc9 
and DAPI (Fig. 3.10). 
The overexpressed EGFP-Ubc9 also demonstrated some degree of co-
localization with the endogenous SUMO-1 (or sumoylated substrates) and SUMO-
2/3 (or their conjugated proteins). However, the overall localization and expression 
pattern of the endogenous SUMO-1 and SUMO-2/3 or their conjugated proteins have 
not been grossly altered by the overexpression of EGFP-Ubc9 when the localization 
of the SUMO isoforms or sumoylated substrates in the cells are compared with cells 
with and without transfection. 
3.2.6 Subcellular Localization of PIAS Proteins 
The localization pattern of the EGFP-PIAS proteins was very similar. EGFP-
PIASl，EGFP-PIAS3 and EGFP-PIASxa are located inside the nucleus only and 
they are especially abundant in the nucleoplasm. They could not be detected inside 
other parts of the cells (Fig. 3.11, 3.12 and 3.13). They formed specific nuclear 
speckles instead of dispersing inside the nucleus. Nevertheless, the nuclear speckles 
formed by the EGFP-PIAS proteins were not exactly the same as that of SUMO-1, 
SUMO-2/3 or sumoylated protein. This phenomenon suggests that each PIAS has its 
specific interacting partners including the sumoylated substrates. Not one of the 
PIAS proteins would bind to all of the proteins conjugating with SUMO. 
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3.2.7 Subcellular Localization of PIASl Fragments 
As mentioned in the "materials and methods" section, the four PIASl 
fragments encoded the region flanking the SP-RING, the essential domain for E3 
ligase activity. EGFP fusion proteins with two of them (PIAS 1-141-476 & PIASl-
321-476) (Fig. 3.15 and 3.17) are located inside the whole nucleus similar to the full 
length PIASl; however, they did not only appear in the nucleoplasm excluding the 
nucleolus. EGFP fusion proteins of another two fragments (PIAS 1-141-410 & 
PIAS 1-321-410) (Fig. 3.14 and 3.16) also localized mainly in the nucleus but there 
were relatively low levels detectable in the cytoplasm. Thus it seems that the SP-
RING domain is crucial for the nuclear localization while the N-terminal and the C-
terminal regions may not be the essential region for the localization. 
For the longest fragment, PIAS 1-141-476, it formed speckles inside the 
nucleus which colocalized with the endogenous SUMO or SUMO-conjugated 
proteins (Fig. 3.15). This reveals that such overexpressed fragment may bind to the 
endogenous SUMO isoforms or SUMO-conjugated proteins, or induce the change of 
sumoylation pattern by facilitating some proteins to become sumoylated. 
' For the shortest fragment, PIAS-321-410, fusion proteins with EGFP also 
formed nuclear speckles but the amount and the size was much smaller than that of 
the longest fragment (Fig. 3.16), this suggests that either the regions in front of or 
following the SP-RING may take part in the localization, and this question could be 
answered by the other two fragments. The sumoylated pattern stained by 
immunostaining also showed the colocalization between PIAS 1-321-410 and the 
SUMO isoforms or sumoylated proteins have been detected in cytoplasm but the 
level was low. 
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EGFP fusion protein with PIAS 1-141-410 is located mainly in the nucleus 
and is expressed slightly in the cytoplasm (Fig. 3.14). The SUMO pattern also shifted 
from the nucleus to cytoplasm to some extent, this implies that the region following 
SP-RING also takes part in localization and the overexpression of SP-RING may 
alter the endogenous sumoylation pattern by catalyzing sumoylation where it locates. 
However, the deletion of region 141 to 321 did not reduce the formation of nuclear 
speckles significantly. 
The definite location of PIAS 1-321-476 inside the nucleus further confirmed 
the importance of the region following the SP-RING in nuclear localization. The 
retainment of 410 to 476 caused the fragment to reappear inside the nucleus only 
(Fig. 3.17). This gives the clue about the presence of nucleus retention motif lies in 
the region (410 — 476) or a corollary is that deletion of this region disrupts this motif. 
Nonetheless, there was no dramatic decrease in the formation of nuclear speckles 
when this recombinant was transfected compared with that formed with the shortest 
fragment. 
3.2.8 Subcellular Localization of SUMO-1 
The human SUMO-1 was also overexpressed under the EGFP system. The 
overexpressed EGFP-SUMO-1 is mainly located in the nucleus and some speckle 
structures were formed inside the nucleus, but a very low level of EGFP-SUMO-1 
has been observed in the cytoplasm (Fig. 3.18). The images captured under the 
visualization of EGFP-SUMO-1 and probed by anti-SUMO-1 conjugated with Cy3 
were superimposed with each other. This showed that the antibody used for 
immunostaining was functional and specific to SUMO-1 only and suggesting that the 
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overexpressed EGFP-SUMO-1 was translated correctly and functional so that such 
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3S DijferentiaC Trotein "Expression 
Tattem after Transient Transfection 
of SUMO-1 
To identify SUMO-1 related proteins, which are directly conjugated to 
SUMO-1 or differential expressed due to the presence of SUMO-1, the protein 
expression profiles of two liver cell lines, WRL-68 and HepG2, have been mapped 
by Two-Dimensional Gel Electrophoresis (2D electrophoresis). WRL-68 is a normal 
liver cell line while HepG2 is a hepatocellular carcinoma cell line, they were chosen 
because it was hoped that some of the SUMO related protein associating with cancer 
could be identified. Before the preparation of samples for 2D electrophoresis, these 
two cell lines were transiently transfected by pEGFP-C 1 -SUMO-1, hence the mature 
form of human SUMO-1 conjugating with EGFP at its N-terminal was ovcrexpressed, 
and pEGFP-Cl was also transfected to act as a mock transfection control. EGFP 
fusion was employed instead of other fusion tags since the transfection efficiency 
could be estimated easily by direct observation under fluorescent microscopy. 
Due to the nuclear localization of SUMO-1, which has been shown by the 
subcellular localization study in this project (Fig. 3.18) and the sumoylated substrates 
are mainly located in the nucleus, the transfected cells were fractionated and the 
nuclear fraction was collected for protein, expression profiling. The fractionation may 
enrich the nuclear sumoylated proteins and other SUMO-related proteins. 
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3.3.1 Protein Expression Profiles after Transient 
Transfection 
After transient transfection, there were differences in the protein expression 
profiles in both the WRL-68 and HepG2 nuclear fractions. It seemed that the amount 
of proteins loaded were not the same in the two cases (WRL-68 & HepG2 profiling); 
therefore, the proteins profiles between these two cell lines were not compared. 
Some high molecular weight proteins appeared in the EGFP-SUMOl 
overexpressing WRL-68 cells comparing with the EGFP expressing control (Fig. 
3.21); some proteins were differentially expressed in the EGFP-SUMO-1 
overexpressing HepG2 cells compared with the EGFP expressing control (Fig. 3.22). 
3.3.2 Identification of the Differential Expressed Proteins 
The differentially expressed proteins were picked and identified by mass 
spectrometry. In HepG2 cell line, there were two protein spots shown to be highly 
upregulated (Fig. 3.23 and 3.24). These two proteins have been identified as 
heterogeneous nuclear ribonucleoprotein A2/B1 isoform B1 (hnRNP A2/B1 isoform 
B l ) (Fig. 3.28A), and uracil DNA glycosylase (UDG) (Fig. 3.29A) by mass 
spectrometry. The peptide spectrums of these two proteins were listed (Fig. 3.26 and 
3.27). In both cases of protein identification, the top three candidates were identified 
as the same protein (Fig. 3.28B and Fig. 3.29B), in which, a subunit of 
glyceraldehyde-3-phosphate dehydrogenase is the nuclear isoform of UDG. This 
- i 
gave a high confident level that protein identification study was valid. 
The peptides in each protein sample were further dissociated during mass 
spectrometry by gas molecule collision; the ions formed were daughter ions. The 
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daughter ions formed were also matched with the protein database in order to further 
confirm the trypsinized peptides belonged to the predicted protein. Ten of the 
daughter ions were found to be part ofhnRNP A2/B1 isoform B1 while three of them 
were confirmed to be part of UDG (Fig. 3.28C and Fig. 3. 29C). 
The expression level of hnRNP A2/B1 isoform B1 was much higher in the 
HepG2 cells overexpressing EGFP-SUMO-1 when compared with that of the control 
cells overexpressing EGFP. And this was the similar case for the UDG. These two 
proteins are responsible for RNA processing; this suggests the importance of SUMO-
1 in this cellular activity. • 
In the WRL-68 cell line, the overexpression of EGFP-SUMO-1 induced the 
formation of some high molecular weight proteins (Fig. 3.25), which might be 
sumoylated or not sumoylated. The upregulated sumoylated proteins could not be 
identified in this study due to their low abundance. Further investigation is required 
to confirm their identities and their sumoylation status. 
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Fig. 3 . 2 1 Differential expression profiles of nuclear extracts of WRL-68 cell line overexpressing 
EGPF-SUMO-1 and EGFP. There were some high molecular weight proteins that appeared in the cells 
overexpressing EGFP-SUMO-1 (indicated by arrows)�^  
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Fig. 3.22 Differential expression profiles of nuclear extracts of HepG2 cell line overexpressing 
EGPF-SUMO-1 and EGFP. Some proteins were differentially expressed after the overexpression of 
EGFP-SUMO-1 when compared with that of control cells overexpressing EGFP. 
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HepG2- hnRNP A2/B1 isoform Bl 
pH 8.4 9.4 pH 8.4 9.4 
kDa kDa 
EGFP-SUMO-1 EGFP only 
Fig. 3.23 Upregulation of heterogeneous nuclear ribonucleoprotein A2/B1 isoform Bl 
(hnRNP A2/B1 isoform B l ) after overexpression of EGFP-SUMO-1. The protein spot in the red circle 
was identified as hnRNP A2/B1 isoform B l , but the corresponding spot was not detected in the 
control HepG2 cells overexpressing EGFP only. Since the strip used had a linear pH range, pH 3.0 -
10，the pH value was estimated by an equation, (pH difference between the two ends of the strip 
/length of the strip) x width measured from the positive end of the strip to the desired position. 
HepG2-UDG 
pH 8.8 9.5 pH 8.8 9.5 
kDa kDa 
H L H L 
EGPF-SUMO-1 EGFP only 
Fig. 3.24 Upregulation of uracil DNA glycosylase (UDG) after overexpression of EGFP-
SUMO-1. The protein spot indicated by the red circle was identified as UDG, but the corresponding 
spot detected in the control HepG2 cells overexpressing only EGFP was detected at a much lower 
level. Since the strip used had a linear pH range, pH 3.0 - 10, the pH value was estimated by an 
equation, (pH difference between the two ends of the strip /length of the strip) x width measured from 
the positive end of the strip to the desired position. 
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WRL-68 
kDa kDa 
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Fig 3.25 Difference in the expression profiles of the WRL-68 cells overexpressing EGFP-
SUMO-1 and EGFP. Both panels, A and B, show the appearance of high molecular weight proteins 
in the WRL-68 cells overexpressing EGFP-SUMO-1, but the level of the corresponding proteins in 
that of control cells overexpressing EGFP was much smaller. Since the strip used had a linear pH 
range, pH 3.0 - 10, the pH value was estimated by an equation, (pH difference between the two ends 
of the strip /length of the strip) x width measured from the positive end of the strip to the desired 
position. 
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Fig. 3.26 Peptide mass spectrum of hnRNP A2/B1 isoform B l . The red peaks were predicted 
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Fig. 3.27 Peptide mass spectrum of UDG. The red peaks were predicted to be belonged to the 
identified protein. 
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Mascot Result (hnRNP A2/B1 isoform B1) 
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Fig. 3.28 Top scored protein identified as hnRNP A2/B1 isoform B1 by Mascot. A: The 
Mascot search result showed that the protein with the highest score is hnRNP A2/B1 isoform Bl. B: 
The top three proteins identified are also hnRNP A2/BL C: Ten of the daughter ions dissociated from 
the selected peptides were matched with that of hnRNP A2/B1 isoform Bl. 
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Fig. 3.29 Top scored protein identified as uracil DNA glycosylase (UDG) by Mascot. A: The 
Mascot search result showed that the protein with the highest score is UDG. B: The top three proteins 
identified are also UDG and nuclear isoform of UDG (G3PDH). C: Three of the daughter ions 
dissociated from the selected peptides were matched with that of UDG. 
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3.4 Confirmation of VijferentiaCCy 
XxjyressedC Trotevns m CeCCs 
Overexjyressmg SlLMO-i 
In the previous section，two proteins have been identified as having increased 
expression level after overexpression of SUMO-1; they were heterogeneous nuclear 
ribonuclear protein A2/B1 isoform B l (hnRNP A2/B1 isoform B l ) and uracil D N A 
glycosylase (UDG). The transcription level and translation level of these proteins 
were verified by RT-PCR and western blotting respectively in order to investigate 
the upregulation of the proteins either through regulation of transcription or 
translation level. 
3.4.1 RT-PCR Analyses 
� 
3.4.1.1 Downregulation ofRNA Transcript of hnRNP A2/B1 isoform 
Bl 
The transcription level of hnRNP A2/B1 isoform B l in the HepCi2 cells after 
overexpression of EGFP and EGFP-SUMO-1 fusion was examined. For the hnRNP 
A2/B1 isoform B l transcripts, it is interesting that the level was 1.78-fold down-
regulated after overexpression of EGFP-SUMO-1 when compared with tha+ o f E G F P 
(Fig. 3.30). It seems that the overexpression of human matured SUMO-1 would 
induce the downregulation of hnRNP A2/B1 isoform B l at the R N A level; however 
this is opposite to the result of two-dimensional electrophoresis which shows an up-
regulation. This suggests that the regulation of the expression of hnRNP A2/B1 by 
^ 124 
Chapter 3 Results 
SUMO-1 occurs at both the transcriptional level (slight down-regulation) and also 
occurs at the translation level (up-regulation). 
3.4.1.2 No Significant Change in the Transcription Level of UDG 
The transcription level of UDG with overexpression of SUMO-1 in HepG2 
cells was no significant change (Fig. 3.31) comparing with the empty vector control. 
This suggests that the upregulation of the expression of U D G by SUMO-1 does not 
occur at the transcriptional level but rather starts from the translational level instead. 
I 
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Fig. 3.30 The RNA transcript level of hnRNP A2/B1 after transient transfection of EGFP-
SUMO-1 and EGFP. The RNA transcript level of hnRNP A2/B1 was downregulated after 
overexpression of SUMO-1 when compared with empty vector control, p-actin was employed as 
internal control for normalization. 
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Fig. 3.31 The RNA transcript level of UDG after transient transfection of EGFP-SUMO-1 and 
EGFP. The RNA transcript level of UDG was no significant change after overexpression of SUMO-1 
when compared with empty vector control, p-actin was employed as an internal control for 
normalization. 
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3.4.2 Western Blotting 
To examine the protein expression level of hnRNP A2/B1 isoform B1 and 
UDG after overexpression of SUMO-1 in HepG2 cells, western blotting were 
employed by using an anti-hnRNP A2/B1 antibody and an anti-UDG antibody which 
were commercially available. The overexpression of EGFP and EGFP-SUMO-1 was 
detected by anti-GFP antibody and their expression level was different (Fig. 3.32 and 
Fig. 3.33)，however this may be not directly correlated with difference in the 
transfection efficiency since the efficiencies o f E G F P and EGFP-SUMO-1 have been 
estimated by flow cytometry (data not shown), they were around 20% in both cases. 
The expression level of the overexpressed proteins in mammalian cells was 
varied with different fusion proteins similar to the case of bacterial expression, and 
the tag (EGFP in this experiment) was generally expressed in higher level when 
compared with the fusion one. The lower expression level of the fusion protein, 
EGFP-SUMO-1, might cause the effect on the target proteins (hnRNP A2/B1 and 
UDG) to be less significant and then some of the changes in the other cellular protein 
levels might be diluted or masked by this effect. Fortunately, the increase in the 
expression level of two proteins in the EGFP-SUMO-1 overexpressing HepG2 cells 
was still detected. 
3.4.2.1 Upregulation of hnRNP A2/B1 at the Protein Level 
As shown in Fig. 3.32, the protein level of hnRNP A2/B1 o fHepG2 cells was 
upregulated after the transient transfection of pEGFP-SUMO-1 when compared with 
the vector control. In this western blotting analysis, due to the high homology 
between the hnRNP A2/B1 isoforms A2 and B l ; isoform B l has an adJitional in 
frame 12 amino acids insert, they could not be distinguished. 
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Although the transcript level of hnRNP A2/B1 isoform B l was 
downregulated, it is surprising that the translational level may be upregulated. The 
activity of translation factors, e.g. translation initiators, responsible for hnRNP 
A2/B1 may be altered by SUMO-1. Alternatively the hnRNP A2/B1 might have a 
longer half-life upon modification with SUMO-1, either indirectly by interacting 
with a different protein partner or directly by less degradation due to proteases. 
3.4.2.2 Different Molecular Weight of hnRNP A2/B1 Was Detected 
After overexpression of EGFP-SUMO-1, the expression of hnRNP A2/B1 
with the expected molecular weight, 38kDa, was slightly increased. Besides, some 
proteins of hnRNP A2/B1 with smaller molecular weight, around 35kDa and 20kDa, 
were detected; this may due to alternative splicing of the mRNA transcripts, 
degradation, premature transcription or translation. The result may correlate with that 
of RT-PCR, the downregulation of the transcripts may be also because of alternative 
splicing of the mRNA and more probably, premature transcription. A weak band, the 
hnRNP A2/B1 which was larger than 50kDa was also detected after transfection of 
’ pEGFP-SUMO-1. The sumoylation rate could be boosted by overexpression of 
SUMO and more than one possible sumoylation sites have been predicted to be 
presence in the hnRNP A2/B1 isoform B l by the SUMOplot™ 
(http://www.abgent.com/doc/sumoplot); thus, the protein band with the molecular 
weight 50kDa may be the sumoylated hnRNP A2/B1. 
3.4.2.3 Upregulation of UDG at the Protein Level 
Although the RT-PCR analysis showed that the number of U D G transcripts 
has not been increased after the overexpression of EGFP-SUMO-1, the protein 
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expression level of U D G in transfected HepG2 cells was elevated (Fig. 3.33). This 
suggests that the translation of UDG was increased with an increasing level of 
SUMO-1. SUMO-1 may be responsible for the regulation of UDG translation 










Fig. 3.32 The protein expression level of hnRNP A2/B1 of HepG2 cells under the 
overexpression of EGFP and EGFP-SUMO-1. Multiple bands of hnRNP A2/B1 were detected after 
overexpression of EGFP-SUMO-1. The expression of EGFP and EGFP-SUMO-1 were confirmed by 
anti-GFP antibody while the normalization of the samples was estimated by an anti-P-actin antibody. 
The putative sumoylated hnRNP A2/B1 was indicated by an arrow. The native form of hnRNP A2/B1 
was shown in the red circle, the bands detected with lower molecular weight might be the products 
from alternatively splicing, premature transcription, premature translation or degradation. 
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Fig. 3.33 The protein expression level of UDG of HepG2 cells under the overexpression of 
EGFP and EGFP-SUMO-1. The protein level of UDG was significantly increased after the transient 
transfection of EGPF-SUMO-1. The overexpression of EGFP-SUMO-1 and EGFP was confirmed by 
probing with an anti-GFP antibody while the normalization pattern of the samples was determined by 
an anti-p-actin antibody. 
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3,5 Expression & Purification of ！Human 
TIJAS Troteins & I P J J ^ I S j fragments 
The mechanism of the catalysis of SUMO transfer from E2 to a target 
substrate by E3, especially by PIAS proteins, is still unclear, in order to have a better 
view, solving the structures of the human PIAS were attempted. The PIAS proteins 
were expressed in prokaryotic system with various purification approaches. 
3.5.1 Expression of Human PIAS Proteins 
The full length human PIAS genes, PIASl , PIAS3, PIASxa ana PIASxp, 
were cloned into two expression vectors, pET28m and pGEX-6P-l. Six histidines 
were tagged to the N-terminal expressed proteins when the target protein was 
expressed from pET28m while a glutathione S-transferase (GST) tag was fused to 
the N-terminal of the recombinant when it was expressed from pGEX-6P-l. Both 
tags would facilitate the purification by using corresponding affinity columns. 
Both the expression level and solubility of the full length PIAS proteins 
expressed in these two vectors were very low in all the tested expression conditions 
including lowering the expression temperature and expressing in different E. coli 
strains (Fig. 3.34)，this may be because of their large size; each PIAS protein is 
around 70kDa, and such large molecular weight does not favor good level of 
expression. The low yield of the expression increased the difficulty in the 
purification step, thus the full length PIAS proteins have not been further purified 
and smaller PIAS 1 fragments v/ere designed. 
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Expression & Solubmtv Test of GST - PIAS3 
Fig. 3.34 Expression and solubility tests of GST — PIASl and GST — PIAS3. GST - PIASl 
(97kDa) and GST - PIAS3 (94kDa) were expressed in E. coli strain B834+ at 16°C and 30ml of 
bacterial culture was collected at different time points, 5 hrs, 6 hrs and overnight after IPTG addition. 
Their expression and solubility levels were examined by 8% SDS - PAGE. Lanel: Non induce 
control. Lane 2: Soluble fraction, 5 hrs after IPTG induction. Lane 3: Insoluble fraction, 5 hrs after 
IPTG induction. Lane 4: Soluble fraction, 6 hrs after IPTG induction. Lane 5: Insoluble fraction, 6 hrs 
after IPTG induction. Lane 6: Soluble fraction, overnight after IPTG induction. Lane 7: Insoluble 
fraction, overnight after IPTG induction. There was nearly no expression of GST - PIASl has been 
induced while GST - PIAS3 has been expressed but it remained in the insoluble fraction. Similar 
situations have been observed in other PIAS proteins tagged with His^ and GST in all the tested 
conditions. 
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3.5.2 Expression of PIASl Fragments 
Due to the high homology between the PIAS proteins, solving one of their 
structures may help to solve the others and understand how they work in the 
sumoylation catalysis. Four fragments of PIASl were then designed basing on the 
secondary structure prediction to prevent any structural disruption. The four 
fragments encoded 141 - 410, 141 - 476, 321 - 410 and 321 - 476 amino acid 
residues and all of them included the SP-RING which is essential in the E3 ligase 
activity. The designed fragments were then cloned into the above expression vectors 
and an additional one, pMAL-c2P, which is an edited vector in that the enterokinase 
cleavage site was replaced by that of PreScission protease. The expressed protein 
from pMAL-c2P had a maltose binding protein fused to the N-terminal which helped 
in increasing the solubility [Pryor & Leiting, 1997; Hammarstrom et al, 2002]. 
In the small scale expression screening, PIASl fragments cloned in different 
expression vectors (Hise tag, GST tag and MBP tag) were transformed in various 
expression strains for expression, and different time points and temperature for 
expression were tested. The PIASl fragments fused with either a His tag or GST tag 
• showed the very low expression level and solubility. The MBP tag increased the 
expression level and the solubility greatly (Fig. 3.35); hence all the fragments were 
expressed in a large scale with a MBP tag. 
The optimal expression conditions of the PIASl fragments have been found: 
the optimal conditions for both MBP - PIASl 一 141 - 410 and MBP - PIASl -
321 一 476 using B834 E. coli strain were incubating at 16°C for overnight after IPTG 
induction, that for MBP - PIASl - 141 - 476 using B834+ was expressing for 6 
hours at 2 5 X while that for MBP - PIASl - 321 - 410 using B834+ was to express 
at 1 6 � C for overnight. ‘ 
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Expression & Solubmtv Test of MBP - PIAS1 - 321 -410 
Fig. 3.35 Expression and solubility tests of GST - PIASl - 321 - 410 and MBP - PIASl — 
321 - 410. GST - PIASl - 321 — 410 (37kDa) and MBP - PIASl - 321 - 410 (57kDa) were 
expressed in E. coli strain B834+ at 16°C and 30ml of bacterial culture was collected at two time 
points, 6hrsand overnight after IPTG addition. Their expression and solubility levels were examined 
by SDS — PAGE. Lanel: Non induce control. Lane 2: Total lysate, 6 hrs after IPTG induction. Lane 3: 
Soluble fraction, 6 hrs after IPTG induction. Lane 4: Insoluble fraction, 6 hrs after IPTG induction. 
Lane 5: Total lysate, overnight after IPTG induction. Lane 6: Soluble fraction, overnight after IPTG 
induction. Lane 7: Insoluble fraction, overnight after IPTG induction. The expression level of PIASl — 
321 — 410 tagged with GST was low comparing with MBP tagged one and nearly all GST tagged 
fusions remained in the insoluble faction while some of the MBP fusions remained in the soluble 
fraction. 
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3.5.3 A Trial of Purification of MBP-PIASl-321-410 
In this section, one of the four fragments, MBP-PIASl-321-410 was purified 
and tag removal was attempted. This was used as a pilot study because it is the 
shortest fragment; the optimized purification protocol would be a guide for the others. 
3.5.3.1 On Column Cleavage of MBP Tag 
After the MBP fusion proteins were bound to the amylose resin and all non-
specific bound proteins were removed, the elution of PIAS 1-321-410 was tried 
directly by on column cleavage with the help of PreScission protease which cleavage 
site was located in the linker region between the MBP and PIASl-321-410. 
Generally, overnight incubation with the PreScission protease would be able to 
cleave the fusion and addition of cleavage buffer (low salt buffer with ISOmM NaCl 
for normal functioning of the protease) would allow the cleaved protein to be eluted 
in the flowthrough. However, the PIAS 1-321-410 could not be eluted by the addition 
of PreScission protease but remained in the resin (Fig. 3.36) which seemed that the 
protease cleavage was hindered by some factors. 
3.5.3.2 Cleavage after Elution ‘ 
Due to the presence of unknown factors which reduced the cleavage 
efficiency of the PreScission protease, the fusion protein (MBP-PIASl-321-410) was 
eluted by 20mM maltose before clcavage in order to get rid of the steric hindrance 
given by the interaction with the resin. 
After an overnight cleavage, the MBP tags of the recombinants were still not 
removed (Fig. 3.37); suggesting that the binding with the resin may not be the main 
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cause of unsuccessful cleavage, the nature of the fusions induced some difficulties of 
the protease access. 
The general properties of the PIAS proteins were analyzed by the software, 
http://www.ics.uci.edu/~baldig/scratch/, including the secondary structure, 
hydrophobicity and number of disulfide bond formation based on the amino acid 
sequences. In the analysis, the P I A S l protein was predicted to have seven disulfide 
bonds and four of them are inside the fragment, PIAS 1-321-410. It is then suspected 
that the formation of non-specific intermolecular disulfide bond might be the 
possible factor that hindered the cleavage by inducing aggregation. 
3.5.3.3 High Concentration of DTT Used ‘ 
Higher concentration of DTT, from 2mM to lOmM，was added to the lysis 
buffer and then the purification was performed and tag removal attempted again. The 
recombinant proteins were eluted by maltose before the cleavage in order to prevent 
any hindrance given by the interaction of resin. Surprisingly, the elevated 
concentration of D T T worked in this experiment (Fig. 3.38); some of the tags could 
, b e removed from the fusions, revealing that non-specific intermolecular disulfide 
bonds were formed and then when aggregation was induced, the cleavage site might 
be masked or the interaction of the fusion with the protease might be prevented. 
3.5.3.4 Separation of the Cleaved and Non Cleaved Proteins 
Since the size difference of the cleaved and those non cleaved target proteins 
was very large, approximately 42kDa difference in the molecular weight due to the 
presence of the M B P tag, they were separated by gel filtration. Unfortunately, they 
could not be separated, and eluted together at the void volume (Fig. 3.39). This may 
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be due to the incomplete dissociation of the non-specific intermolecular disulfide 
bonds even by a relatively high concentration of DTT (lOmM) or other non-specific 
binding, e.g. hydrophobic interaction, between the fusions, which still associated the 
cleaved and the non-cleaved one. 
The less aggregated form of the MBP-PIASl-321-410 was found in the 
presence of lOmM of DTT, and such a concentration of DTT was added in all the 
buffers used in the following purification steps. 
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On Column Cleavage of MBP-PIASl-321 ^ 10 
1 2 3 kPa 
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Fig. 3 3 6 On column cleavage of MBP from MBP-PIAS 1-321-410 by PreScission protease in 
buffer containing 2mM DTT. Lane 1: amylose resin after binding of MBP-PIAS 1-321-410. Lane 2: 
Flowthrough after incubation with PreScission protease and then addition of cleavage buffer, no 
PIAS 1-321 "410 was detected. Lane 3: Resin after the cleavage, the MBP-PIAS 1-321-410 was still 
bound to the amylose resin. 
Cleavage after Elution 
1 2 kDa 
一 77 
Fig. 3.37 Cleavage of MBP from MBP-PIAS 1-321-410 by PreScission protease in buffer containing 
2mM DTT after maltose elution. Lane 1: Eluted MBP-PIAS 1-321-410 without addition of Protease protease. 
Lane 2: MBP-PIAS 1-321-410 after overnight incubation of Protease protease , no band shift was observed, 
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Cleavage of MBP Tag in Buffer Containing 10mM DTT 
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Fig. 3.38 PreScission protease cleavage of MBP-321-410 in buffer containing 1 OmM DTT. A 
band with size corresponding to PIASl-321-410 was observed. 
Gel Filtration of the Cleaved and Not Cleaved MBP-PIAS1-321410 
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Fig. 3 3 9 Separation of MBP-PIAS 1-321-410 and the cleaved one, PIAS 1-321-410, by gel 
filtration. Three lanes were the elution fractions from gel filtration. All of them were eluted together at 
the void volume. 
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3.5.4 Purification of the PIASl Fragments 
3.5.4.1 Purified by Affinity Column (Amylose Resin) 
For each protein preparation of the PIASl fragments, the recombinant protein 
was expressed at the optimal condition and 4L of bacterial culture was prepared. All 
the four PIASl fragments were partially purified by amylose resin (Fig. 3.40), a 
major band was observed in each elution. The partial purified proteins were collected 
for further purification. 
3.5.4.2 Purified by Heparin Column 
The eluted fraction from the affinity column was purified by heparin column 
since the presence of the SP-RING in the four fragments and the high homology 
between the SP-RING and zinc finger [Hochstrasser, 2001; Jackson, 2001; Schmidt 
& Muller, 2003], while zinc finger is a common domain in D N A binding protein, 
thus the SP-RING may also possess the DNA binding affinity. Both the ligand and 
charge specificity of heparin provide a specific medium for D N A binding protein 
•• purification. 
In the heparin column purification, all the four fragments were further 
purified (Fig. 3.41A-D); however, they gave broad peaks in the elution profiles and 
that they were generally eluted from 10% of buffer B (an elution buffer containing 
2M NaCl) to 30 - 40% of buffer B (Fig. 3.41E). The broad peak suggests that each 
PIASl fragments existed as several populations with different binding affinities to 
the heparin rather than as one species only. There were a lot of target proteins that 
remained in the flowthrough, this reveals that the aggregation of the proteins induced 
the steric hindrance to lower the heparin binding affinity of the protein. 
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3.5.4.3 Purified by Gel Filtration 
All the heparin eluted fractions were pooled and concentrated for gel 
filtration. In gel filtration, the protein mixture was separated by size so that the target 
protein could be separated from the impurities. The four fragments were eluted as a 
sharp peak separately at volume, 40ml，which is equal to the void volume of the gel 
filtration column used (Fig. 3.42E), suggesting that aggregation occurred. There were 
some impurities that coeluted with the target protein (Fig. 3.42A-D); this may be due 
to the aggregation induced non-specific binding of proteins. 
.1 
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Purification by Amylose Resin 
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Fig. 3.40 The MBP-PIASl fragments purified by passing through amylose resin. All the 
fragments were partially purified and major target bands were observed. 
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Purification by Heparin Column 
A B 
Fiowthrough Elution kDa kDa 
^ ― I Fiowthrough Elution 
64 vi 
•—103 
.—50 L • 
' ^ , , I 
1 ^ 7 
MBP-PIAS1-141 ~ 410 MBP-P丨AS1-141 - 476 
C D 
Fiowthrough Elution kDa Fiowthrough Elution 
p i i — . kDa 
MBP-PIAS1 -321 -410 MBP-PIAS1 -321 〜476 











了 jg lu t ioTPf l^k 
V i J f t t J y-TJ i I”‘f -nf^^ l>f«Af -«‘i \ 
« I ‘ t t I I ' I I 1 I / i 1 t I t t I t I I t I I I I I I I I I I 
11 m 丨：11 i i r - H h h U j 111 m I 
Fig. 3.41 Purification of the MBP-PIAS 1 fragments by heparin column. A-D: the purity of the 
eluted fractions of each fragment was shown; the first lane was the fiowthrough from the column while 
the other lanes were the eluted fractions. E: the elution profile of MBP-PIAS 1-141-410. 
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Purification bv Gel Filtration 
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Purification of the MBP-PIASl fragments by gel filtration column. A-D: the purity of the eluted fractions of 
each fragment was shown. The elutions still contained some impurities. E: the elution profile of MBP-PIASl-321 "476 from gel 
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3.5.5 Co-expression & Purification of PIASl Fragments & 
E2 
3.5.5.1 Co-expression of PIASl Fragments & E2 
Co-expression of the interacting partners with the target proteins increases the 
solubility of the target proteins in some cases [Veijola et al, 1996; Weickert & Curry, 
1997], since the interacting partner may provide the interface for the proper folding 
of the target protein. The intact SP-RING has been found to be essential for the 
interaction with Ubc9 [Kahyo et al, 2001] and due to the aggregation of the MBP-
PIASl fragments during purification, the PIASl fragments were then co-expressed 
with His6 tagged Ubc9 (E2) in order to relieve the aggregation. 
The pMAL-PIASl fragments were co-transformed with pET-Ubc9 and then 
induction was carried out by an addition of IPTG to induce the expression of MBP-
PIASl fragments and His6-Ubc9. For each trial of protein purification, 4L bacterial 
culture was prepared. The co-expression protein was firstly purified by amylose resin. 
3.5.5.2 Co-purification of PIASl Fragments & E2 by Amylose 
In order to maintain the interaction between PIASl fragments and Ubc9, low 
salt (ISOmM NaCl) lysis buffer was used instead. However, the expression level of 
MBP-PIAS 1-141-476 was greatly reduced when co-expressing with Ubc9, thus it 
was difficult for further purification. The MBP-PIASl fragments were also partially 
purified after passing through the amylose resin, the MBP-PIAS 1-321-410 and MBP-
PIAS 1-321-476 showed the weak interaction with Ubc9 that a faint band with 
molecular weight corresponding to His6-Ubc9 was observed in the elution of these 
two fragments (Fig. 3.43C-D). In the elution of the other two fragments, MBP-
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PIAS 1-141-410 and MBP-PIASl-141-476 (Fig. 3.43A-B), the His6-Ubc9 was not 
co-eluted or it was co-eluted but the level was too low for detection. 
3.5.5.3 Co-purification of PIASl Fragments & E2 by Heparin 
The elution from the amylose was loaded to the heparin directly except those 
of the MBP-PIAS1-141-476 with His6-Ubc9; the yield of the recombinant protein 
was too low for further purification. Even co-expression and purification of the 
PIASl fragments with Ubc9, they seem forming aggregates since there were a large 
portion of the PIASl fragments that remained in the flowthrough (Fig. 3.44A-C); 
they could not bind to the heparin column, this may be also due to the aggregation 
that caused hindrance. - After purification by heparin column, the purity of the 
fragments was not high, and interestingly, some of the elution fractions contained the 
Ubc9 but its elution was not evenly with either MBP-PIAS 1-321-410 or MBP-
PIAS1-321-376 (Fig. 3.44A-C), suggesting various populations of the PIASl 
fragments existed with different Ubc9 affinity during purification or that the Ubc9 
also had the binding ability to the heparin column. A wide peak was also observed in 
the elution profile of each purified PIASl fragments (Fig. 3.44D)，MBP-PIAS 1-141-
410, MBP-PIAS 1-321-410 and MBP-PIAS 1-321-476, revealing that more than one 
species of the fragments existed, which may also be due to aggregation. 
3.5.5.4 Co-purification of PIASl Fragments with Ubc9 by Gel 
Filtration 
The heparin eluted fractions containing the target protein were pooled 
together and concentrated for gel filtration. The purity of the purified proteins, MBP-
PIAS1-141-410, MBP-PIAS 1-321-410 and MBP-PIAS 1-321-476, was not very high 
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and the weak band of Ubc9 was disappeared from the elution of the PIASl fragments 
(Fig. 3.45A), this suggests that the interaction between the MBP-PIASl-321-410, 
MBP-PIAS 1-321-476 and Ubc9 was very weak. Although the expression and 
purification of the PIASl fragments were preformed with Ubc9, they still aggregated 
together; this was shown by a sharp peak that eluted at the void volume. The 
aggregation was confirmed by the co-elution of the PIASl fragments with blue 
dextran (Fig. 3.45B), which was a marker for the measurement of void volume. 
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Co-purification with Ubc9 by Amvlose Resin 
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Fig. 3.43 The MBP-PIASl fragments purified by passing through amy lose resin. All the 
fragments were partially purified and major target bands were observed. A small portion o f H i v U b c 9 
was co-eluted with MBP-PIASl-321-410 and MBP-PIASl-321-410. 
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Co-purification with Ubc9 by Heparin Column 
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Fig. 3.44 Purification of the PIASl fragments with Ubc9 by heparin column. A-C: the purity 
of the elution from the heparin column. Lane 1-13 were eluents and lane 14 was flowthrough. The 
protein bands in yellow box were the target PIASl fragments while those in blue box were Ubc9. D: a 
typical elution profile of the PIASl fragments with Ubc9. 
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Co-purification with Ubc9 by Gel Filtration 
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Fig. 3 . 4 5 Purification of the PIAS 1 fragments with Ubc9 by gel filtration. A: The purity of the 
MBP-PIAS 1 fragments was shown. Lane 1: elution of MBP-PIAS 1-141-410 from gel filtration, lane 2: 
elution of MBP-PIASl-321-410 from gel filtration, lane 3: elution of MBP-PIAS 1-321-476 from gel 
filtration. The target proteins were indicated by the arrows. B: The elution profile of MBP-PIAS 1-
321-476 with blue dextran. 
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3.5.6 Urea Treatment for Purification of PIASl Fragments 
3.5.6.1 Purification by Amylose Resin 
The procedures and results of the PIASl fragments purification were the 
same as the previous section since urea could not be added before passing through 
the amylose resin, addition of any denaturant alters the three dimensional structure of 
the protein especially the hydrogen bonding, and any change in the MBP structure 
reduces its affinity to the amylose resin. And the fusion protein would remain in the 
flowthrough without any binding to the resin. Urea was then added to the eluted 
protein to a final concentration to be 2M for heparin column purification. 
3.5.6.2 Purification by Heparin 
The addition of urea was generally considered as useful in reducing the size 
of aggregates by breaking the hydrophobic forces [Ostolaza et al，1991], thus a 
relatively low concentration of urea (2M) was then added before purifying the PIASl 
fragments by passing through heparin column in order to attempt to release the 
aggregation. 
After the heparin purification, the MBP-PIASl fragments were further 
purified, however, the purity was still not high enough for the structural studies (Fig. 
3.46A-D). It seems that the addition of urea did not alter the P I A S l fragment binding 
affinity to heparin, as the proportion of the target bound to the column was similar to 
that without urea. A relatively sharp peak was observed in the elution profile of the 
PIASl fragments (Fig. 3.46E), suggesting that the number of populations has been 
reduced by urea. 
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3.5.6.3 Purification by Gel Filtration 
Again, the target protein containing fractions were pooled for gel filtration 
purification. All the purified MBP-PIASl fragments were not in high purity for 
structural studies (Fig. 3.47A-B), and aggregation was also observed in the fragments 
no matter whether 2M urea was added or not. A sharp peak at the void volume in the 
elution profile was observed in all the four fragments, this supports that aggregation 
occurred in each target protein (Fig. 3.47C). It seems that 2M urea still could not 
relieve the aggregation although a sharper peak appeared in the elution profile of the 
heparin column. Higher urea concentration and addition of other denaturant may be 
used as other approaches for decreasing the number and size of the soluble 
aggregates.- “ 
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Purification by Heparin Column With the Addition of 2M Urea 
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Fig. 3.46 Purification of the MBP-PIASl fragments by heparin with 2M urea. A-D: The 
purity of the purfied protein was shown. E: an elution profile of MBP-PIASl-141410，it was similar 
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In this study, several aspects relating to sumoylation especially the part 
correlating with the E3 ligases, PIAS, have been studied. The tissue distribution 
study on PIAS suggests the importance of PIAS on various tissues while the 
subcellular localization analysis shows the nuclear located sumoylation pathway, and 
the SUMO-interacting motif of PIASl and SP-RING were thought to be responsible 
for nuclear speckles formation and nuclear localization respectively. The nuclear 
protein profiles of two liver cell lines, WRL-68 and HepG2, with or without 
overexpression of SUMO-1 were verified and attempts were made to identify 
differentially expressed proteins. The identities of two upregulated proteins after 
overexpression of SUMO-1 in HepG2 cells were found, they were hnRNP A2/B1 
isoform B l and UDG. Two of them are related to carcinogenesis; hence this provides 
insight for understanding the role of sumoylation on liver cancer. Finally, the PIAS 
proteins and PIASl fragments were expressed and purified using various approaches; 
although no pure proteins could be obtained for a structural study, the results still 
give a general guideline for future purification. 
4.1 Tissue Specificity ofTIJAS Troteins 
4.1.1 Principle of Tissue Specificity Study 
In this project, the tissue expression patterns of the five human PIAS genes 
have been studied by semi-quantitative PCR screening of Multiple Tissue cDNA 
Panels. Multiple Tissue cDNA Panels are sets of commercially available first-strand 
157 
Chapter 4 Discussion 
CDNA synthesized from mRNA extracted from 16 human tissues. Each panel has 
been normalized by several house-keeping genes to ensure that the target mRNA 
abundance could be accurately assessed. Hence, by designing gene specific primers 
and amplifying the cDNA from the panels as templates, the relative amount of gene 
expression could be quantified indirectly. 
4.1.2 Importance of Sumoylation 
In this study, the tissue specificities of human PIAS proteins have been 
investigated. All PIAS mRNA transcripts have been detected in all the tissues 
examined, this is similar in other studies but more extensive samples were examined 
in this study- [Chung et al, 1997; Gross et al, 2001], the consistency with some 
previous findings confirms the validity of the assay for the tissue distribution 
investigation. 
Besides the sumoylation E3 ligases PIAS, other sumoylation components, E l , 
E2 and SUMO isoforms have been found to be expressed ubiquitously in a variety of 
human tissues [Mannen et al, 1996; Azuma et al, 2001; Golebiowski et cd, 2003; 
Bohren et al, 2004; Kobayashi et al, 2004; Xu & Au, 2005], the presence of 
complete SUMO components in all tissues suggests the importance of sumoylation in 
normal functioning of different cell types. This hypothesis could be further 
confirmed by the type of substrates. Many targets of sumoylation are transcription 
factors, D N A integrity and cell signaling molecules which are essential for many 
I types of cells; hence that is why sumoylation happens in almost all kinds of tissues. 
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4.1.3 Role of Sumoylation in Reproduction 
As aforementioned, there are previous reports that E l , E2 and SUMO 
isoforms have been discovered as expressed ubiquitously in a wide variety of tissues. 
However, in this project, it was found that the E3 ligases, PIAS, although they were 
expressed in all kinds of tissues, they had their tissue specific expression patterns. 
Such phenomenon may be explained by the fact that different tissues have their 
specific protein expression profiles including different target substrates for 
sumoylation to act on, each PIAS is responsible for a set of substrates by providing 
the substrate specificity for S U M O conjugation. 
Among the tissues examined, testis expressed the PIAS genes with the 
highest level, especially'PIAS 1，PIASxa and PIASy. The expression level of PIAS3 
was the highest in prostate. By Northern blotting carried out by other research groups, 
P I A S l , PIAS3, P I A S x a and PIASxp have been detected especially high level in 
testis [Valdez et al, 1997; Moilanen et al, 1999; Tan et al, 2000; Zheng et al, 2004]. 
The high expression level of some PIAS proteins in male reproduction organs reveals 
a significant role of sumoylation in male reproduction. Therefore, there are a lot of 
studies focusing on the role of sumoylation on spermatogenesis. Recent studies have 
shown that SUMO-1 , P I A S l and PIASx expression levels in male germ cell 
development varied in different developmental stages [Yan et al, 2003; Vigodner & 
Morris, 2005], and three PIAS, P I A S l PIAS3 and PIASx have their spermatogenesis 
related substrates, androgen receptor (AR) and A R co-activator [Moilanen et al, 1999; 
Sharma et al, 2003], for instance. Taken together, sumoylation really takes part in 
male reproduction, however, in this study, no particular PIAS has been found to be 
especially highly expressed in female reproductive organs, and also little is known 
about the role as well as sumoylated proteins participating in female reproduction 
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and germ cell development, sumoylation may involve in reproduction but male 
specific. 
4.1.4 Functional Role of Sumoylation in Other Tissue 
Apart from reproduction, sumoylation involves in other cellular functions 
because the S U M O pathway components have been detected in most tissues and 
following testis, pancreas and liver were the tissues that expressing relatively high 
level of PIAS identified in this investigation. However, how sumoylation taking part 
in the specific function of pancreas and liver remains unclear, and a few of substrates 
have been known to be specific to these two organs [Descombes et al’ 1990; 
Chakrabarti et al, 2000; Giorgino et al, 2000; Kim et al, 2002; Lalioti et cd’ 2002; 
Wood et al, 2003], the only fact is that sumoylation relates to diabetes [Bohren et al, 
2004; Trajkovski et al, 2004] while the mechanism remains enigmatic. Exploring 
sumoylated proteins in pancreas and liver would help to know more about how 
sumoylation regulates the functioning in the organs. 
The expression of PIAS is crucial for normal cell functioning, the differential 
expression of PIAS members correlates with malignancy [Wang & Banerjee，2004]. 
Any change in the sumoylation pattern of the cells would also induce cancer as some 
of the substrates relate to cell cycle regulation [Azuma et al, 2003; Tago et al’ 2005] 
D N A repair [Hardeland et al, 2002; Stelter & Ulrich, 2003; Zhao & Blobel, 2005] 
and apoptotic pathway [Besnault-Mascard et al, 2005; Shinbo et al, 2005], etc. 
Thus, in this project, one of the aims is identification of SUMO-related 
proteins in liver in order to realize the liver specific function of sumoylation and find 
out the differential expression of SUMO-related proteins, which may not be directly 
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4.2 SuBceCCuCar LocaCization of SUMO 
Tatfiway 
4.2.1 SUMO Conjugation Occurs in the Nucleus 
Most of the S U M O pathway components have been expressed in human liver 
cell lines, WRL-68 and HepG2，under EGFP expression system in order to 
investigate their subcellular localization. These two cell lines were selected for the 
study because the function of sumoylation in the liver was aimed to be clarified and 
there were no reports about the subcellular localization of the S U M O pathway 
components in liver cells. In general, there was no large difference in the localization 
of the examined S U M O pathway components between these two cell lines. 
The E l , E2 and some of the full length PIAS examined were located inside 
nucleus, this reveals the importance of sumoylation of nuclear proteins and the 
occurrence of sumoylation was mainly in the nucleus only. 
The large E l subunit, SAE2, has been shown to localize in the nucleus and 
interestingly, it appeared in nucleoplasm exclusively; this was similar to the HeLa 
•cell line [Azuma et al, 2001]. The appearance of SAE2 in nucleus may be due to the 
presence of a nuclear localization signal at its C-terminal [Lois & Lima, 2005]. But 
the smaller subunit, S A E l , has been demonstrated as expressed throughout the whole 
cell, which disagreed with the previous finding [Azuma et al, 2001]. In the report of 
Azuma group, the endogenous S A E l was located by immunostaining, it was located 
in the nucleus only, this was probably because of an assembly of S A E l and SAE2 to 
； 
form a heterodimer, E l [Johnson et al, 1997; Desterro et al 1999]. However, in this 
study, the subunits of E l were studied one by one by overexpressing the S A E l and 
SAE2 separately instead of expressing them together. The mislocalization of S A E l 
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without association with SAE2 revealed that its location inside is nucleus and the 
proper functioning depends on the assembly with SAE2. 
The localization of Ubc9 (E2) may explain the discovery of sumoylated 
proteins outside nucleus. Ubc9 was determined as locating throughout the whole cell, 
such a result agreed with a previous study [Kobayashi et al, 2004]. The presence of 
E2 inside the nucleus suggests that sumoylation occurs in the nucleus. However, in 
the cytoplasm of the cells, no E l has been found, this implies that the occurrence of 
sumoylation may be inside the nucleus only or there is undiscovered sumoylation 
responsible E l . 
The E3s, some of the PIAS examined, were found to be located inside the 
nucleus also. EGFP-PIASxP has not been expressed properly in the two cell lines 
chosen while the localization of PIASy has not been determined in this study. 
Nevertheless, two of them have been found in the nucleus [Gross et al, 2001; 
Miyauchi et al, 2002; Arora et al, 2003]. The place of pathway components usually 
reflects the place of occurrence and necessity. Sumoylation is catalyzed by PIAS 
hence it is thought to be happening in nucleus and relied by transcription factors and 
'other nuclear proteins, e. g. thymidine D N A glycosylase (TDG) [Hardeland et al, 
2002] and Bloom syndrome gene (BLM) helicase [Eladad et cd, 2005]. However, the 
location of PIAS and E l was in nucleus excluding the nucleoli, it seems that the 
synthesis of ribosomal R N A may not require sumoylation. 
4.2.2 Does Sumoylation Occur Outside the Nucleus? 
Since the PIAS members do not locate outside the nucleus and E2, Ube9, 
locates throughout a cell, it seems that the sumoylation catalyzed by PIAS may not 
be responsible for nucleus trafficking which is one of the suggested functions of 
163 
Chapter 4 Discussion 
sumoylation, other E3 ligases locating in other parts of the cells excluding nucleus 
would be responsible for such function. Apart from the PIAS, RanBP2 and Pc2 are 
the other two groups of E3 ligases. RanBP2 is located at the nuclear pore complex 
[Wu et al, 1995] and helps the transportation of RanGAPl from the nucleus to 
cytoplasm through sumoylation [Matunis et al, 1998]. However, Pc2 also localizes 
inside nucleus similar to the PIAS [Cavalli & Paro, 1998]. The sumoylation targets 
o f P c 2 identified are nuclear proteins [Kagey et al, 2003]; Pc2 thus may also catalyze 
sumoylation in the nucleus exclusively. 
The mysterious appearance of cytoplasmic sumoylated substrates could not 
be explained by the presence of nuclear or nuclear pore localized E3 ligases, other E3 
ligases especially locating in cytoplasm may be discovered later like that of 
ubiquitination; there are a lot of various types of ubiquitination E3 ligases locating in 
different parts of the cells and catalyzing the transfer of ubiquitin to a wide range of 
target proteins. 
4.2.3 Dots-like Structure Formed by the PIAS 
In this study, the PIAS, PIASl , PIAS3 and PIASxa, not only have been 
localized in the nucleus, they have been also found to be forming speckle structures, 
which are also observed in other previous reports [Miyauchi et al, 2002; Tan et al, 
2002; Munarriz et al, 2004]. The formation of speckles may be due to the interaction 
of the ovcrexpressed PIAS to the sumoylated substrate and the other possibility, the 
binding to the scaffold attachment factors inside the nucleus [Tan et al, 2002]. 
The nuclear matrix binding ability of the PIAS demonstrates their importance 
in the nucleus size and shape maintenance and transcription regulation. The SAP 
domain of the PIAS has been suggested to be the essential component of binding to 
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the A/T rich region of DNA [Okubo et al, 2004]. It is not then surprising that the 
PIAS proteins recruit some transcription factors and D N A integrity factors, and 
regulate their activities. Nevertheless, the regulation of transcription factors does not 
purely depend on sumoylation; there are some cases that the interaction with the 
PIAS would be enough to elevate or repress the activities of the transcription factors 
[Liu et al, 2001; Arora et al, 2003; Gross et al, 2004]. 
There are many studies explaining the nuclear retention property. The SAP 
domain [Okubo et al, 2004] and the newly identified PINIT motif [Duval et al, 2003] 
have been suggested as the key components for the DNA binding. However, some 
contradicting findings have been found in this study. 
4.2.4 SAP Domain and PINIT Motif Are Not Essential for 
Nuclear Targeting 
There are two putative nuclear localization signals (NLS) in the PIAS 1, they 
are located at amino acid residues 56 - 64 and 368 - 380, it is then not surprising that 
. the full length PIASl has been discovered as nuclear located. Besides, there are two 
motifs that have been suggested to be nuclear targeting, the SAP domain and PINIT 
motif. It is then interesting to find out which part of the protein, the NLS or one of 
the domains or an undefined region, is the crucial region for the nuclear retention. 
Four fragments of PIASl have been designed based on the secondary 
structure prediction in order to abolish the tertiary structure and hence the function of 
the fragments. The four fragments encoding the 141 - 410, 141 — 476, 321 - 4 1 0 and 
321 - 476 amino acid residues of the full length human PIASl (Fig. 4.1). All four 
fragments include the SP-RING domain which is crucial for the ligase activity, as the 
removal of this domain may abolish the whole protein function. The first two 
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fragments, 141 - 410 and 141 - 476，contain nearly the whole PINIT, only the first 
12 amino acids of the PINIT motif have been removed. 
PIASl — | — I PINIT H SP R(MG~1-| SIM f — 
PIASl 141 - 410 I PINIT H SP-RIMG 卜 
PIASl 141 - 476 I P\m SPR IMG H $ I m | -
PIASl 321 -410 SP RIMG 
PIAS1 321 - 476 — SP-R\m }^$丨，/|-
Fig. 4.1 Schematic diagram of the PIASl fragments. The four fragments contain the SP-
RING, while the PIASl 141 - 4 1 0 and 141 - 4 7 6 includes almost the whole PINIT also. 
The fragments examined mainly located inside the nucleus, although the SAP 
domains, the DNA binding domains, of the fragments are removed. SAP domain 
may not be the most important domain for nuclear retention. Also, deletion of the 
nuclear retention motifs, PINIT motifs, did not induce the dispersion of the 
fragments outside nucleus since the fragments 321 - 410 and 321 — 476 have been 
localized inside nucleus. Such contradictory finding has been reported before [Wong 
et al, 2004]. But the deletion of the amino acid residues starting from 410 seems to 
start to mislocalize the fragments as small portions of 141 - 410 and 321 - 410 have 
been found in the cytoplasm. The only domain remained in each fragment is SP-
RING, it may play a role in the localization of PIASl through the interaction with the 
nuclear proteins or there may be another undefined signal for nuclear targeting; this 
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could be further investigated by determination the subcellular localization of the 
fragments of other PIAS proteins. 
4.2.5 Signal Involves in the Formation of Nuclear Speckles 
Another interesting finding is that the deletion of the amino acid residues 410 
to 476 would reduce the size and number of the nuclear speckles. This phenomenon 
has not been reported yet. Although the dots-like structure of the PIAS was firstly 
predicted as due to the presence of the SAP domain to interact with the nuclear 
scaffold attachment factors and then recruitment of other D N A regulation factors 
[Tan et al, 2002], this is not the case in this study since the four designed fragments 
do not include the SAP (domain anymore but speckles were also formed. 
The region, 410 to 476, contains a consensus SUMO interaction motif nears 
its end. The sequence of the consensus SUMO interaction motif (SIM) is 
• • X S X S / T a a a ("i|/" is a hydrophobic residue; "a" is an acidic residue and " X " is 
any amino acid), which of PIASl is TIDSSSDEE, locates between the amino acid 
„ residues 464 to 472, thus two PIASl fragments, 141 - 410 and 321 - 410 does not 
contain this motif. Hence, the SUMO interaction motif of the PIASl fragments 
examined may be responsible in the formation of nuclear speckles through the 
interaction with endogenous SUMO or sumoylated substrates, and then recruits other 
interacting proteins including the PIASl fragments to form a large complex that 
appears as a dot under microscopy. Some other undefined signal for the formation of 
nuclear speckles may exist, this requires further investigations. 
The SUMO interacting property of the PIAS 1 fragments could be confirmed 
by some binding assays, in vitro or in vivo pull down assays for instance, in order to 
ensure the fragments designed still could bind to SUMO. And the essence of the 
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SUMO interacting motif in the formation of nuclear dots could be further 
investigated by studying the localization of the PIASl fragments with mutation 
inside the SUMO interaction motif and more fragments could be designed near the 
motif to refine the region which is crucial for the speckle formation. 
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4,3 THfferenHaCCy Expressed Troteins 
under SlLMO-i Overexj}ression 
In order to study the role of sumoylation on liver cancer, the nuclear protein 
profiles of WRL-68 and HepG2 have been studies. Unfortunately, it seemed that the 
amount of proteins loaded for the lEF separation were different between the two cell 
lines, it was not suitable to compare their protein profiles directly and hence 
comparison of the profiles of the cell lines with or without SUMO-1 overexpression 
was only carried out in an intra-cell line manner but not in an inter-cell line manner. 
The HepG2 profiles showed more protein spots than that of WRL-68, since profiling 
of the two cell lines were not preformed together, some of the experimental 
conditions such as time for sample absorption to the lEF strips were different, these 
might induce the difference. 
4.3.1 Increase in High Molecular Weight Proteins 
In the WRL-68 cells, the transient transfection of pEGFP-SUMO-1 induced 
. the appearance of high molecular weight proteins. This phenomenon also has been 
reported in both mammalian cells and yeast after overexpression of SUMO isoforms 
and SMT3 (yeast SUMO-1 homology) respectively [Li et al, 2004; Zhou et al, 2004; 
Gocke et al’ 2005; Hannich et al, 2005], the proteins have been identified as 
sumoylated high molecular weight proteins in other studies by immunoblotting; this 
is probably due to the increase in the sumoylation rate by the elevated SUMO 
concentration in the cells. The overexpression of SUMO isoforms hence has been 
widely employed for sumoylation substrate identification to overcome the difficulties 
of identification of the low abundant sumoylated proteins since the ratio of 
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sumoylated proteins is very low and its dynamic property causes the removal of 
SUMO from the sumoylated proteins by SUMO-specific proteases during cell lysis 
[Vertegaal et al, 2004; Gocke et al, 2005]. The induced high molecular weight 
proteins in the WRL-68 cells could not be identified by mass spectrometry in this 
study unfortunately. They are whether sumoylated or not may be confirmed by 
western blotting analysis by using an anti-SUMO-l antibody. 
4.3.2 Upregulation of hnRNP A2/B1 & UDG in Protein 
Level 
In the overexpressing EGFP-SUMO-1 HepG2 cells, some proteins were 
differentially expressed comparing with the EGFP empty vector control, two of their 
identifies have been found by mass spectrometric protein finger printing, they were 
heterogeneous nuclear ribonucleoprotein A2/B1 isoform B1 (hnRNP A2/B1 isoform 
B l ) and uracil D N A glycosylase (UDG). Then their upregulation through whether 
transcription or translation level after transient transfection of pEGFP-SUMO-1 was 
“ then examined by RT-PCR and western blotting analysis respectively. Surprisingly, 
the RNA transcripts of hnRNP A2/B1 isoform B1 were found to be decreased but the 
protein level was increased after overexpression of SUMO-1, due to the 
indistinguishable isoform of A2 and B l , the upregulated protein may be A2 or B1. 
Also, the mRNA level of UDG showed no significant increase though the protein 
level was increased. This reveals that SUMO-1 upregulates the hnRNP A2/B1 and 
UDG in a transcription independent manner; i.e. SUMO-1 does not increase the 
transcription rate and hence the R N A level, and does not stabilize the mRNA of 
hnRNP A2/B1 isoform B1 and UDG. 
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However, the upregulation of these proteins shown in the 2D gels was higher 
than that verified by western blotting analysis; this may be due to different sample 
preparation methods. In the two dimensional electrophoresis experiment, nuclear 
proteins of the cells were fractionated for the analysis while total cell lysates were 
employed for the western blotting. The difference of band intensity in the 2D gels 
were more significant than that of western blotting, this suggests that the SUMO-1 
overexpression may target these two proteins into the nucleus so that their protein 
levels in nuclear fraction were detected in higher level than in total lysates. 
Moreover, the hnRNP A2/B1 and U D G protein expression upregulated by 
SUMO-1 might be by affecting the factors for translation, e.g. initiation and 
elongation factors, however, there is no report about sumoylation of translation 
factors, further identification of sumoylation substrates especially which are 
responsible for translation, would provide insights for the exploration of the 
relationship between sumoylation and translation. 
Another mechanism of upregulation of proteins by S U M O is protecting 
proteins from degradation by competing for the same lysine for conjugation with 
•ubiquitin [Desterro et al, 2000; Stelter & Ulrich，2003]. For both isoforms A 2 and B l 
of hnRNP A2/B1, no previous finding has been documented about their 
ubiquitination targeted degradation, hence the mechanism of SUMO-1 increasing the 
expression of hnRNP A2/B1 remains unknown. The elevated level of U D G after the 
overexpression of SUMO-1 may be due to the protection from ubiquitination, U D G 
is ubiquitinated and then degraded during S phase [Fischer et al, 2004], 
synchronization of the cells at S phase and detection of the amount of U D G may help 
the investigation of how SUMO-1 upregulating the U D G in the HepG2 cells. 
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4.3.3 Variants of hnRNP A2/B1 Formed 
In this study, it was found that some bands with molecular weight smaller 
than expected have been detected in the HepG2 cells under the overexpression of 
EGFP-SUMO-1. These isoforms may be the alternative spliced variants of hnRNP 
A2/B1 or products from premature transcription or translation or they could be the 
degradative products. It has not been reported that there are smaller isoforms of 
hnRNP A2/B1; hence the identities of the variants and how SUMO-1 induced the 
appearance of these variants are not known although some of the mRNA processing 
factors are sumoylated in the cells [Li et al, 2004; Vassileva & Matunis, 2004]. 
A very weak band corresponding to the sumoylated hnRNP A2/B1 has also 
been detected in the SUMO-1 overexpressing HepG2 cells. As mentioned before, 
sumoylation would be generally promoted in the SUMO-1 overexpression 
environment, the rate of sumoylation on hnRNP A2/B1 may be also stimulated in 
this case. In vitro assay may be performed to confirm the sumoylation status of 
hnRNP A2/B1 isoform B l since there is no previous studies documented how about 
it could be sumoylated in vivo and in vitro. 
4.3.4 Possibility of Sumoylation on hnRNP A2/B1 isoform 
Bl & UDG 
Since the hnRNP A2/B1 isoform B l is suspected to be sumoylated in vivo, 
the presence of sumoylation site has been scanned by using software SUMOplot™ 
(http://www.abgent.com/doc/sumoplot). There are eight putative sumoylation sites 
have been found and two of them are predicted with very high probability (Fig. 4.2). 
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1 MEKTLETVPL ERKKREKEQF RKLFIGGLSF ETTEESLRHY YEQWGKLTDC 
51 W H R D P A S K R SRGFGFVTFS SHAEVDAAMA ARPHSIDGRV VEPKRAVARE 
101 ESGKPGAHVT VKKLFVGGIK EDTEEHHLRD YFEEYGKIDT lEIITDRQSG 
151 KKRGFGFVTF DDHDPVDKIV LQKYIfriNGH NAEVRKALSR QEHQEVQSSR 
201 SGRGGNFGFG DSRGGCGNFG PGPGSNFRGG SDGYGSGRGF (H)GYNGYGGG 
251 PGGGNFGCSP GYGGCRGGYG GGGPGYGNQG CGYGCGYDHY GGGNYGSGNY 
301 NDFGNYHQQP SHYGPHKSGN FGGSRNMGGP YGGCNYGPGG SGGSGGYGGR 
351 SRY 
Fig. 4.2 Sumoylation motif prediction of hnRNP A2/B1 isoform Bl . Motifs colored in blue 
are possible sumoylation motifs with low probability while those in red are high probability. 
On the other hand, the possibility of UDG becoming sumoylated has also 
been estimated by using the software. Surprisingly, although there is no potential 
sumoylated UDG detected in the western blotting analysis, the scanning of the 
possible sumoylation sites from the amino acid sequence also revealed the high 
possibility of UDG becoming sumoylated. There are seven probable sumoylation 
sites have been discovered and five of them are highly scored (Fig. 4.3). No potential 
sumoylated UDG has been detected in the western blotting analysis which may be 
because of the low abundance of its sumoylated form even under SUMO-1 
overexpressing environment or the dynamic nature of sumoylation and 
desumoylation. It would then be interesting to investigate both hnRNP A2/B1 
isoform Bl and UDG to find out whether they could be sumoylated or not and the 
effect of their being sumoylated. 
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1 MGKVKVGVHC FGRIGRLVTR AAFHSGKVDI VAINDPFIDL NYHVYMFQYD 
51 STHGKFHGTV KAENGKLVIN GMPITIFQER DPSKIKWGDA GAEYWESTG 
101 VFTTHEKAGA HLQGGAKRVI ISAPSADAPH FVMGVNHEKY DNSLKIISNA 
151 SCTBTCLAPL AKVIHDNFGI VEGLHTTVHA ITATQKTVDG PSGNCGVHAA 
201 GLSRTSSLPL LALKAVGKVI PELNGKLTGH AFRVPTANVS W D L T C R L E K 
251 PAKYDDIKKV VKQASEGPLK GILGYTEHQV VSSDFMSDTH SSTFDAGAGI 
301 ALNDHFVKLI SWYDNEFGYS N R W D L H A S K E 
Fig. 4 3 Sumoylation motif prediction of UDG. Motife colored in blue are possible 
sumoylation motifs with low probability while those in red are high probability. 
4.3.5 Possible Roles of SUMO-1 on hnRNP A2/B1 isoform 
Bl 
Heterogeneous nuclear ribonucleoproteins (hnRNPs) are a family of RNP-
binding proteins which consists of more than 20 different members ranging in size 
from 30 to 120kDa [Choi & Dreyfiiss，1984; Pinol-Roma et al, 1988]. They are 
involved in many RNA metabolic activities including pre-mRNA processing, 
translation regulation, mRNA stability and mRNA nuclear and cytoplasmic shuttling 
[Economidis & Pederson，1982; Dreyfiiss, 1986; Kiledjian et al’ 1997; Ostareck et al, 
1997; Mili et al, 2001]. The hnRNP member identified in this study, hnRNP A2/B1 
isoform Bl, is a product from alternative splicing of A2/B1 gene [Kozu et al, 1995]. 
Both hnRNP A2 and Bl are responsible for pre-mRNA splicing [Mayeda et al’ 1994], 
and their amino acid sequences are very similar in that the Bl variant includes a 12 
amino acid insert [Burd et al, 1989]. 
Some reports about the relationship between sumoylation and hnRNPs have 
been documented. A few of the hnRNPs have been identified as sumoylated 
substrates [Li et al, 2004; Vassileva & Matunis, 2004], and interestingly, most of the 
putative sumoylation motifs of these hnRNPs are located in the RNA-binding 
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domain. This may raise the question of whether sumoylation is involved in hnRNPs 
RNA-binding activity. For hnRNP A2/B1 isoform Bl, two putative sumoylation 
motifs with high probability are found to be located in the second RNA-binding 
domain (Fig. 4.4)，this strengthens the hypothesis that SUMO conjugation regulates 
the RNA-binding activity of hnRNPs and hence controls the mRNA metabolic 
activities. 
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1 5 1 [ K K W F U F V ! � ’ DDHUyVDKXV lUKYtfl'IHUH NAEVyiCAlSR QEHQEVQSSR 
2 0 1 SCRGGNFCFG DSRCGGGNFG PGPG3NFRCG SDCYCSCRCF 仰GYNGYGGG 
2 5 1 PCCCNFOGSr OYGGGRCGYG GGGPGYGNQC GCYGCCYDIIY GGGNYGSGNY 
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Fig.4.4 Domain scan of hnRNP A2/B1 isoform Bl . Sequence in green box is the 1 幼 
predicted RNA-binding domain while those in yellow is the one. Amino acid sequence colored in 
blue is putative sumoylation motif with low probability and that in red is the motif with high 
probability. The domain prediction is performed by using InterProScan provided by EMBL, 
http://www.ebi.ac.uk/. 
4.3.6 Mechanism of Sumoylation on mRNA Processing 
Due to the rising number of the identification of the hnRNPs being 
sumoylation substrates and hnRNPs are the main proteins that take part in mRNA 
splicing, the role of sumoylation on mRNA splicing becomes clearer. hnRNP C and 
M are another hnRNPs members that have been identified as sumoylation substrates; 
the SUMO conjugation reduces their nucleic acid binding activity [Vassileva & 
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Matunis, 2004]. The alternation of nucleic acid binding activity of linRNPs may be 
similar to that of transcription factors which DNA binding would be facilitated by 
exposing or stabilizing the nucleic acid binding domain or reduced by masking 
[Goodson et al, 2001; Hong et al, 2002; Ungureanu et al, 2005]. 
Besides, mRNA splicing requires the involvement of the hnRNP complexes, 
i.e. hnRNPs usually work in a complex instead of working as a single protein, and 
hence the SUMO attachment may help the recruitment of other hnRNPs by providing 
a new interaction interface as SUMO is essential in many protein-protein interactions 
[Song et al, 2004], 
Moreover, the transport of mRNA from the nucleus to cytoplasm usually 
needs the binding of hnRNP. This reveals that hnRNPs are capable of shuttling 
between nucleus and cytoplasm, and the trafficking of hnRNPs may then require 
sumoylation. The E3 ligase of sumoylating hnRNP C and M is RanBP2 which 
locates at the nuclear pore [Vassileva & Matunis, 2004], and it may assist the 
hnRNPs shuttling via sumoylation. 
4.3.7 Possible Roles of SUMO-1 on UDG 
Uracil D N A glycosylase is responsible for the removal of uracil which is 
incorporated into D N A accidentally [Bessman et al, 1958] or formed by deamination 
of existing cytosine residues [Shapiro & Klein, 1966; Hayatsu, 1977]. The nuclear 
isoform of UDG, which is upregulated under the overexpression of SUMO-1, has 
been discovered as a subunit of a 37kDa of glyceraldehyde-3-phosphate 
dehydrogenase (G3PDH), and unlike G3PDH, the functional form of U D G is a 
monomer instead of tetramer [Meyer-Siegler et al, 1991] . The D N A binding activity 
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of UDG is suggested to be the responsibility of the activity of the NAD+ - binding 
site[Ovadie/a/, 1971]. 
Although UDG has not been found to be sumoylated in this study, the 
sumoylation motif prediction and the discovery of a sumoylated form of its close 
relative, thymine-DNA glycosylase (TDG) [Hardeland et al’ 2002], show a high 
chance that UDG is sumoylated in vivo. The putative sumoylation motifs are again 
concentrated in the putative DNA binding domain, NAD+ - binding site (Fig. 4.5). 
Thus, the DNA binding affinity of UDG may also be regulated by SUMO 
conjugation. 
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Fig. 4.5 Domain scan of UDG. Sequence in yellow box is the NAD^-binding domain. 
Amino acid sequence colored in blue is putative sumoylation motif with low probability and that in 
red is the motif with high probability. The domain prediction is performed by using InterProScan 
provided by EMBL, http://www.ebi.ac.uk/. 
The UDG closely related base excision repair enzyme, TDG, the SUMO-1 
conjugation modulates the DNA binding affinity by induction of conformational 
change and hence the dissociation of the TDG from the AP site [Steinacher & Schar， 
2005]. The alternation of the DNA binding activity of TDG by sumoylation suggests 
an occurrence of a similar situation in UDG. Confirmation of sumoylation on UDG 
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and then determination of its D N A binding affinity would be worthwhile in order to 
understand the mechanism underlying the base excision repair ability of UDG. 
4.3.8 Importance of SUMO on Genome Integrity 
There are more than 10 sumoylated proteins taking part in the maintenance of 
the intact genome structure, they include T D G [Hardeland et al, 2002], Topi [Mao et 
al 2000], Top2 [Bachant et al, 2002], P C N A [Hoege et al, 2002] and W R N [Kawabe 
et al, 2000]，etc. The discovery of the sumoylated substrates which are responsible 
for this function is still expanding; this reveals the important role of sumoylation on 
this aspect. U D G may be a new candidate of sumoylated protein which participates 
in the genome protection by base excision repairing. 
Since there are a lot of sumoylated proteins responsible for the genome 
structure maintenance and the sumoylation highly regulates their activities, defect on 
either S U M O conjugation pathway or mutations on these proteins induced inability 
for conjugation may sometimes induce lethal effect; thus this raises another issue that 
sumoylation may be involved in carcinogenesis. 
4.3.9 Sumoylation and Carcinogenesis 
In this study, there is a clue that sumoylation may be highly related to 
carcinogenesis. The upregulated proteins, hnRNP A2/B1 isoform B l and UDG, are 
closely linked with carcinogenesis since hnRNP A2/B1 isoform B l has been 
discovered as a biomarker of lung, breast and pancreatic cancer [Tockman et al, 1997; 
Fielding et al, 1999; Sueoka et al, 1999; Zhou et al, 2001; Yan-Sanders et al, 2002; 
Wu et al, 2003] while the malfunction of U D G reduces the repairing of mismatched 
D N A and then the appearance of cancer results [Moon et al, 1998; Rayany et al, 
178 
Chapter 4 Discussion 
2000; Fan & Wilson, 2005]. Since these two proteins relate to different type of 
cancer, it seems that their differential expression may induce cancer but may not be 
tissue specific; they may not be liver cancer specific. Although sumoylation on these 
two proteins may correlate with cancer, the link is obscure. It is then interesting to 
study the effect of SUMO expression on the hnRNP A2/B1 isoform B l and UDG in 
both normal and cancer cells, especially liver cancer cells since there is no reports 
has been documented about the correlation between these two proteins with 
sumoylation in liver cancer. 
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4,4 Trotein "Purification of tfie J-Cuman 
TIJAS Troteins & yjJ^LSj fragments 
4.4.1 Low Expression Level & Solubility of the PIAS 
Proteins 
The expression level of the human full length PIAS proteins under 
prokaryotic expression system was low; and it was sometimes too low for detection 
by Coomassie staining SDS-PAGE, thus it might require western blotting to confirm 
the induced expression. The low expression level may be due to the large size of the 
proteins; their sizes without any fusion tag ranging from 65kDa to 70kDa, which 
may be too large for bacterial expression. Large protein size requires a lengthy 
mRNA for translation, however, the longer the mRNA transcribed, the higher the 
chance of premature transcript formation. The secondary structure of the mRNA may 
also be involved in the low expression level of the ovcrexpressed protein, the mRNA 
may form specific secondary structure based on base pairing, and the structure may 
stop the translation prematurely by preventing further movement of ribosomes along 
„ the mRNA. The number of secondary structures formed increases with the length of 
the mRNA transcript. Both properties of long mRNA transcript may explain why 
large proteins generally could not be expressed well in a prokaryotic system. 
Alternatively, the mammalian specific tRNAs are sometimes rare in some bacterial 
expression strains, and this also poses a problem of low expression levels. 
Besides, the low solubility of the ovcrexpressed proteins, especially of the 
mammalian type, is another common problem that occurs in prokaryotic expression 
systems, and this also happened with the expression of the human PIAS proteins in 
this study. The insolubility of the expressed mammalian proteins may be due to the 
improper folding of the mammalian protein inside the bacterial cellular environment. 
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The large amount of expressed protein inside the E.coli may also facilitate the non-
specific interaction between the overexpressed proteins, particularly through the 
hydrophobic interaction, this may induce aggregation of the target proteins, and 
inclusion bodies form if the aggregation is severe, this further made the purification 
difficult. Incorrect disulphide bond formation of the target proteins is cne of the 
reasons of low solubility of large scale expression in a prokaryotic system. The 
unfavorable redox environment inside the bacterial cellular compartment does not 
favor the disulphide bond formation, disulphide bridges may form improperly and 
the incorrect intermolecular disulphide bond may induce aggregation. B y prediction 
from the amino acid sequence, there are six to seven disulfide bonds predicted in the 
five human PIAS proteins (http://www.ics.uci.edu/~baldig/scratch/), suggesting that 
the problem of disulphide bond formation may be the cause of insolubility. Because 
of the low expression level and solubility of the full length human PIAS proteins, 
four P I A S l fragments flanking the SP-RING were designed for expression. 
4.4.2 High Expression Level & Solubility of PIASl 
Fragments 
The expression level of the PIAS 1 fragments with the help of maltose binding 
protein (MBP) tag was high but low when tagged with His6 and glutathione S-
transferase (GST) tag. M B P is a molecular chaperone that interacts with the unfolded 
proteins to facilitate the recombinant proper folding [Richarme & Caldas’ 1997; 
Kapust & Waugh, 1999; Bach et al, 2001] and its bacterial protein nature drives its 
expression level to be high in bacterial cells and hence the conjugated protein [Maina 
et al, 1988; Pryor & Ldting，1997]. Since both the solubility and expression level of 
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the PIAS fragments were high after fusion to MBP, all the fragments were expressed 
and purified with MBP tag. 
4.4.3 Incorrect Disulfide Bond Formation of the PIASl 
Fragments 
For both the structural and functional study, due to the large size of the MBP 
tag, which is larger than the fragments, the removal of the tag was attempted by 
PreScission protease with a cleavage site located at a linker between the MBP tag 
and the target protein. However, at a buffer condition with low DTT concentration 
(2mM), the tag of each fragment could not be removed whether it is on column 
cleavage or cleavage after elution; whereas at a higher DTT concentration (lOmM), 
some of the fusion tags could be removed but the cleavage was not 100%, revealing 
that aggregation occurs between the recombinant PIASl fragments. This may be 
because of the formation non-specific intermolecular disulfide bonds. The number of 
disulfide bonds was not reduced much in the PIAS 1 fragments comparing with that 
„ of the full length and; the full length contains seven possible disulfide bonds while 
there are at least four disulfide bonds in the shortest PIASl fragment. Thus lOmM of 
DTT was adopted in the following purification steps to provide a reducing 
environment to dissociate the aggregated MBP-PIAS 1 fragments to become 
monomeric. ‘ 
4.4.4 MBP-PIASl Fragments Formed Soluble Aggregates 
The tag removed recombinant could not be separated from that tag containing 
fusions by gel filtration and they were all eluted together at the void volume even the 
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difference of the sizes between them was very large, suggesting that they were still 
associated together to form soluble aggregates, which may be due to the unbroken 
non-specific intermolecular disulfide bonds. This causes great difficulty in the 
purification steps for the structural study. Formation of such soluble aggregates is a 
common phenomenon occurring in many MBP tagged fusions [Sachdev & Chirgwin, 
1999; Nomine et al, 2001]. 
4.4.5 A Low Concentration of Urea Cannot Dissociate the 
Soluble Aggregates 
The soluble aggregates were tried to be dissolved by a relatively low 
concentration of urea (2M), which could not work nevertheless, although some 
proteins could tolerate such urea concentration without any unfolding [Garcia-Borron 
et al, 1985], and the fusion proteins were still eluted at the void volume in the gel 
filtration analysis. It seems that the non-specific intermolecular hydrophobic 
interaction between the MBP-PIASl fragments was very strong or other stronger 
- interactions, e.g. disulfide bond, exist between the proteins. Hence for the 
dissociation of the soluble aggregates, a much higher concentration of urea and DTT 
may be employed to break both the hydrophobic interactions and the disulfide bonds 
respectively. Or stringent conditions for denaturing the aggregates and then refolding 
of the proteins may be another approach for the purification of the MBP-PIASl 
fragments. 
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4.4.6 Aggregation May Weaken the Interaction between 
the PIASl Fragments & Ubc9 
Co-expression of the MBP-PIASl fragments with Ubc9 was another attempt to 
purify the monomeric or MBP-PIASl fragment -Ubc9 complex, this approach was 
commonly used in other studies in order to increase the solubility of the target 
protein or even produce interacting partner complex for structural studies [Li et al, 
1997; W a n g & C h o n g , 2003]. 
Ubc9 is a putative interacting partner of the PIAS 1 fragments, as the intact SP-
RING has been found to be essential for the interaction [Kahyo et al, 2001]. The 
interacting partner (Ubc9) may provide the interface for the proper folding of the 
PIASl fragments by acting similarly to the chaperones if they are really the 
interacting partners. Unfortunately, this did not work in this experiment, only two of 
the fragments, MBP-PIAS 1-321-410 and MBP-PIAS 1-321-476, showed a weak 
interaction with the Ubc9 during the co-elution from the amylose resin, the other two, 
MPB-PIASl-141-410 and MBP-141-476 did not interact with the Ubc9 also. The 
,„ weakened interaction may be because of the aggregation that masks the binding 
surface of the fragments to Ubc9. If MBP-PIAS 1-321-410 could bind Ubc9, MBP-
PIASl-141-410 and MBP-141-476 should interact with it also since these two 
fragments are longer than MBP-PIAS 1-321-410. Hence no interaction detected 
between these two fragments with Ubc9 suggests that their aggregation is more 
severe than the other two. 
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4.5 ConcCusion 
Considering all the results in this study, several conclusions could be drawn. 
First of all, the specific tissue distribution of each PIAS gene suggests their unique 
roles; they may catalyze the transfer of SUMO from E2 to substrate with different 
substrate specificities. Tissues with high expression level of PIAS including testis, 
pancreas and liver, and it reveals the importance of PIAS in sumoylation for their 
normal functioning. Some tissue specific substrates may be present in those tissues 
for the PIAS to act on. 
The subcellular localization of the SUMO pathway components was also 
reported, and the nuclear located E l , E2 and E3 (PIAS) suggest the location of the 
process of sumoylation to be inside the nucleus. Deletion study of PIASl showed 
that the SP-RING may be the key domain for the nuclear retention while SAP and 
PINIT domains may not be responsible. In P I A S l , the SUMO interacting motif may 
involve in the nuclear speckle formation through interaction with the endogenous 
SUMO isoforms and SUMO-conjugates. 
The overexpression of SUMO-1 induced the differential protein expression of 
HepG2 and WRL-68 cell lines. The overexpression caused the accumulation of high 
molecular weight proteins in WRL-68 cells which may be the sumoylated substrates; 
isolation of such protein may help in the identification of novel SUMO targets. In the 
SUMO-1 overexpressing HepG2 cells, two proteins, heterogeneous nuclear 
ribonucleoprotein A2/B1 isoform B l (hnRNP A2/B1 isoform B l ) and uracil DNA 
glycosylase (UDG), were up-regulated comparing with EGFP overexpressing control. 
Further confirmation by RT-PCR analysis and western blotting were performed, the 
results unravels that the regulation of SUMO-1 on these two proteins was at a 
translational level and to lesser extent at the transcriptional. By sumoylation motif 
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prediction, both up-regulated substrates were the putative target of sumoylation, 
suggesting that the up-regulation may be the effect due to reducing the proteins' 
susceptibility to the proteases. 
Although the full length PIAS proteins and PIASl fragments could not be 
purified for both structural and functional studies, some characteristics of the 
proteins in prokaryotic expression were found. The expression level and solubility of 
the full length PIAS proteins were very low; hence they were not suitable for the 
structural study. The four PIAS 1 fragments were expressed at a high level and they 
were soluble only when they were fused with the C-terminal of maltose-binding 
protein (MBP). Nonetheless, the improper intermolecular disulphide bonds may be 
the main reason of soluble aggregates formation, and solving this problem would be 
the key step to further purify PIASl fragments for the structural analysis. 
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4,6 future Tersjpectives 
4.6.1 Identification of the Role of SUMO Interacting Motif 
in the Nuclear Speckle Formation 
The essence of the SUMO interacting motif in the nuclear speckle formation 
would be confirmed by generation of mutants without the motif and substituting the 
amino acid residues with other amino acids and then studying their localization. 
Fragments of other PIAS proteins flanking the corresponding regions of the PIASl 
fragments could also be designed and the subcellular localization could be studied in 
order to define the consensus region for nuclear retention and nuclear speckle 
formation. • “ 
4.6.2 Investigation of Sumoylation on Liver Cancer 
The expression level of hnRNP A2/B1 isoform B l and U D G before and after 
overexpressing SUMO-1 in the normal liver cell line, WRL-68, could be studied in 
' order to investigate the relationship of sumoylation in liver cancer which may have 
differential expression of these two proteins, especially hnRNP A2/B1, which is up-
regulated in various cancers. 
Knock-out experiment of suppression of SUMO-1 expression in HepG2 and 
WRL-68 cell lines could be applied by siRNA induction. The differential protein 
expression profile would then be studied by two-dimensional gel electrophoresis in 
order to fish out any possible SUMO regulated proteins which may be involved in 
hepatocellular carcinomas (HCC) or normal functioning of liver. The expression 
level of hnRNP A2/B1 isoform and UDG could also be determined to further 
confirm that their expression is directly related to SUMO-1 expression. 
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Due to the elevated level of high molecular weight proteins after SUMO-1 
overexpression, this may be a tool for SUMO substrate identification. Their 
sumoylation status would first be examined by using an anti-SUMO-1 antibody, if 
they are sumoylated, further purification or enrichment approach, e.g. 
immunoprecipitation, could be employed to reveal their identities. Liver cell lines 
would be used in this experiment in order to fish out any liver specific or HCC 
related sumoylated proteins. 
4.6.3 Optimization of the Expression & Purification of the 
PIAS Proteins 
Purified PIAS proteins are useful in both functional and structural studies, 
hence further optimization of the expression and purification could be carried out in 
order to produce a large amount of PIAS proteins. It seems that the prokaryotic 
expression system may not be a good choice for generating functional PIAS proteins. 
Other expression systems such as yeast and baculovirus may be adopted, these two 
„ systems are usually expressing mammalian proteins in their native form, and it may 
work also for the PIAS. 
The purified PIAS proteins could be used for structural studies by X-ray 
crystallography in order to unravel the mechanism underlying SUMO transfer 
catalysis, providing substrate specificity and other functions which are sumoylation-
independent, inhibition of some transcription factors for instance. Besides, binding 
assays could be established with the help of the purified PIAS proteins to define the 
region especially for Ubc9 binding, which would then enlighten the investigation of 
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Vector information of pEGFP-Cl used to express the SUMO pathway components 
and PIASl fragments with EGFP for subcellular localization study. 
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Vector information of pET-28m used for prokaryotic expression of the full length 
PIAS and PIASl fragments fused with Hise tag. 
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The Multiple Cloning Sites 
(The highlighted region was deleted in the modified vector) 
Cat. No.: 69864-3 
Adapted from http://www.merckbiosciences.com/docs/docs/PROT/TB074.pdf 
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Appendix 
Vector information of pGEX-6P-l used for prokaryotic expression of full length 
PIAS and PIASl fragments fused with GST tag. 
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Vector information of pMAL-c2P used for prokaryotic expression of PIAS fragments 
fused with MBP tag. 
polylinker 
^ ^ ^ ^ ^ lacZo. 
malE 广 \ rmB 
/ / terminator 
P: / \ \ 
I 丨 pMAL-c2P \ 
I I I A m p r 
1 - M13 ori 
pBR322 ori 
Pt«Scis«ion™ Protow« 
Leu Glu Val Leu Phe Gln+Gly Pro Kpnl EcoRi BamHI Xbat Salt PstI HIndtll 
CTGCAAGTTCTGTTCCAGGGGCCC C ' 、 c 
The Multiple Cloning Sites 
(The enterokinase cleavage site was replaced by that of PreScission protease.) 
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